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Orthotopic Liver transplantation (OLT) has evolved into a routine treatment 
with excellent short and long-term patient survival for various end-stage liver 
diseases.1-3 Several improvements, including those in surgical technique and 
immunosuppression, have contributed to improved survival.4,5 Possibly, 
a reduction in infectious complications after OLT may have contributed 
to this improved patient survival, but this is not well known.6-9 Improved 
patient survival may also be attributed to better donor management, organ 
preservation, as well as intensive care treatment protocols.10-13 Recently, 
it has been shown that, next to the antibiotic regimen, donor and recipient 
genetic polymorphisms in innate immunity contribute to the risk of infection 
after OLT.14 In addition, graft loss due to rejection has virtually disappeared 
since the introduction of tacrolimus.15,16
The success of treating patients with end-stage liver disease with liver 
transplantation has led to an increased demand for donor livers while the 
number of suitable grafts has remained static over the last decades and this 
resulted in longer waiting lists.17
Many centers have expanded their criteria, in consensus, for potential donor 
livers. These include extended criteria donor livers and livers from donation 
after cardiac death (DCD).18-20 According to the Maastricht criteria a no 
touch period is warranted in DCD donors to ensure that cardiac arrest had 
become irreversible as opposed to donors from donation after brain death 
(DBD), where the circulation in the donor is still intact.21-23 DCD donors 
therefore have an additional and inevitable donor warm ischemia time 
(DWIT), which is defined as the time between circulatory arrest and cold 
flush in the donor.24 In addition, a short episode of hypotension between 
ventilation switch-off and cardiac arrest precedes DWIT. This additional 
period in DCD of less and no perfusion respectively, and warm ischemia 
precedes the cold ischemia time (CIT) which starts with cold flush in the 
donor and persists during transportation. CIT ends at the time of removal of 
the donor liver from ice at which the recipient warm ischemia time (RWIT) 
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starts. RWIT ends at reperfusion of the donor liver in the recipient. Unlike 
DWIT in DCD, the CIT and RWIT are also present in donation after brain 
death (DBD). Despite donor selection and reduction of ischemia times, 
livers from DCD donors are more prone to develop severe complications 
such as primary nonfunction (PNF), delayed graft function and, especially, 
biliary nonanastomotic strictures (NAS).25-31
In 2001, a national protocol in the Netherlands has been introduced for 
multi-organ donation from DCD donors to fulfill the increasing demand and 
compensate for the decreasing DBD donation. As to date, approximately 
20% to 30% of all OLTs in our country are performed using livers from DCD 
donors.32 NAS can occur in up to 35% of grafts using DCD donors and are 
considered a significant source of morbidity.33 The exact pathogenesis of the 
development of NAS remains unclear but several theories exist.34
Biliary complications
Biliary complications can occur at any time after OLT. Biliary complications 
include anastomosis leakage leading to bilomas and stricture formation.35 
Biliary strictures can be divided into two different entities: anastomotic 
strictures (AS) occur at the surgical notch of the bile duct anastomosis.36,37 
Local inflammation may lead to scarring which in turn leads to narrowing 
of the anastomosis. NAS are considered as strictures or irregularities 
occurring at least 1 cm above the anastomosis.35,38,39 NAS form a hetero-
geneous group with considerable variation and NAS incidence rates may vary 
widely, perhaps due to lack of a clear definition. In addition, time of presen-
tation may also vary greatly.40 NAS may occur early after OLT, i.e. within the 
first twelve months, or late, even after several years. One study showed that 
NAS occurring early after OLT (< 1 year) was associated with preservation 
related factors, such as cold ischemia time (CIT) and WIT as opposed to late 
presenting NAS, which was more related to the indication for which OLT was 
performed, especially primary sclerosing cholangitis (PSC).40 In OLT for PSC, 
one of the difficulties is that to date there are no diagnostic modalities to 
distinguish recurrent PSC from NAS related to OLT. 
Grafts from DCD are known to develop more NAS than grafts from DBD.41 
NAS – also known as ischemic-type biliary lesions (ITBL) – are associated 
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with an increased risk of bacterial cholangitis, frequent admissions to the 
hospital, endoscopic treatment and retransplantation.42 NAS are most likely 
the result of a complex mechanism involving ischemic, immunologic and 
toxic processes which all affect the biliary tree or its vascular system.43-45 
The microvascular supply of the biliary tree, the peri-biliary plexus, stems 
from the hepatic artery branches and flows into the hepatic sinusoids. 
A decreased blood flow in the peri-biliary plexus after orthotopic liver trans-
plantation may be involved in the development of NAS.46,47 This might be 
the result of microthrombi that develop during the DWIT, CIT and RWIT.48,49 
The most frequently used preservation fluid, University of Wisconsin (UW) 
solution and Histidine-tryptophan-ketoglutarate (HTK) solution, which was 
until recently also used in the Netherlands for liver preservation, may be far 
from perfect.50 Several attempts are being made to improve preservation and 
to reduce ischemia-reperfusion injury (IRI) of liver grafts, including machine 
liver perfusion but also “flush” protocols in which fibrinolytic agents are 
being used to dissolve microthrombi in the microvascular system of the 
biliary tree during procurement of the donor liver.49,51
Apart from IRI and possible microthrombi, there are several other theories 
on the development of biliary strictures. One theory encompasses an altered 
composition of bile after IRI, which occurs after OLT.44 In a porcine model 
of DCD liver transplantation, a warm ischemia period of 30 minutes and 
longer produced bile with a significantly higher bile salt-to-phospholipids 
ratio after transplantation than livers from donors with 0 or 15 minutes warm 
ischemia in the donor.45 Secretion of bile salts might be impaired due to 
an imbalance between hepatobiliary transporter proteins which secrete bile 
salts and multidrug-resistance protein 3 (MDR3) which secretes less phos-
pholipids resulting in an increase of the bile salt/phospholipids ratio. Toxic 
bile salts might lead to injury of the biliary epithelium, especially in case of a 
reduced ‘bicarbonate umbrella’.52,53 In the past, ABO-incompatibility in liver 
transplantation was also associated with the development of NAS, indicating 
that immunological processes are involved in the development of NAS.54 
In ABO-incompatibility this could partially be explained by the fact that the 
ABH-antigen is consistently present on biliary epithelial cells –in contrast to 
hepatocytes– which in turn can initiate an immune reaction that causes local 
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damage to the biliary tissue.55
One theory that supports the involvement of the immune system is the 
loss-of-function mutation of chemokine receptor 5 delta 32 (CCR5Δ32) which 
has been associated with the development of NAS in recent literature.43 
CCR5Δ32 is a protein, which is located on the surface of macrophages, CD4+, 
CD8+ but also natural killer cells, and its main function involves attracting 
immune cells to damaged tissue sites. Impaired functioning of the CCR5Δ32 
might lead to less attraction of immune cells to the biliary tract and sub-
sequent healing of injured tissue. However, the contribution of CCR5Δ32 in 
the development of NAS has been questioned and needs replication in 
larger cohorts to determine its exact role in the development of NAS.56
Activated immune cells also release specific members of the tissue remodeling 
matrix metalloproteinases (MMP). MMPs have been associated with numerous 
conditions such as IBD and cancer and there is strong evidence suggesting 
involvement in IRI as well.57-59
Matrix metalloproteinases
Jerome Gross and Charles Lapierre made the first discovery of MMPs in 
1962 and the first MMPs discovered in human neutrophilic granulocytes, 
was in 1968.60,61 MMPs comprise a large family of proteolytic enzymes that 
are important in physiological and disease-related extracellular matrix (ECM) 
remodelling processes.62 MMPs consist of a signalpeptide or prepeptide, 
a pro-peptide region, a catalytic domain with a zinc binding region and a 
hemopexine domain which is connected with a so called hinge region with 
varying length to the catalytic domain.63
The signalpeptide or pre-peptide consists of a sequence of 17-20 hydrophobic 
amino acids. The hydrophobic portion of the signal peptide is responsible 
for the secretion of MMPs in the endoplasmic reticulum, from which they 
can be released into the extracellular space.64 The propeptide, contains 80 
amino acids with an N-terminal hydrophobic rest. Near the C-terminal end 
of the propeptide is a highly conserved sequence region around cysteine: 
PRCGVPD.65,66 The catalytic domain consists of 160 - 170 amino acid 
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residues and contains binding sites for calcium and zinc ions. The catalytic 
domain is connected to the hemopexin domain by a so-called hinge region. 
This connection region is important for the substrate specificity of MMPs 
which can bind to the substrate itself or establish the binding orientation of 
the catalytic and hemopexin-domain.67 The hemopexin-like domain com-
prises about 200 amino acids that contain four so-called repeats, each with 
about 48 amino acids. The hemopexin domain seems to be important for 
substrate specificity of the MMPs and contributes to binding of the sub-
strates which makes it a key player in activating and inhibiting MMPs.68
MMPs hydrolyze most components of the ECM and play a central role in 
many biological processes such as normal tissue remodeling, embryo-
genesis, wound healing and angiogenesis.69-71 Currently about 26 MMPs 
have been identified, and most are multidomain zinc endopeptidases. 
According to their substrate the members of the family are divided in 
collagenases, stromelysines, gelatinases, membrane-type-(MT)MMPs and 
others.72 Stromelysins (MMP-3 and MMP-11 or stromelysin-1 and -2) and 
matrilysin exhibit the ability to degrade a broad range of substrates, including 
proteoglycans, fibronectin, laminin, gelatin, collagens-III, -IV, and -V, and 
elastin.73 The membrane-type MMPs (MT-MMPs) differ from other MMPs in 
having a C-terminal transmembrane domain (MT1-, MT2-, MT3- and MT5-
MMP) or are anchored to glycosyl phosphatidyl inositol (MT4-MMP, MT6-
MMP), which localizes these enzymes to the surface of cells. MT-MMPs have 
a broad substrate specificity and can degrade interstitial collagens III and I, 
as well as fibronectin, vitronectin, and cartilage proteoglycans.74,75 (Table 1)
In healthy tissue a strict regulation of MMPs is critical in order to maintain 
proper ECM homeostasis. Among other levels of regulation, MMPs are 
precisely regulated by their main endogenous protein inhibitors (TIMPs).76 
Disruption of this balance results in serious diseases such as fibrosis, 
arthritis, and tumour growth. Certain MMPs such as gelatinases (MMP-2, 
MMP-9) have specific characteristics such as digesting components of 
connective tissue matrix and type IV collagen.77 MMPs can no longer be 
solely thought of as ECM destructionists, but as part of a delicate equilibrium 
system through which epithelial and immune cells interact with the stroma.
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Table 1. List of MMPs and their substrate specificity.74,75
MMP-2 and MMP-9
The gelatinases A (MMP-2 or 72-kDa type IV collagenase), and B (MMP-9, 
92-kDa type IV collagenase) can degrade denatured interstitial collagens 
(gelatins), type V collagen, and intact type IV collagen, which is an important 
component of basement membranes.78 The baseline structure of MMP-2 is 
homologous to MMP-9 and is constitutively expressed in almost all human 
tissues but mainly by hepatic stellate cells (HSC), endothelial and epithelial 
cells. MMP-2 is secreted in its zymogen form (pro-MMP-2) and is tightly 
regulated by complex signaling through TIMP-2, TIMP-3 and TIMP-4 which 
all display relevant affinity for the MMP-2 and their adequate secretion is 
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Enzyme Pro-MMP Substrate 
Collagenase   
Collagenase 1 MMP-1 Type I, II and III collagen 
Collagenase 2 MMP-8 Type I, II and III collagen 
Collagenase 3 MMP-13 Type I collagen 
Collagenase 4 MMP-18 Not found in humans 
Gelatinases   
Gelatinase A MMP-2 Type IV, V, VII, IX and X collagen, gelatins 
Gelatinase B MMP-9 Type IV, V, XI, and XVI collagen, laminin, elastin, decorin 
Stromelysin   
Stromelysin 1 MMP-3 Basement membrane glycoproteins, fibronectin,  
E-cadherine, activates plasminogen and MMP-2 
Stromelysin 2 MMP-10 Basement membrane glycoproteins 
Stromelysin 3 MMP-11 Basement membrane glycoproteins 
Matrilysin   
Matrilysin 1 MMP-7 Fibronectin, elastin 
Matrilysin 2 MMP-26 Type IV collagen, fibronectin, fibrinogen 
Membrane-type MMPs  
(MT-MMP)(A) 
  
MT1-MMP MMP-14 Type I, II and III collagen, activates MMP-2 and MMP-13 
MT2-MMP MMP-15 Fibronectin, laminin, activates MMP-2 
MT3-MMP MMP-16 Type III collagen, fibronectin 
MT5-MMP MMP-24 Proteoglycans 
MT4-MMP MMP-17 Fibrinogen, fibrin 
MT6-MMP MMP-25 Type IV collagen, fibronectin, fibrin, casein 
Others   
Macrophage elastase MMP-12 Type IV collagen, elastin, gelatins, fibronectin  
- MMP-19 Type IV collagen, fibronectin 
Enamelysin MMP-20 Amelogenin, aggrecan 
- MMP-21 Type IV, V, VII, IX and X collagen 
CA-MMP MMP-23 Unknown 
- MMP-27 Unknown 
Epilysin MMP-28 Unknown 
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required for a balanced MMP-2/TIMP ratio and MT1-MMP.79 The membrane 
bound activation of pro-MMP-2 ensures that proteolytic activity is localized 
to specific regions of the cell-surface. MMP-2 cleaves a vast repertoire of 
substrates, including cytokines, growth factors, and receptors or binding 
factors but is primarily known for its cleaving properties of gelatin, and types 
IV, V, VII, IX and X collagen which makes MMP-2 a key player in degrading 
ECM.80 Within the catalytic domain of MMP-2 and MMP-9 a threefold 
sequence consisting of 58 amino acids exists of fibronectin type II that can 
bind to gelatin and collagen, which makes these MMPs capable of breaking 
down ECM substrates.81 
MMP-9 is secreted in monomeric form as zymogen (pro-MMP-9) predomi-
nantly from neutrophils and macrophages but the main source in the liver 
is thought to be the Kupffer cells and activation of pro-MMP-9 is amongst 
others mediated by the plasminogen activator/plasmin (PA/plasmin) 
system.82,83 Its expression level and activity is regulated through TIMP-1 and 
TIMP-3 but in vivo experiments have shown that MMP-9 activity can also be 
mediated by trypsin, chemotrypsin, cathepsin B and a variety of cytokines 
and growth factors including interleukins (IL-1), interferons, epidermal 
growth factor (EGF), nerve growth factor (NGF), basic fibroblast growth factor 
(FGF), vascular endothelial growth factor (VEGF), platelet derived growth 
(PDGF), tumor necrosis factor-alpha (TNF-α), transforming growth factor 
(TGF-β) and the extracellular matrix metalloproteinase inducer (EMMPRIN).84 
The active form of MMP-9 is able to digest decorin, elastin, fibrillin, laminin, 
gelatin (denatured collagen), and types IV, V, XI and XVI collagen and also 
activates growth factors like pro-TGF-β and pro-TNF-.85
Genetic variants and its functional implications
MMP-2 and MMP-9 have been associated with numerous diseases such 
as cancer, autoimmune disorders, coronary diseases and diseases, which 
involve degradation such as Alzheimer’s disease.86 The majority of MMP-2 
studies have focused on demonstrating an essential role in promoting cell 
invasiveness during tumor angiogenesis, arthritis, and atherogenesis, as well 
as tumor metastasis where levels of MMP-2 expression can be correlated 
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with tumor grade.87-89 Studies have shown that natural occurring variants 
of MMP-2 affect expression and thus might impact progression of patho-
physiological processes.90 Single nucleotide polymorphisms (SNP) in the 
promoter region of the MMP-2 gene have shown to affect gene regulation. 
The C -> T transition at –1306 of the MMP-2 promoter gene interrupts a Sp1 
binding site.91 Sp1 is a multifunctional protein that can directly interact with 
the basal transcription complex or alternatively function as a more general 
transcription factor and play an important role in directing tissue-specific 
expression.92 A variant that abolishes Sp1 binding, such as the MMP-2 −1306 
C/T polymorphism, has the potential to affect the level and specificity of gene 
transcription. One study showed that the reporter gene expression of the T 
allele in at -1306 was 0.71 lower than the C allele indicating less transcriptional 
activity.91 Several other SNPs in the promoter region have been discovered 
such as the –1575 G/A, –790 C/T and –735 C/T, but these are in complete 
linkage equilibrium with the –1306 polymorphism.93,94
MMP-9 expression is very low in most tissues but increases in response to 
local secretion of inflammatory cytokines and growth factors, most notably 
IL-1 and TNF-α, two highly potent inducers of MMP-9 gene activation.95 
MMP-9 has two promoter gene polymorphisms that have proven to be func-
tionally relevant, namely a (CA)n microsatellite polymorphism at position -90 
and a SNP polymorphism at position –1562.96 Other nonsynonomous SNPs 
have been described but these show no functionally relevant changes in 
levels or activity.97 With the –1562C/T polymorphism in the MMP-9 promoter 
there is a cytosine to thymidine transition at the polymorphic position –1562. 
Several studies have found that this MMP-9 C->T transition polymorphism 
exerts an allelic effect with higher transcriptional activity and higher functional 
MMP-9 serum activity and it has been associated with a higher risk of cardio-
vascular complications in HIV patients and severe coronary atherosclerosis.97,98
Matrix metalloproteinases in liver diseases
MMPs have also been implicated in numerous conditions involving the liver. 
For example, plasma MMP-2 levels were significantly higher in patients with 
hepatocellular carcinoma (HCC) and chronic liver diseases as compared to 
healthy controls and they were more elevated if the Child-Pugh class was 
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higher.99 In contrast, MMP-2 is very low in normal liver tissue.100,101 
These findings imply that MMP-2 may be actively involved in both development 
and progression of various liver diseases or that breakdown and excretion 
of MMP-2 is impaired in this situation. MMPs are also involved in OLT 
and studies have shown changed hepatic expression of various members 
of the MMP/TIMP family during cold preservation injury in both humans 
and rats.59 Hepatic ischemic injury leads to swelling of endothelial cells 
and Kupffer cell activation which in turns leads to secretion of particularly 
MMP-9 and to a lesser extent MMP-2 via HSC.102 During OLT MMP-2 plasma 
levels gradually decrease but MMP-9 plasma levels increase further from the 
anhepatic phase on until 30 minutes after reperfusion, and are related to the 
degree of tissue injury and thus seem to be involved in early IRI.103 Further-
more, after OLT, neutrophil infiltration and matrix degradation was observed, 
which is accompanied by an increase of MMP-9 in patients with rejection 
in the first week after OLT, while neither MMP2 level nor MMP9 level are 
related to peak ALT in the first week after OLT.103,104  Inhibitors of MMP have 
been studied in rat models mimicking IRI showing significant improvement 
in liver function and liver injury.105,106 In addition, several other studies have 
studied the relationship between MMP-2 and MMP-9 and the development 
of acute cellular rejection after OLT suggesting that MMPs might also be 
involved in immunological processes after OLT.107, 108
Outline of the studies described in this thesis
Liver transplantation for end-stage liver disease has become a standard treat-
ment for end-stage liver diseases with excellent long-term results. However, 
due to scarcity of DBD donor livers many centers have expanded their donor 
pool by using donor livers with “extended criteria” and DCD livers. Chapter 2 
elaborates on 20 years of OLT for chronic liver disease at the Leiden University 
Medical Center and describes long-term outcome after OLT using livers from 
both DBD and DCD. The analysis focuses on differences in patient survival 
and graft survival in the first and second decade, and after DBD- versus 
DCD-OLT. Causes of recipient mortality and changes in these parameters 
were studied. The evaluation not only includes indications for OLT but also 
parameters of the surgical technique such as intraoperative blood loss. 
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Influence of other aspects such as ischemia-reperfusion variables for both 
DBD and DCD donors is described. In addition indications for re-OLT were 
assessed for both decades. 
Biliary complications, especially NAS, frequently occur after OLT and development 
is often insidious. NAS development after OLT seems predominantly the 
result of IRI and probably subsequent collagen deposition surrounding the 
bile ducts. One of the commonly accepted markers of IRI is an increased 
serum level (peak) of alanine aminotransferase (ALT), which occurs within 
the first week post OLT. This elevation is more marked for DCD-OLT than 
for DBD-OLT and the evaluation of the relationship between peak ALT and 
the development of NAS after OLT is described in chapter 3. When there is 
a clinical suspicion of NAS after OLT, i.e., due to jaundice, fever or itching, 
invasive procedures such as endoscopic retrograde cholangiography (ERC) 
or percutaneous transhepatic cholangiography (PTC) or magnetic resonance 
cholangiography (MRC) are the choices of modality for confirmation. 
However, these are invasive and expensive and may have side effects. Most 
centers routinely assess patients in the outpatient clinic with serum liver 
enzymes and abdominal ultrasound (US). The study on the predictive value 
of US and serum liver enzymes assessments for detecting the development 
of NAS post OLT is described in chapter 4. 
MMP-2 and MMP-9 are the most potent degrading enzymes of type IV collagen; 
the main component of the extracellular matrix (ECM). Functional single 
nucleotide polymorphisms (SNPs) of MMP-2 and MMP-9, which affect their 
activity, may therefore play a role in development of biliary strictures and 
thereby potentially influence the incidence of NAS. Chapter 5 reports on the 
relationship between gene promoter polymorphisms of MMP-2 and MMP-9 
in both recipient and donor and the incidence of NAS after OLT. In primary 
sclerosing cholangitis (PSC) the hallmark of the disease, like in NAS, is 
stricture formation of the bile ducts. OLT is often indicated in PSC, which is 
considered a chronic inflammatory disease of the bile ducts. The results of a 
study on the relationship between gene promoter polymorphisms of MMP-2 
and MMP-9 and disease severity in patents with PSC, as defined by patient 
mortality or OLT, are described in chapter 6.
Gene polymorphisms might have the potential to be used as a marker to 
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evaluate chimerism after OLT. Chimerism in transplantation refers to the 
coexistence of two different populations of (genetically) distinct cells that 
originate from both donor and recipient. Chapter 7 describes the use of 
MMP-2 and MMP-9 donor/recipient gene promoter profiles in liver 
biopsies and in blood after OLT as a marker for chimerism. These findings 
were related to clinical outcomes such as acute cellular rejection. 
In chapter 8 the results of the different studies described in this thesis are 
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This study evaluates long-term outcomes after orthotopic liver transplantation 
(OLT) using both livers from donation after brain death (DBD) and cardiac 
death (DCD). Retrospective analysis was performed on 321 OLTs between 
September 1992 and March 2011, divided into two decades. Patient survival 
improved significantly in the second decade with 1, 5- and 10-year survival 
rates of 91%, 83% and 77%. Graft survival improved similarly. DCD-OLT 
showed non-significantly lower patient survival and significantly lower graft 
survival. Most frequent indications for re-OLT were hepatic artery thrombosis 
(HAT) and biliary non-anastomotic strictures (NAS) in both decades, the 
latter occurring more often after DCD-OLT. Death due to sepsis declined 
significantly in the second decade (5-year cumulative incidence (CI) 3.4% 
vs.15.6%, respectively; p<0.01) as well as death due to recurrent hepato-
cellular carcinoma (5-year CI 9.7% vs. 1.5%, p<0.01). Multivariate analysis 
revealed that intraoperative blood loss was independently associated with 
recipient mortality in the first decade (adjusted hazard ratio (aHR):1.07; 
p<0.01) as well as in the second decade in addition to MELD score >30 
(aHR: 5.03; p<0.01). In conclusion, long-term survival was significantly better 
in the second decade. DCD-OLT non-significantly impacted patient survival, 




Orthotopic liver transplantation (OLT) has evolved into a routine treatment 
for end stage liver disease, including acute and chronic liver failure, and 
for hepatocellular carcinoma (HCC) and metabolic disorders.1-3 Numerous 
advances in surgical techniques, organ preservation and post-transplant care 
have led to a significant increase in OLTs in many centers with improved 
5- and 10-year patient and graft survival.4 Recognition, treatment and 
prevention of long-term complications such as renal dysfunction due to 
immuno-suppression, recurrence of primary liver disease and rejection 
have improved markedly over these years.5,6 With an increasing number of 
patients eligible for liver transplantation many centers have accepted livers 
from extended criteria donors (ECD) in the last decade.7,8 Apart from these 
ECD livers, also livers from donation after cardiac death (DCD) are accepted, 
primarily due to shortage of livers from donation after brain death (DBD). 
Livers from DCD donors are more susceptible to complications, especially 
nonanastomotic biliary strictures (NAS).9 OLT with livers from DCD donors 
remains controversial in some countries and centers.10 NAS can occur in up 
to 25 – 30% after OLT with a liver from a DCD donor,11,12 which is probably 
related to an inevitable donor warm ischemia time (DWIT) between cardiac 
arrest and organ preservation.13 It remains increasingly important to identify 
risk factors for graft failure, retransplantation and recipient mortality for both 
DCD and DBD OLT. The current study analyzes long-term outcome and risk 
factors for complications and death during 20 years of OLT for chronic liver 
disease at a single center with livers from both DBD and DCD donors. 
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Patients and Methods
From September 1992 until March 2011 a total of 321 orthotopic liver trans-
plantations (OLT) for chronic liver disease (CLD) in 275 recipients were 
performed at the Leiden University Medical Center in the Netherlands. From 
2001, in addition to livers from DBD also livers from DCD donors were 
transplanted, using a strict national protocol that was approved by the Dutch 
Transplantation Society with informed consent and allocation according to 
the regular waiting list.  All first OLTs performed for CLD performed from 
September 1992 through 2001 were considered to be in the first 
decade (n=95), and from January 2002 through March 2011 was considered 
the second decade (n=180). Follow-up was until December 2011. All data 
were reviewed retrospectively. Patient, donor and surgical characteristics, 
as well as graft loss, causes of recipient mortality and retransplantations 
were obtained from our local medical digital database, medical, anesthetic 
and surgical patient charts and endoscopy reports.
Medical treatment before and after transplantation
All patients received immunosuppressive agents according to protocol: 
cyclosporine A or tacrolimus, prednisone during the first half-year. Patients 
with renal impairment received azathiopurine before 2001, or mycophenolate 
mofetil from 2001 onwards. Since 2001 basiliximab was given on day 0 and day 
4 post OLT. In addition, patients received 24 h of prophylactic antibiotics 
intravenously (gentamycine, cefuroxim, penicililin G and metronidazol) and 
3 weeks of oral selective bowel decontamination (polymyxin/neomycin, 
norfloxacin and amfotericin B) after OLT. In some cases sirolimus was used 
after 3 months in which case the calcineurin-inhibitor was lowered or 
discontinued. 
In both decades hepatitis B immunoglobulin (HBIG) was used for OLT in 
chronic HBV patients and in the second decade nucleoside/nucleotide analogs 
were added. Patients with HCC received adjuvant systemic doxorubicin 
before OLT or no treatment in the first decade, whereas in the second decade 
local tumor ablation while on the waiting list was performed radiofrequency 
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ablation (RFA), transarterial chemo-embolization (TACE), or percutaneous 
ethanol injection (PEI). In both decades HCC patients were under radiological
 surveillance while on the waiting list. This surveillance schedule in the 
second decade was more intensive with 3-monthly CT scans, compared to 
6-monthly ultrasound in the first decade. 
Donor surgery and ischemia times
Donor surgery was performed as described previously.14 In case of DCD 
donors a donor warm ischemia time (DWIT) was present, defined as the 
time between circulatory arrest and cold flushing with preservation fluid. 
Cold ischemia time (CIT) was defined as the time between this preservation 
flush and the removal of the liver from ice at the time of implantation in the 
receiving center. The recipient warm ischemia time (RWIT) was defined as 
the time from removal of the donor liver from ice, until reperfusion. 
Recipient surgery and routine follow-up
Lab MELD scores were assessed at the time of OLT to define severity of liver 
disease. OLT was mostly performed according to standard procedures with 
‘piggyback’cavo-caval anastomosis, porto-portal and hepatic artery to hepatic 
artery anastomosis. Only the first 2 years were with venovenous bypass and 
caval interposition. Blood loss during surgery was accurately measured. In 
some cases the hepatic artery was anastomosed to the aorta via an iliac 
conduit. A duct-to-duct biliary anastomosis over an 8-12 Ch stent was 
performed if possible. The biliary stent was removed endoscopically after 6 
weeks with ERCP or earlier as indicated. Further cholangiography was 
performed as indicated by cholestasis, ultrasound findings or cholangitis. 
Ultrasound (US) was performed routinely on day 0, 1 and 7, and subsequently 
at 3, 6, 12 months and yearly after OLT to detect hepatic artery thrombosis 
(HAT) and bile duct dilatation, which can be an indication for the presence 
of anastomotic or nonanastomotic strictures (NAS).15 NAS was defined as 
any stricture or irregularity occurring >1cm above the bile duct anastomosis 
requiring intervention. A CT scan was performed in the first week after OLT 
and in case of abdominal sepsis or suspicion of HAT. A liver biopsy was 
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performed at 6 months and yearly in case of hepatitis C or recurrent hepatitis 
B, while in the first decade additional protocol liver biopsies at 1 week, 1 year 
and yearly were performed in all patients.
Outcome
Primary endpoints were graft survival and patient survival. Graft survival was 
defined as time from initial transplant to graft loss, patient death, or last 
follow-up. Patient survival was considered from time of first transplantation 
to patient death or censored at last known follow-up. Secondary endpoints 
were causes of recipient mortality and indications for retransplantation. 
Statistical analyses
Statistical analysis was performed using SPSS 20. A Student t-test was used 
for normally distributed continuous variables, Mann-Whitney U test for 
non-equally distributed variables and Chi-square for categorical variables. 
Survival analysis was performed using the Kaplan-Meier method, risk factor 
analysis was performed using univariate and multivariate stepwise forward 
Cox regression. If a p-value of <0.15 was found in the univariate analysis the 
parameter was taken into account in the multivariate analysis. A p-value of 
<0.05 was considered significant. 
Ethical statement
This retrospective study was performed according to the guidelines of the 




Donor, surgical and recipient variables
A total of 275 first OLTs were performed in nearly 20 years. A total of 46 
retransplantations were performed of which 41 patients underwent a first 
retransplantation, 4 underwent a second retransplantation and one patient 
underwent a third retransplantation. Livers from DBD donors were used in 
278 transplantations and in 43 cases livers from a DCD donor were used. All 
DCD-OLTs, except one, were performed in the second decade. Median blood 
loss during surgery in the first decade was 6.8 L whereas median blood loss 
in the second decade was 3.5 L (p<0.01).  In line with the decline in blood 
loss, the amount of used blood products such as Fresh Frozen Plasma (FFP) 
and erythrocytes and other fluids administered during surgery was lower in 
the second decade.(Table 1a)
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Donor variables     
Type of donor n (%)    <0.01 
DBD 234 (85.1) 94 (98.9) 140 (77.8)  
DCD 41   (14.9) 1   (1.1) 40   (22.2)  
Donor gender n (%)    0.80 
Male 139 (50.5) 47 (49.5) 92 (51.1)  
Female 136 (49.5) 48 (50.5) 88 (48.9)  
Donor age (median, range) 46 (9 – 78) 41 (9 – 68) 46 (15 – 78) <0.01 
Donor blood type n (%)    0.65 
A 108 (39.9) 39 (41.1) 69 (38.3)  
B 32   (11.6) 10 (10.5) 22 (12.2)  
AB 124 (45.1) 44 (46.3) 80 (44.4)  
0 11   (4.0) 2   (2.1) 9   (5.0)  
Days on ventilation  
(median, range) 
1.5 (0 – 21) 1.3 (0 – 21) 1.5 (0 – 21) 0.38 
Surgical variables     
Retransplantation n (%) 41 (14.9) 19 (20.0) 22 (12.2)  
Blood loss (L) (median, IQR) 4.1 (2.4 – 6.9) 6.8 (3.8 – 11.7) 3.5 (2.2 – 5.8) <0.01 
FFP (L) (median, IQR) 2.4 (1.5 – 3.8) 3.6 (2.3 – 6.8) 2.1 (1.5 – 3.0) <0.01 
Packed RBCs (L) (median, IQR) 1.7 (1.0 – 2.8) 2.8 (1.8 – 3.6) 1.5 (0.8 – 2.3) <0.01 
 








Don r vari bles     
Type of don r n (%)    <0. 1 
DBD 234 (85.1) 94 (98.9) 140 (77.8)  
DCD 41   (14.9) 1   (1.1) 40   (22.2)  
Don r gender n (%)    0.80 
Male 139 (50.5) 47 (49.5) 92 (51.1)  
Female 136 (49.5) 48 (50.5) 88 (48.9)  
Don r age (median, range) 46 (9 – 78) 41 (9 – 68) 46 (15 – 78) <0. 1 
Don r blood type n (%)    0.65 
A 108 (39. ) 39 (41.1) 69 (38.3)  
B 32   (11.6) 10 (10.5) 22 (12.2)  
AB 124 (45.1) 44 (46.3) 80 (44. )  
0 11   (4.0) 2   (2.1) 9   (5.0)  
Days on ventilation  
(median, range) 
1.5 (0 – 21) 1.3 (0 – 21) 1.5 (0 – 21) 0.38 
Surgical vari bles     
Retransplantation  (%) 41 ( 4.9) 19 (20. ) 22 (12.2)  
Blood loss (L) (median, IQR) 4.1 (2.4 – 6.9) 6.8 (3.8 – 11.7) 3.5 (2.2 – 5.8) <0. 1 
FFP (L) (median, IQR) 2.4 (1.5 – 3.8) 3.6 (2.3 – 6.8) 2.1 ( .5 – 3.0) <0. 1 
Packed RBCs (L) (median, IQR) 1.7 (1.0 – 2.8) 2.8 (1.8 – 3.6) 1.5 (0.8 – 2.3) <0. 1 
 








Donor variables     
Type of d nor  (%)    <0. 1 
DBD 234 (85.1) 94 ( 8.9) 140 (77.8)  
DCD 41   ( 4.9) 1   ( . ) 40   (22. )  
Donor gend r n (%)    0.80 
Male 139 (50.5) 47 ( 9.5) 92 (51. )  
Female 136 (49.5) 48 (50.5) 88 (4 .9)  
Donor age (median, range) 46 (9 – 78) 41 (9 – 68) 46 (15 – 78) <0. 1 
Donor blo d type n (%)    0.65 
A 108 (39. ) 39 (41. ) 69 (38.3)  
B 32   (11.6) 10 ( .5) 22 (1 . )  
AB 124 (45.1) 4  ( 6.3) 80 (4 . )  
0 11   (4.0) 2   ( .1) 9   (5.0)  
Days on ve tilation  
(median, range) 
1.5 (0 – 21) 1.3 (0 – 21) 1.5 (0 – 21) 0.38 
Surgical variables     
Retransplanta ion  (%) 41 (14.9) 19 (20. ) 22 (1 . )  
Blo d l ss (L) (median, IQR) 4.1 (2.4 – 6.9) 6.8 (3.8 – 11.7) 3.5 (2.  – 5.8) <0. 1 
FFP (L) (median, IQR) 2.4 (1.5 – 3.8) 3.6 (2.3 – 6.8) 2.1 (1 5 – 3.0) <0. 1 
Packed RBCs (L) (median, IQR) 1.7 ( .0 – 2.8) 2.8 (1.  – 3.6) 1.5 (0.8 – 2.3) <0. 1 
 
Table 1a. Donor and surgical variables at first transplantation. 
DBD: donation after brain death, DCD: donation after cardiac death, FFP: Fresh Frozen 
Plasma, RBC: (packed) Red Blood Cells, L: Liters, IQR: Interquartile range
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Of the recipients 69.1% were male. Median recipient age at OLT was higher 
in the second decade compared to the first decade (53 vs. 49 years, 
respectively; p<0.01). The most frequent indication for OLT was HCC 
(23.0%) followed by alcoholic liver disease (ALD) (18.2%). HCC was the 
most common indication for OLT in both decades with a non-significant 
increase in the second decade (16.8% vs. 26.1%, p=0.10). Other indications 
for liver transplantation also had not changed significantly in the second 
decade. Median MELD score was significantly higher in the second decade 
compared to the first decade (19 versus 14 respectively; Mann Whitney U 
p<0.01) (Table 1b)
Ischemia-reperfusion variables
Ischemia-reperfusion (IR) variables were analyzed for DBD and DCD donors 
separately. DBD donors had a median CIT of 630 minutes and a median 
RWIT of 35 minutes for both decades combined. In the first decade DBD 
donors had a significantly longer median CIT of 720 minutes compared to 
the second decade which showed a median CIT of 600 minutes (p<0.01). 
This was also the case for the RWIT (median 36 min vs. 34 min, respectively; 
p<0.01). Median DWIT in case of livers from DCD donors was 17 minutes. 
CIT for OLT with a DCD donor was significantly shorter compared to OLT 
with a DBD donor (DBD: 600 min vs. DCD 486 min; p<0.01). No difference 
was seen for the RWIT in these groups with medians of 34 minutes for DBD-
OLT and 33 minutes for DCD-OLT (p= 0.83), respectively. First week peak AST 
and peak ALT were significantly higher for DCD donors than for DBD donors in 
the second decade. A list of ischemia-related variables is shown in table 2. 
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Gender n (%)    0.68 
Male 190 (69.1) 64 (67.4) 126 (70.0)  
Female 85   (30.9) 31 (32.6) 54   (30.0)  
Recipient age (median, range) 52 (17 – 70) 49 (19 – 68) 53 (17 – 70) <0.01 
MELD score (median, range) 16 (6 – 40) 14 (6 – 40) 19 (6 – 40) <0.01 
Urgency    0.25 
T 253 (92.0) 84 (88.4) 169 (93.9)  
H 22   (18.0) 11 (11.6) 11   (6.1)  
Indications for 1st OLT n (%)     
ALD 50 (18.2) 14 (14.7) 36 (20.0) 0.33 
HCC  63 (23.0) 16 (16.8) 47 (26.1) 0.10 
HCV 33 (12.0) 12 (12.6) 21 (11.7) 0.85 
PSC 32 (11.6) 13 (13.7) 19 (10.6) 0.44 
HBV 19 (6.9) 10 (10.5) 9   (5.0) 0.13 
Metabolic disorders 10 (3.6) 1   (1.1) 9   (5.0) 0.17 
PBC 12 (4.4) 6   (6.3) 6   (3.3) 0.35 
AIH 10 (3.6) 5   (5.3) 5   (2.8) 0.32 
Other 46 (16.7) 18 (18.9) 28 (15.6) 0.50 
 









Gender n (%)    0.68 
Male 190 (69.1) 64 (67.4) 126 (70.0)  
Female 85  (30.9) 31 (32.6) 54  (30.0)  
Recipient age (median, range) 52 (17 – 70) 49 (19 – 68) 53 (17 – 70) <0.01 
MELD score (median, range) 16 (6 – 40) 14 (6 – 40) 19 (6 – 40) <0.01 
Urgency    0.25 
T 253 (92.0) 84 (8 .4) 169 (93.9)  
H 2   (18.0) 11 (11.6) 11  (6.1)  
Indications for 1st OLT n (%)     
ALD 50 (18.2) 14 (14.7) 36 (20.0) 0.3  
HC   63 (23.0) 16 (16.8) 47 (26.1) 0.10 
HCV 3  (12.0) 12 (12.6) 21 (11.7) 0.85 
PSC 32 (11.6) 13 (13.7) 19 (10.6) 0.4  
HBV 19 (6.9) 10 (10.5) 9  (5.0) 0.13 
Metabolic disorders 10 (3.6) 1  (1. ) 9  (5.0) 0.17 
PBC 12 (4.4) 6  (6.3) 6  (3. ) 0.35 
AIH 10 (3.6) 5  (5.3) 5  (2.8) 0.32 
Other 46 (16.7) 18 (18.9) 28 (15.6) 0.50 
 









Gend r n (%)    0.68 
Male 190 (69.1) 64 ( 7.4) 126 (70.0)  
Female 85   (30.9) 31 (32.6) 54   (30.0)  
Recipient age (median, range) 52 (17 – 0) 49 (1 – 68) 53 (17 – 0) <0.01 
MELD score (median, range) 16 (  – 40) 14 (6 – 40) 19 (6 – 40) <0.01 
Urgency    0.25 
T 253 (92.0) 84 ( 8.4) 169 ( 3.9)  
H 22   (18.0) 11 ( 1.6) 11   (6.1)  
Indications for 1st OLT n (%)     
ALD 50 (18.2) 14 ( .7) 36 (20.0) 0.33 
HCC  63 (2 .0) 16 ( .8) 47 (26.1) 0.10 
HCV 33 (12.0) 12 ( .6) 21 ( 1.7) 0.85 
PSC 32 (11.6) 13 (13.7) 19 ( 0.6) 0.44 
HBV 19 (6.9) 10 ( .5) 9   (5.0) 0.13 
Metabolic disorders 10 (3.6) 1   ( .1) 9   (5.0) 0.17 
PBC 12 (4.4) 6   ( .3) 6   (3.3) 0.35 
AIH 10 (3.6) 5   ( .3) 5   (2.8) 0.32 
Other 46 (1 .7) 18 ( .9) 28 (15.6) 0.50 
 
Table 1b. Baseline recipient variables at first transplantation.
Donorvariables     








CIT (min) 720 (540 – 902) 600   (492 – 695) <0.01 486 (402 – 573) <0.01 
RWIT (min) 36 (33 – 48) 34   (30 – 40) <0.01 33  (30 – 38) 0.83 
1st week peak AST (IU/L)  716 (434 – 1329) 1004   (324 – 1105) 0.04 2259  (1134 –  3903)
 
<0.01 
1st week peak ALT (IU/L)  396 (225 – 804) 542  (540 – 1938) 0.04 1525 (680 – 2818) <0.01 
DWIT (min)    17  (13 – 21) - 
 
)
Table 2. Ischemia-reperfusion variables. 
*Mann-Whitney U test; ‡Decade analysis encompasses DBD-OLTs; ¶DCD second decade 
vs. DBD second decade
MELD: Model for End Stage Liver Disease, T: Transplantable, H: High Urgency, ALD: Alcoholic 
Liver Disease, HCC: Hepatocellular Carcinoma, HCV: Hepatitis C Virus, PSC: Primary Sclerosing 
Cholangitis, HBV: Hepatitis B Virus, PBC: Primary Biliary Cirrhosis, AIH: Autoimmune Hepatitis 
DBD: Donation after brain Death, DCD: Donation after Cardiac Death, CIT: Cold Ischemia 
Time, RWIT: Recipient Warm Ischemia Time, DWIT: Donor Warm Ischemia Time, 




Patient and graft survival
One, 5- and 10-year patient survival after OLT in the first decade was 78%, 
63% and 53%, respectively. The second decade showed significant improvement 
in patient survival rates with 1, 5- and 10-year patient survival rates of 91%, 
83% and 77% (log rank p<0.01) (Figure 1a). Graft survival rates also showed 
a similar improvement in the second decade compared to the first decade 
(first decade 71%, 54%, 42%, second decade 82%, 74%, 67%, respectively; 
log rank p<0.01) (Figure 1b). Overall patient survival in the second decade 
at 1, 5 and 10 years after OLT was not significantly different for OLT with 
DCD donors compared to DBD donors (DCD: 90.0%, 75.7%, 69.4% vs. 
DBD: 92.1%, 85.6%, 79.2%, p=0.27) (supplemental figure 1a). One, 5 and 
10-year graft survival in case of DCD-OLT in the second decade was worse as 
compared to DBD-OLT (DBD: 85.6%, 78.1%, 72.6% vs. DCD: 75.0%, 54.7%, 
48.6%; p=0.01) (supplemental figure 1b). In the second decade patient 
survival for patients with a pre-OLT MELD score of >30 had worse survival 
with 1 and 5 year survival rates of 61.5% and 49.2% compared to survival 
rates at 1 and 5 year of 95.0% and 88.4% for patients with a MELD score ≤30 
(p<0.01, supplemental figure 2a). Patients with a MELD score >30 (n=4) in the 
first decade did not show worse survival compared to patients with a MELD 
score ≤30. In addition, a MELD score between 20 and 30 did not have an 
impact on patient survival. (Data not shown)
Retransplantations
A total of 46 retransplantations were performed, of which 41 first retrans-
plantations. HAT and NAS were the most frequent indications for retrans-
plantation (Table 3). One year cumulative incidence (CI) of retransplantation 
due to HAT was 7.2% in the first decade compared to 4.1% in the second 
decade (p=0.35). Five years CI of retransplantation due to NAS in DBD 
donors was in both decades not significantly different (first decade 6.2% vs. 
second decade 4.7%, respectively; p=0.75). However, in the second decade 
5-year CI of retransplantation due to NAS for OLT with a DCD donor was 14.8% 
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Figure 2
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Patient (A) and graft (B) survival improved significantly in the second decade compared to the 
first decade. 
A: Retransplantations due to HAT showed a nonsignificant decline in the second decade 
compared to the first decade (4.1% vs. 7.2%, respectively, p=0.35). 
B: Retransplantations due to NAS occurred significantly more often after DCD-OLT than 




 First decade  Second decade  
  
Years after 1st transplantation 
  
Years after 1st transplantation 
 
 <1 >1 – 5 >5 Total 
(First) 
 <1 >1 – 5 >5 Total 
(Second) 
Total 
Pts at risk 95 62 44 95  180 146 132 180 275 
Indication for 1st 
retransplantation 
n (%) 
          
HAT 6 (6.3)  1 (1.3) 7  (7.4)  7 (3.9) 1 (0.7)  8 (4.4) 15 (5.4) 
PNF 2 (2.1)   2  (2.1)  2 (1.1)   2 (1.1) 4 (1.5) 
NAS 2 (2.1) 2 (2.4)   4  (4.2)  7 (3.9) 3 (2.1)  10 (5.6) 14 (5.1) 
Venous 
occlusions 
1 (1.1)  1 (1.3) 2  (2.1)      2 (1.0) 
Recurrence HCV      2 (1.1)   2 (1.1) 2 (1.0) 
Rejection 1 (1.1) 1 (1.2) 2 (2.5) 4  (4.2)      4 (1.5) 
Total 12 (12.6) 3 (3.6) 4 (5.0) 19 (20)  18 (8.9) 4 (2.7) 0 (0) 22 (12.2) 41 (14.9) 
Table 3. Causes of retransplantation after the first transplantation. HAT and NAS are the most 
frequent causes of retransplantation in both decades.
Table 4. Causes of recipient mortality after OLT in both decades. 
 
 First decade Second decade  
  
Years after 1st  transplantation 
  
Years after 1st transplantation 
 
 <1 >1 – 5 >5 Total (First)  <1 >1 – 5 >5 Total 
(Second) 
Total 
Pts at risk 95 74 59 95  180 164 154 180 275 
Causes of recipient 
mortality n (%) 
          
Liver failure 1 (1.1)  1 (1.7) 2 (2.1)  1 (0.6) 1 (0.6)  2 (1.1) 4 (1.5) 
Respiratory   1 (1.7) 1 (1.1)   1 (0.6)  1 (0.6) 2 (0.7) 
Infection 10 (10.5) 3 (4.1) 4 (6.8) 17 (17.9)  6 (3.3)  1 (0.6) 7 (3.9) 24 (8.7) 
Cardiovascular 5 (5.3)  2 (3.4) 7 (7.4)  2 (1.1) 3 (1.8) 2 (1.3) 7 (3.9) 14 (5.1) 
Carcinoma (other than 
liver etiology) 
 2 (2.7) 2 (3.4) 4 (4.2)  2 (1.1) 2 (1.2)  4 (2.2) 8 (2.9) 
Livernecrosis/bleeding 3 (3.2)  1 (1.7) 4 (4.2)  2 (1.1)   2 (1.1) 6 (2.2) 
Recurrence primary 
disease 
          
 HCC  1 (1.1) 6 (8.1)  7 (7.4)  2 (1.2)   2 (1.1) 9 (3.3) 
 Other  1 (1.1) 4 (5.4) 2 (3.4) 7 (7.4)      7 (2.5) 
GVHD      2 (1.1)   2 (1.1) 2 (0.7) 
Other      1 (0.6) 1 (0.6)  2 (1.1) 2 (0.7) 
Total 21 (22.1) 15 (20.3) 13 (22) 49 (51.6)  18 (10) 8 (4.8) 3 (1.9) 29 (16.1) 78 (28.4) 
HAT: Hepatic Artery Thrombosis, PNF: Primary Nonfunction, NAS: Nonanastomotic Strictures. 
PNF was defined as non-life sustaining function of the liver requiring retransplantation or 
leading to death within seven days after liver transplantation.
Infection was the main cause of recipient mortality in both decades. Other causes of recurrence 
primary disease included cholangiocarcinoma, alcoholic liver disease and recurrence of multiple 
endocrine neoplasia (MEN) syndrome. HCC: Hepatocellular Carcinoma, GVHD: Graft-versus-
Host-Disease
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Causes of recipient mortality
Causes of recipient mortality in both decades are given in table 4. Infection 
was the most prevalent cause of recipient mortality in both decades. 
Five-year CI of death due to infection post-OLT declined significantly in the 
second decade compared to the first decade (first decade 15.6% vs. second 
decade 3.4%; p<0.01) (Figure 3a). Five-year CI of death due to recurrence of 
HCC declined from 9.7% in the first decade to 1.4% in the second decade 
(p<0.01). (Figure 3b) Death due to cardiovascular events remained stable in 
the past two decades (5-year CI in first decade 4.3% vs. 3% in the second 
decade, respectively; p=0.34) (figure 3c). The most frequent cause of mortality 
in recipients with a pre-OLT MELD >30 in the second decade (n=15) was 
infection (n=3); In this group one-year CI of death due to infection was 20% 
compared to 2.0% for patients with a pre-OLT MELD score ≤30 (p<0.01; 
supplemental figure 2b).
Univariate and multivariate analysis
Cox regression analysis of pre-operative and operative risk factors with 
mortality as outcome was performed for each decade separately. In the first 
decade blood loss during surgery, recipient age and RWIT were independent 
risk factors for recipient mortality in the univariate analysis and thus were 
taken into account in the multivariate analysis. Multivariate analysis showed 
blood loss during surgery as an independent risk factor for recipient mortality 
in the first decade (aHR=1.05, p=.0.02). In the second decade blood loss 
during surgery (aHR= 1.10; p=0.01) as well as MELD score >30 (aHR=5.03; 
p<0.01) were significant risk factors for recipient mortality. (Table 5a and 5b)
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Figure 3
A      B
C
Chapter 2
A: Five-year cumulative incidence rates of death due to infection post-OLT was 15.6% in 
the first decade but declined significantly to 3.4% in the second decade. (p=0.01). 
B: Recipient mortality caused by recurrent HCC occurred more often in the first decade 
compared to the second decade (9.7% vs. 1.4%, respectively; p<0.01)
C: Cardiovascular events as cause of recipient mortality remained stable in the second 
decade. (first decade: 4.3% vs. second decade: 3%, respectively; p=0.34)
45
Improved patient survival and its determinants
 
    Univariate analysis  Multivariate analysis 
Variables  n (%)  HR (95% CI) p-value  HR (95% CI) p-value 
Year of LT (years) Continuous  0.95 (0.85 – 1.06)  0.15   
Donor gender        
 Male  47 (49.5) 1.22 (0.70 – 2.15)  0.48   
                                     Female Reference 48 (50.5) 1 (reference)    
Donor age (years) Continuous  0.99 (0.97 – 1.01)  0.26   
Recipient gender        
 Male  64 (67.4) 1.35 (0.73 – 2.52) 0.34   
                                     Female Reference 31(32.6) 1 (reference)    
Recipient age (years) Continuous  1.04 (1.01 – 1.07)    0.02 0.97 (0.94 – 0.99) 0.06 
Blood loss during  
surgery (L) 
Continuous  1.06 (1.01 – 1.10)     0.01 1.05 (0.99 – 1.08)    0.02
CIT (min) Continuous  1.00 (0.99 – 1.01)  0.48   
RWIT (min) Continuous  1.02 (1.00 – 1.04)  0.02 1.02 (0.99 – 1.05) 0.14 
MELD score        
 >30  4 (4.2) 1.14 (0.28 – 4.72)  0.85   
 30 Reference 91(95.8) 1 (reference)    
Table 5a. Multivariate analysis for risk factors for recipient mortality in the first decade. 
Table 5b. Multivariate analysis for risk factors of recipient mortality in the second decade. 
 





 HR (95% CI)
 




Year of LT (years) Continuous  0.92 (0.78 – 1.08) 0.29   
Donor gender        
 Male  140 (77.8) 1.47 (0.70 – 3.07) 0.31   
                                     Female Reference 40 (22.2) 1 (reference)    
Donor age (years) Continuous  1.00 (0.97 – 1.03) 0.99   
Recipient gender        
 Male  126 (70.0) 1.16 (0.51 – 2.61) 0.73   
                                     Female Reference 54 (30.0) 1 (reference)    
Recipient age (years) Continuous  1.01 (0.98 – 1.05) 0.53   
Blood loss during  
surgery (L) 
Continuous  1.10 (1.01 – 1.19)   0.02 1.10 (1.02 – 1.19)     0.01
CIT (min) Continuous  1.00 (1.00 – 1.00) 0.26   
RWIT (min) Continuous  1.03 (0.99 – 1.07) 0.18   
MELD score        




5.03 (1.96 – 12.89) <0.01 
 30 Reference 15 (8.3) 1 (reference) 
   
Blood loss during surgery remained a significant risk factor for recipient mortality (HR: 1.05; p=0.02)
CIT: Cold Ischemic Time, RWIT: Recipient Warm Ischemic Time, MELD: Model for End Stage 
Liver Disease
Blood loss during surgery and MELD score >30 were independent risk factors for recipient 
mortality after OLT. (aHR blood loss = 1.10, p=0.01, aHR MELD score>30= 5.03, p<0.01)




Many lessons can be learned from this long-term single center study. In the 
second decade of liver transplantation at our institute 1, 5 and 10-year patient 
survival rates improved significantly as compared to the first decade (91%, 
83% and 77% as compared to 78%, 65% and 53%, respectively). The indications 
for OLT had not changed in the second decade although a nonsignificant 
increase in OLT due to HCC was observed, which is in line with indications 
for OLT across Europe16,17. Due to a shortage of donor livers many centers 
have expanded their criteria for acceptance of potential donor livers.18,19 
Donor age was significantly higher in the second decade as compared to the 
first decade. Also, the usage of livers from DCD donors was introduced in 
2001 in a national protocol with allocation according to the waiting list.7 Only 
livers from Maastricht category 3 donors were transplanted, and about 25% 
of DCD donors were excluded for liver donation. 20,21 Despite the strict DCD 
protocol, this leads to a nonsignificant difference in recipient mortality for 
OLT with DCD donors compared to DBD OLT. This is in line with our 
previously published national 3-year data but in the present study, significantly 
lower graft survival rates for DCD OLT were observerd compared to DBD.22,23 
Donor variables such as CIT and RWIT were shorter in the second decade for 
DBD donors, and also peak AST and peak ALT were significantly lower in the 
second decade for DBD donors. In contrast, despite lower CIT for OLT with 
livers from DCD donors, peaks of AST and ALT remain significantly higher 
in DCD OLT compared to DBD OLT indicating more severe ischemia-
reperfusion injury (IRI) in DCD OLT.  DCD donors are more prone to 
ischemia damage probably because they are exposed to an additional donor 
warm ischemic time (DWIT).24 Possibly, during DWIT microthrombi may 
develop in the peribiliary plexus and sinusoids, resulting in more IRI as 
indicated by higher peaks AST and ALT and probably more NAS in DCD OLT 
than in DBD OLT despite shorter CIT.25,26 Better preservation techniques are 
required in order to improve results of DCD OLT.  
In line with improved patient survival, graft survival has also improved in the 
second decade. With improved immunosuppressive medication such as 
tacrolimus, therapy-resistant and chronic rejections have virtually disappeared, 
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illustrated by the fact that no retransplantations for chronic rejection had to be 
carried out in the second decade. 
However, the retransplantation rate has remained stable in the second 
decade as compared to the first with HAT and NAS being the most frequent 
indications for retransplantation in both decades. With the introduction of 
DCD donors retransplantations due to NAS were more frequent than for 
DBD donors (5-year CI DCD 13.4% vs. DBD 4.3%; p=0.01), and this was 
responsible for the significantly worse graft survival and nonsignificantly lower 
patient survival compared to OLT with a DBD donor. As recently shown, the 
higher morbidity rate leads to higher cost per life year for OLT with a DCD 
donor compared to a DBD donor.27
Death due to infection post-OLT patient was the most prevalent cause of 
death in both decades. However, the cumulative incidence of death due to 
infection declined from 15.6% in the first decade to 3.4% in the next decade. 
This suggests that, although some risk factors for post-OLT infection are 
not amenable to intervention, such as polymorphisms in innate immunity, 
other interventions have likely resulted in reducing post-OLT infections.28,29 
For instance, improved tailoring of immunosuppression therapy has led to 
avoidance of overdosing of immunosuppressive therapy, which probably also 
resulted in a reduction of mortality due to sepsis.30-32 
Additionally, the reduction of blood loss during surgery in the second 
decade may have contributed to the reduced infection rate since it has been 
shown that intra-operative blood loss during OLT is associated with post-OLT 
mortality due to septicemia, probably partially related to a less immuno-
suppressed state and less reoperation.33-36. Moreover, blood losss during 
surgery reflects surgical performance and is known to impact patient 
survival.33,37-39 The current study showed that in both decades blood loss 
during surgery to be an independent risk factor for recipient mortality.
The second most prevalent cause of patient mortality after OLT was recurrence 
of hepatocellular carcinoma (HCC). A significant decrease in mortality due 
to recurrence of HCC was noticed in the second decade despite less stringent 
transplantation criteria in that decade (including down staging to within 
Milan criteria) at our institute.40 The reduced mortality can most likely be 
attributed to the introduction of adjuvant treatment by local tumor 
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ablation before OLT with radiofrequency ablation, transarterial chemo-
embolization and percutaneous ethanol injection combined with radiological 
surveillance.41,42 Non-hepatic malignancies as cause of recipient mortality 
showed a non-significant decrease in the second decade compared to the 
first decade which might be due to less immunosuppression. Remarkably, 
patient mortality due to cardiovascular events remained stable in the second 
decade as compared to the first decade. More awareness and better management 
of risk factors like obesity, smoking, hypertension, diabetes and hyperlipidemia 
are needed before and after OLT to diminish long-term cardiovascular morbidity 
and mortality.43
A MELD score >30 was an independent predictor for worse patient survival 
compared to patients with a MELD score <30 in the group of patients that 
were transplanted in the second decade. This is in line with some previous 
reports indicating worse post-transplant survival with pre-OLT MELD scores 
of >30, although other studies do not report an impact of MELD score on 
post-transplantation mortality.44,45 The fact that MELD score was not an 
independent risk factor for survival in the first decade is probably due to 
small numbers. This is probably due to the fact that recipients with very high 
MELD scores were usually denied OLT in the first decade. In the first two 
weeks after OLT, infection was the most frequent cause of recipient mortality 
in recipients with MELD>30 and the increased mortality during this period 
was responsible for the difference in patient survival compared to recipients 
with lower MELD scores. This increased susceptibility for infections is in line 
with a previous study that reported intra-abdominal bacterial infections in 
42% of patients with a pre-OLT MELD score of >40.46 
In conclusion, a marked improvement in not only short-term but also 
long-term patient survival after OLT has been achieved over the last 20 years 
in our center. The main reasons for better survival were less death due to 
post LT infection, less recurrence of HCC and better surgical and anesthetic 
techniques as reflected by less blood loss during surgery. Based on the risk 
factors for mortality, further improvements in treatment protocols by reducing 
blood loss during surgery and better selection and treatment of recipients 
especially in the case of high MELD scores may result in further improvements 
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in patient survival rates. Other aspects, such as further reduction in immuno-
suppression in tolerant recipients, improved prevention and treatment of 
sepsis and especially the prevention of NAS in OLT with DCD donors along 
with early indentification and treatment of cardiovascular risk factors may 
also contribute to an even better long-term patient survival. 
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A: MELD score >30 impacted patient significantly after OLT
B: Patients with a pre-OLT MELD score >30 died more often due to infection compared to 
patients with a pre-OLT MELD score ≤30 
A: Patient survival was nonsignificantly lower after DCD-OLT compared to DBD-OLT
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Scarcity of donor livers for orthotopic liver transplantation (OLT) has led to the 
use of livers from donation after cardiac death (DCD). DCD livers are known 
to have more ischemia-reperfusion injury (IRI) reflected by high peak alanine 
aminotransferase (ALT) within the first week post-OLT and carry a high risk 
of biliary nonanastomotic strictures (NAS). It is unknown whether an 
association exists between peak ALT and the risk to develop NAS in DCD and 
brain death donated OLT (DBD). We retrospectively reviewed two cohorts of 
OLT performed with livers from DBD (n=401) or DCD (n=97) from two liver 
transplantation centers between 2000 and 2012. Optimal cut-off value of peak 
ALT for development of NAS post DCD-OLT was established at ≥1300 IU/L. In 
the combined cohorts, four-year cumulative incidence of NAS after DCD-OLT 
was 51.4.1% in patients  with high ALT peak post-OLT, compared to 11.6% in 
patients with low ALT peak. (p<0.001). The independent ohorts showed similar 
results. No such relation was observed post DBD-OLT. Multivariate analysis 
revealed peak ALT ≥1300 IU/L to be independently associated with develop-
ment of NAS post DCD-OLT (adjusted hazard ratio (aHR) = 4.96 confidence 
interval (CI) (1.73 – 14.24)) adjusted for cold ischemic time (CIT), primary 
sclerosing cholangitis (PSC) and donor age. Peak ALT is a good clinical marker 
for the risk to develop NAS post DCD-OLT and can be used to distinguish 




Orthotopic liver transplantation (OLT) has evolved into routine treatment 
for advanced liver disease with excellent short and long-term survival.1,2 An 
increasing number of patients eligible for liver transplantation and a decreasing 
number of donors after brain death (DBD) have led to the expansion of 
criteria for acceptance of potential liver grafts in the last decade.3,4 OLT with 
livers from donation after cardiac death (DCD) has become common.  
However, OLT with a liver from a DCD donor carries a high risk for development 
of nonanastomotic biliary strictures (NAS).5 NAS can occur in up to 25 – 45 
% after OLT with a DCD donor and is considered a major cause of morbidity 
and reduced graft survival.6-8 Early recognition of an increased risk to develop 
NAS may be valuable to provide timely intervention. Several ischemic 
parameters have been evaluated such as cold ischemic time (CIT), recipient 
warm ischemic time (RWIT) and donor warm ischemia time (DWIT) as 
potential predictors of NAS in DCD and DBD donors, but clinical use of 
these parameters for predicting NAS has remained controversial.9,10 Livers 
retrieved from DCD have an inevitable DWIT between cardiac arrest and 
organ preservation, which may lead to a higher peak alanine aminotransferase 
(ALT) and asparate aminotransferase (AST) in the first week after OLT.11 It is 
likely that the higher incidence of NAS after OLT with DCD livers is largely 
the results of the additional ischemia-reperfusion injury (IRI) due to the 
DWIT.12-14 We therefore hypothesized that a relation may exist between first 
week post-OLT peak aminotransferases and the risk for NAS development, 
especially after DCD OLT. This hypothesis was examined in two independent 
centers for OLT with DBD and DCD livers.
Peak alanine aminotransferase and development of NAS
58
Methods and Materials
A total of 498 first consecutive OLTs for chronic liver diseases were included 
from two liver transplantation centers with a minimum follow-up of 7 days. 
From the Leiden University Medical Center (LUMC; cohort A) a total of 176 
OLTs could be included in the time-period of October 2001 until March 2011 
next to 322 OLTs from the University Medical Center Groningen (UMCG: 
cohort B) performed in the time-period of July 2000 until June 2012. Patient 
follow-up for both groups was until July 2012. This included OLTs using livers 
from DBD as well as– from 2001 on within a strict protocol – DCD donors. 
Donor surgery
In case of DCD donors a donor warm ischemia time (DWIT) was measured, 
defined as the time between circulatory arrest and cold flush with preservation 
fluid in the donor. Cold ischemia time (CIT) was defined as the time between 
cold flush with preservation fluid in the donor and removal of the liver from 
ice during the transplantation procedure. The recipient warm ischemia time 
(RWIT) was defined as the time of removal of the donor liver from ice until 
reperfusion of the donor liver in the recipient. 
Recipient surgery and routine follow-up 
In both centers OLT with standard technique of ‘piggy-back’cavo-caval anas-
tomosis, porto-portal and hepatic artery to hepatic artery anastomosis was 
perfomed in most recipients. In some cases the hepatic artery was anastomosed 
to the aorta via an iliac conduit. A duct-to-duct biliary anastomosis -over a 8-12 
Ch stent in the LUMC, no stent in UMCG- was performed if possible. 
The biliary stent was removed endoscopically with endoscopic retrograde 
cholangiography (ERC) at 6 weeks or earlier as indicated. In the first year blood 
liver biochemistry was performed daily in the first two weeks, weekly in the 
following two weeks, monthly thereafter in the first year, and then every three 
months. In both cohorts, ultrasound (US) was performed routinely on day 
0, 1 and 7, and subsequently at 3, 6, 12 months and yearly after OLT. ERC or 
magnetic resonance cholangiography (MRC) and other imaging studies were 
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performed when indicated. A liver biopsy was performed per protocol at 6 
months in the LUMC, and further as indicated in both centers. In both cohorts 
pre-OLT baseline parameters, including laboratory model for end-stage liver 
disease (MELD) scores were evaluated (n=449). Due to missing variables 49 
MELD scores could not be computed (cohort A n=8, cohort B n=41).  
IRI and NAS
The degree of hepatocellular injury was evaluated by postoperative serum levels 
of alanine aminotransferase (ALT). Serum ALT was determined during the 7 
consecutive days after OLT and measured by routine biochemical methods. 
The highest level of peak ALT was evaluated individually and reflected IRI. 
NAS was considered as any treated stricture or irregularity of the intra- or 
extrahepatic bile ducts occurring at least 1 cm above the anastomosis post-
OLT. Analysis of NAS development was performed in both the combined 
cohort as well the individual cohorts. Nonanastomotic biliary strictures that 
did not require intervention and anastomotic strictures were not included 
in the definition of NAS for the current study.  In addition, cases of hepatic 
artery thrombosis (HAT) occurring after OLT were also excluded.  
Statistical analyses
Statistical analysis was performed using SPSS 20.0. A Student t-test was used 
for normally distributed continuous variables, Mann-Whitney U test was used 
for variables that were not normally distributed, and Chi-square test was done 
for categorical variables. The optimal cutoff-value for peak ALT is defined as the 
point with the most significant split for association with NAS or no NAS as 
determined by log-rank test. Using the calculated cut-off value, a peak ALT 
below this value was considered as mild IRI whereas a peak ALT above this 
value was considered as severe IRI. Cumulative incidence curves were 
established using one minus survival incidence rates according to the Kaplan-
Meier method and risk factor analysis was performed using univariate and 
multivariate stepwise forward Cox regression analysis. If a p-value of <0.20 was 
found in the univariate analysis the parameter was taken into account in the 
multivariate analysis. A p-value of <0.05 was considered statistically significant.
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Results
Cohort A consisted of 176 OLTs, with 138 DBD donor livers and 38 DCD 
donor livers. Cohort B consisted of 322 OLTs with 263 DBD donor livers and 
59 DCD donor livers.  Median follow-up in cohort A from OLT until develop-
ment of NAS was 5.0 months (range 1 – 84) and median follow-up in cohort 
B from OLT until development of NAS was 4.9 months (range 0.3 – 57). 
Donor and surgical variables
Median donor age for DCD donors was significantly lower compared to DBD 
donors in cohort A (45 vs. 51, respectively; p=0.002) as well in cohort B (42 
vs. 50, respectively; p=0.003). Cold ischemic time (CIT) was significantly 
shorter for DCD donors than DBD donors in cohort A (DBD 598 min vs. 
DCD 498 min; p<0.01) and a similar trend was seen in cohort B (DBD 468 
min vs. DCD 451 min; p=0.110). Recipient warm ischemia time (RWIT) was 
not significantly different for both types of donors in both cohorts. Median 
donor warm ischemia time (DWIT) in case of DCD-OLT was 17 minutes in 
both cohorts. Median peak ALT was significantly higher after OLT using DCD 
donors than after DBD-OLT in cohort A (DBD: 543 IU/L vs. DCD: 1172 IU/L; 
p<0.001) and the same outcome was seen in cohort B (DBD: 814 IU/L vs. 
DCD: 1783 IU/L; p<0.001). Similar results were observed for median peak 
AST after DCD-OLT compared to DBD-OLT in cohort A (DBD: 1004 IU/L vs. 
2048 IU/L, p<0.001) as well cohort B (DBD: 1066 IU/L vs. DCD 2618 IU/L, 
p<0.001). Due to the strong correlation between peak AST and peak ALT fur-
ther analysis was performed for peak ALT only (Pearson’s coefficient=0.845, 
p<0.001). In general both cohorts were comparable but some incidental dif-
ferences were observed between cohort A and B. For instance, CIT was sig-
nificantly longer for DBD-OLT in cohort A compared to cohort B (p<0.001).  
In cohort B, peak ALT was significantly higher after DBD-OLT compared to 
cohort A (p<0.001). Though a trend to a higher rate of NAS development 
was seen in cohort A compared to cohort B this did not reach statistical 
difference (χ2=2.35, p=0.184). (Table 1) 
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Table 1. Baseline characteristics. Data presented as median (range) for continuous variables 
and percentage (number) for categorical variables. 
DBD = Donation after brain death, DCD = Donation after cardiac death, MELD = Model for 
End-Stage Liver Disease, OLT = Orthotopic Liver Transplantation, ALD = Alcoholic Liver Disease, 
HCC = Hepatocellular Carcinoma, PSC = Primary Sclersoing Cholangitis, PBC = Primary Biliary 
Cirrhosis, HBV = Hepatitis B Virus, AIH = Auto-Immune Hepatitis, HCV = Hepatitis C Virus, 
NAS = Nonanastmotic strictures, CIT = Cold ischemic time, RWIT = Recipient warm ischemic time, 
DWIT = Donor warm ischemia time, AST = Aspartate aminotransferase, ALT = Alanine 
aminotransferase
 












 51 (16 – 78) 45 (15 – 70) 50 (14 – 86) 42 (14 – 65) 
Donor gender % (n)   0.103   0.249 
 Male 47.8 (66) 63.2 (24)  50.2 (132) 59.3 (35)  
 Female 52.2 (72) 36.8 (14)  49.8 (131) 40.7 (24)  
Recipient age (median, 
range) 
53 (21 – 70) 54 (18 – 69) 0.978 52 (17 – 68) 54 (19 – 68) 0.168 
Gender % (n)   0.109   0.650 
 Male 66.7 (92) 80.5 (33)  57.8 (152) 61.0 (36)  
 Female 33.3 (46) 19.5 (8)  42.2 (111) 39.0 (23)  
MELD (median, range) 18 (6 – 40) 19 (6 – 35) 0.711 15 (6 – 40) 12 (7 – 40) 0.079 
Diagnosis pre-OLT % (n)   0.908   0.760 
 ALD 20 (28) 19.5 (7)  15.2 (40) 13.6 (8)  
 HCC 25 (35) 29.3 (10)  2.7 (7) 1.7 (1)  
 PSC 10 (12) 12.2 (5)  20.9 (55) 20.3 (12)  
 PBC 2.9 (4) 5.3 (2)  5.7 (15) 8.5 (95)  
 HBV 5.7 (8) 2.4 (1)  5.3 (14) 1.7 (1)  
 AIH 2.9 (4) 2.6 (1)  8.0 (21) 5.1 (3)  
 HCV 12.1 (17) 12.2 (5)  8.3 (21) 10.2 (6)  
 Metabolic 4.3 (6) 7.3 (3)  8.7 (23) 6.8 (4)  
 Other 17.1 (24) 9.8 (4)  25.5 (67) 32.2 (19)  
NAS % (n) 12.3 (17) 42.1 (16) 14.8 (39) 27.1 (16) 
CIT (median, range) 598 (268 – 1090) 498 (296 – 728) 468 (150 – 854) 451 (318 – 580) 0.110 
RWIT (median, range) 33 (16 – 71) 33 (20 – 53) 0.873 45 (27 – 93) 44 (29 – 79) 0.666 
DWIT (median, range) - 17 (11 – 31)  - 17 (7 – 78)  
Peak AST (median, range) 1004 (46 – 10454) 2048 (200 – 11808) 1066 (64 – 14750) 2618 (221 – 19590) 











In the combined cohort NAS developed in 33.0% after DCD-OLT and in 
14.0% after DBD-OLT (χ2=19.43, p<0.001). Optimal cut-off value of serum 
ALT was calculated using log-rank statistics in the combined cohort (A and 
B) for DCD-OLT (n=97) and was established at ≥1300 IU/L (supplemental 
figure 1).  Using the calculated cut-off value, a low peak ALT of <1300 IU/L 
was considered as mild IRI whereas a high peak ALT ≥1300 IU/L was consid-
ered as severe IRI. After DCD-OLT, severe IRI preceded NAS development in 
49.1% cases compared to 10.0% in the mild IRI group (χ2=16.27, p<0.001). (Table 2) 
Four-year cumulative incidence (CLI) of NAS development was 51.4% in case 
of severe IRI compared to 11.6% when mild IRI occurred after DCD-OLT (log-
rank p<0.001; Figure 1a). No association could be found between peak ALT 
≥1300 IU/L and NAS after DBD-OLT, neither in the individual cohorts nor for 
the combined group. In addition, no other optimal cut-off value for NAS de-
velopment after DBD-OLT could be identified. Based on the cut-off value de-
termined for DCD-OLT four-year cumulative incidence of NAS after DBD-OLT 
in the combined group was 9.4% when peak ALT was ≥1300 IU/L compared 
to 6.0% when peak ALT was <1300 IU/L (log-rank p=0.999; Figure 1b). The 
defined cut-off value of peak ALT ≥1300 IU/L was also evaluated after DCD-
OLT in the participating cohorts individually. NAS developed significantly 
more often following severe IRI after DCD-OLT than after mild IRI in cohort A 
(73.7% vs. 10.5%; χ2=15.55, p<0.001) and similar results were seen in cohort 
B (36.8% vs. 9.5%; χ2=5.11, p=0.032). Four-year CLI of development of NAS 
after DCD-OLT in cohort A was 74% when severe IRI preceded compared to 
12.5% for mild IRI (log-rank p<0.001; Figure 2a).  Cohort B revealed similar 
incidence rates for development of NAS after DCD-OLT of 39.1% after severe 
IRI compared to 11.1% in case of mild IRI (log-rank p=0.056; Figure 2b).  
Univariate and Multivariate analysis
Cox regression analysis for risk of NAS development was performed for DCD 
and DBD donors separately. For DCD-OLT, donor age, CIT and peak ALT 
≥1300 were significantly associated with NAS in univariate analysis at the 
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p<0.20 value and were thus included in the multivariate analysis. PSC as in-
dication for OLT, as well as the center at which OLT was performed were not 
associated with development of NAS in the univariate analysis for DCD-OLT. 
Multivariate analysis showed peak ALT ≥1300 to be the single independently 
associated factor for the development of NAS after DCD-OLT, adjusted for 
CIT and donor age. (adjusted hazard ratio (aHR) = 4.96, confidence interval 
(CI) = 1.73 – 14.24), p=0.003) (Table 3). Multivariate analysis revealed PSC as 
indication for OLT to be the only independently associated parameter for the 
development of NAS after DBD-OLT (aHR = 2.18, CI = 1.22 – 3.88, p = 0.008). 
(Table 4)
Peak alanine aminotransferase and development of NAS
 Combined cohorts (A and B) Cohort A Cohort B 
Graft 
type 
DBD DCD DBD DCD DBD DCD 





% (n)  
NAS 
% (n) 


















            
Mild 85.6 (250) 14.4 (42) 90.0 (36) 10.0 (4) 87.3 (96) 12.7 (14) 89.5 (17) 10.5 (2) 84.6 (154) 15.4 (28) 90.5 (19) 9.5 (2) 
Severe 87.2 (95) 12.8 (14) 50.9 (26) 49.1 (28) 89.3 (25) 10.7 (3) 26.3 (5)  73.7 (14) 86.4 (70) 13.6 (11) 63.2 (24) 36.8 (14) 
 2=0.16, p=0.749 2=16.27, p=<0.001 2=0.08, p=1.000 2 =15.55, p<0.001 2=0.14, p=0.851 2=5.11,  p=0.032 
 Combined cohorts (A and B) Cohort A Cohort B 
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type 
DBD DCD DBD DCD DBD DCD 
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Mild 85.6 (250) 14.4 (42) 90.0 (36) 10.0 (4) 87.3 (96) 12.7 (14) 89.5 (17) 10.5 (2) 84.6 (154) 15.4 (28) 90.5 (19) 9.5 (2) 
Severe 87.2 (95) 12.8 (14) 50.9 (26) 49.1 (28) 89.3 (25) 10.7 (3) 26.3 (5)  73.7 (14) 86.4 (70) 13.6 (11) 63.2 (24) 36.8 (14) 
 2=0.16, p=0.749 2=16.27, p=<0.001 2=0.08, p=1.000 2 =15.55, p<0.001 2=0.14, p=0.851 2=5.11,  p=0.032 
Table 2. Two-by-two table representing development of NAS respective of degree of 
ischema-reperfusion injury (IRI). 
DBD = Donation after Brain Death, DCD = Donation after Cardiac Death, 
NAS = Nonanastomotic strictures, IRI = Ischemia-reperfusion Injury
 Combined c horts (A and B) Cohort A Cohort B 
Graft 
type 
 DBD DCD DBD DCD 
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Mild 85.6 (250) 4.4 (42) 90.0 (36) .0 (4) 7 3 96) 12.7 (14) 8 .5 (17) 10.5 (2) 84.6 (154) 15.4 (28) 90.5 (19) 9.5 (2) 
Severe 87.2 (95) 2 8 14) 50 9 26) 49 1 28 9 3 25) 10.7 (3) 2 .  (5)  7 .7 (14) 86.4 (70) 13.6 (11) 63.2 (24) 36.8 (14) 
 2=0.16, p=0.749 =16.27 =<0. 01 2= .08, p=1.000 2 =1 .55 < . 01 2=0.14, p=0.851 2=5.11,  p=0.032 
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Figure 1
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Cumulative incidence (CLI) of non-anastomotic strictures (NAS) development after 
orthotopic liver transplantation (OLT) with donor livers from donation after cardiac death 
(DCD) (A) reached 51.4% at 48 months when peak alanine aminotransferase (ALT) ≥1300 
IU/L (n=57) compared to 11.6% when peak ALT <1300 IU/L (n=40) (p<0.001). (B) CLI 
rates of NAS after DBD-OLT did not differ between recipients with mild or severe ischemia-
reperfusion injury (IRI). CLI rates were calculated using one minus survival incidence rates 
with the Kaplan-Meier test and compared using log-rank test. 
 
 
   Univariate analysis Multivariate analysis 
Variables DCD -OLT  % (n) HR (95% CI) p-value HR (95% CI) p-value 
Donor age Continuous  1.03 (1.00 – 1.06) 0.044 1.02 (1.00 – 1.05) 0.101 
Donor gender Male 60.8 (59) 1.48 (0.71 – 3.07) 0.295   
 Female (reference) 39.2 (38) 1 (reference)    
Recipient age at OLT Continuous  0.79 (0.97 – 1.04) 0.791   
Recipient gender Male 69.1 (67) 0.78 (0.37 – 1.61) 0.496   
 Female (reference) 30.9 (30) 1 (reference)    
MELD score Continuous  1.02 (0.99 – 1.06) 0.240   
Peak ALT Severe (1300 IU/L) 58.8 (57) 5.51 (1.93 – 15.73) 0.001 4.96 (1.73 – 14.24) 0.003 
 Mild (<1300 IU/L) 41.2 (40) 1 (reference)    
CIT  Continuous  1.00 (0.99 – 1.01) 0.165 1.00 (1.00 – 1.01) 0.259 
RWIT Continuous  0.98 (0.95 – 1.02) 0.317   
DWIT Continuous  1.01 (0.98 – 1.04) 0.581   
PSC as indication PSC 17.5 (17) 1.29 (0.50 – 3.34) 0.604   
 Other indications 82.5 (80) 1 (reference)    
Study Center Cohort B 60.8 (59) 0.66 (0.33 – 1.31) 0.232   
 Cohort A 39.2 (38) 1 (reference)    
 
 
    
 
   Univariate analysis Multivariate analysis 
Variables DBD -OLT  % (n) HR (95% CI) p-value HR (95% CI) p-value 
Donor age Continuous  1.01 (0.99 – 1.03) 0.251   
Donor gender Male 49.4 (198) 0.99 (0.59 – 1.67) 0.991   
 Female (reference) 50.6 (203) 1 (reference)    
Recipient age at OLT Continuous  0.98 (0.96 – 1.00) 0.080 0.98 (0.96 – 1.01) 0.140 
Recipient gender Male 60.8 (244) 1.68 (0.95 – 3.03) 0.074 1.66 (0.92 – 3.00) 0.091 
 Female (reference) 39.2 (157) 1 (reference)  1 (reference)  
MELD score Continuous  1.00 (0.97 – 1.03) 0.979   
Peak ALT Severe (1300 IU/L) 72.8 (292) 1.00 (0.55 – 1.83) 1.000   
 Mild (<1300 IU/L) 27.2 (109) 1 (reference)    
CIT  Continuous  1.00 (1.00 – 1.00) 0.836   
RWIT Continuous  1.01 (0.98 – 1.03) 0.553   
PSC as indication PSC 16.7 (67) 2.52 (1.44 – 4.41) 0.001 2.18 (1.22 – 3.88) 0.008 
 Other indications 83.3 (334 1 (reference)  1 (reference)  
Study Center Cohort B 65.6 (263) 1.17 (0.66 – 2.07) 0.586   
 Cohort A 34.4 (138) 1 (reference)    
 
Table 3. Univariate and multivariate analysis of risk factors for development of NAS after 
DCD-OLT in the combined cohort.
HR = Hazard ratio, CI = Confidence intervals, OLT=Orthotopic liver transplantation, MELD 
= Model for End-stage Liver Disease, ALT = Alanine aminotransferase, DWIT= Donor warm 
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Peak alanine aminotransferase and development of NAS
Cumulative incidence (CLI) rates of non-anastomotic strictures (NAS) development 
respective of degree of ischemia-reperfusion injury (IRI) in cohort A (A) (n=38) and cohort 
B (B) (n=59). CLI rates were calculated using one minus survival incidence rates with the 
Kaplan-Meier test and compared using log-rank test. 
 
 
   Univariate analysis Multivariate analysis 
Variables DCD -OLT  % (n) HR (95% CI) p-value HR (95% CI) p-value 
Donor age Continuous  1.03 (1.00 – 1.06) 0.044 1.02 (1.00 – 1.05) 0.101 
Donor gender Male 60.8 (59) 1.48 (0.71 – 3.07) 0.295   
 Female (reference) 39.2 (38) 1 (reference)    
Recipient age at OLT Continuous  0.79 (0.97 – 1.04) 0.791   
Recipient gender Male 69.1 (67) 0.78 (0.37 – 1.61) 0.496   
 Female (reference) 30.9 (30) 1 (reference)    
MELD score Continuous  1.02 (0.99 – 1.06) 0.240   
Peak ALT Severe (1300 IU/L) 58.8 (57) 5.51 (1.93 – 15.73) 0.001 4.96 (1.73 – 14.24) 0.003 
 Mild (<1300 IU/L) 41.2 (40) 1 (reference)    
CIT  Continuous  1.00 (0.99 – 1.01) 0.165 1.00 (1.00 – 1.01) 0.259 
RWIT Continuous  0.98 (0.95 – 1.02) 0.317   
DWIT Continuous  1.01 (0.98 – 1.04) 0.581   
PSC as indication PSC 17.5 (17) 1.29 (0.50 – 3.34) 0.604   
 Other indications 82.5 (80) 1 (reference)    
Study Center Cohort B 60.8 (59) 0.66 (0.33 – 1.31) 0.232   
 Cohort A 39.2 (38) 1 (reference)    
 
 
    
 
   Univariate analysis Multivariate analysis 
Variables DBD -OLT  % (n) HR (95% CI) p-value HR (95% CI) p-value 
Donor age Continuous  1.01 (0.99 – 1.03) 0.251   
Donor gender Male 49.4 (198) 0.99 (0.59 – 1.67) 0.991   
 Female (reference) 50.6 (203) 1 (reference)    
Recipient age at OLT Continuous  0.98 (0.96 – 1.00) 0.080 0.98 (0.96 – 1.01) 0.140 
Recipient gender Male 60.8 (244) 1.68 (0.95 – 3.03) 0.074 1.66 (0.92 – 3.00) 0.091 
 Female (reference) 39.2 (157) 1 (reference)  1 (reference)  
MELD score Continuous  1.00 (0.97 – 1.03) 0.979   
Peak ALT Severe (1300 IU/L) 72.8 (292) 1.00 (0.55 – 1.83) 1.000   
 Mild (<1300 IU/L) 27.2 (109) 1 (reference)    
CIT  Continuous  1.00 (1.00 – 1.00) 0.836   
RWIT Continuous  1.01 (0.98 – 1.03) 0.553   
PSC as indication PSC 16.7 (67) 2.52 (1.44 – 4.41) 0.001 2.18 (1.22 – 3.88) 0.008 
 Other indications 83.3 (334 1 (reference)  1 (reference)  
Study Center Cohort B 65.6 (263) 1.17 (0.66 – 2.07) 0.586   
 Cohort A 34.4 (138) 1 (reference)    
 
Table 4.Univariate and multivariate analysis of risk factors for development of NAS after 
DBD-OLT in the combined cohort. 
HR = Hazard ratio, CI = Confidence intervals, OLT=Orthotopic liver transplantation, 
MELD=Model for End-stage Liver Disease, ALT = Alanine aminotransferase, DWIT= Donor 
warm ischemic time, RWIT = Recipient warm ischemic time, CIT = Cold ischemic time, 
PSC = Primary Sclerosing Cholangitis
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Discussion
The current data shows that ischemia-reperfusion injury (IRI), defined as 
peak serum ALT ≥1300 IU/L post OLT is strongly associated with the 
development of NAS after DCD-OLT with a 4-year cumulative incidence rate 
of NAS of 51.4%. The incidence of NAS in DCD-OLT in case of peak ALT 
<1300 IU/L was not different from the incidence of NAS in DBD-OLT. In the 
multivariate analysis peak ALT ≥1300 IU/L was independently associated with 
the development of NAS after DCD-OLT. This association was observed after 
adjustment not only for ischemia times, PSC as indication for OLT, recipient 
gender and recipient age, but also the center at which OLT was performed, 
which were no independent risk factors. After DBD-OLT, peak ALT was not 
associated with the development of NAS, whereas PSC was a risk factor in 
these patients. 
NAS is a common problem after OLT leading to considerable morbidity and 
mortality. It has been hypothesized that IRI may play an important role in 
the development of NAS.(15) DCD grafts are known to be more prone to IRI 
due to an additional donor warm ischemic time (DWIT) and to have more 
biliary complications after OLT. (8) Several markers have been associated 
with the development of NAS after OLT such as cold ischemic time (CIT), 
recipient warm ischemic time (RWIT) but also chemokine receptors such 
as chemokine receptor 5 Δ32 (CCR5Δ32) and matrix metalloproteinase-2. 
(MMP-2)16,17 In The Netherlands currently about 20% of OLT is with DCD 
donation since in 2001 a strict national protocol was implemented (18). An 
incentive was the increasing demand of donor livers and decreasing DBD 
donation in our country. In this national protocol only Maastricht category 3 
donors below 55 years of age, with a DWIT below 30 minutes, a body mass 
index <28, and a mean arterial pressure <50 mm Hg for maximum 15 min-
utes were accepted, which excludes about 25% of DCD donors. In addition, 
CIT was kept as short as possible which explains the shorter CIT in DCD 
versus DBD OLT. These livers were allocated according to the regular waiting 
list. Using these criteria we reported in a previous study similar one- and 
3-year patient survival for DCD (85% and 80%, respectively) and DBD (86.3% 
and 80.8%, respectively) OLT, and graft survival rates that did not differ 
Chapter 3
67
significantly (74% and 68% versus 80.4% and 74.5%, respectively).3 The role 
of prolonged ischemia times is most extensively described for DBD-OLT but 
definitions of CIT and RWIT vary between centers and there are mixed results 
on using ischemic times as potential predictors for NAS after DBD-OLT and 
relatively few data exist on potential predictors for development of NAS after 
DCD-OLT.19-21  
Ischemia times, especially CIT, are kept shorter for DCD compared to DBD 
in order to reduce IRI and hopefully compensate for DWIT-induced injury. 
However, ischemia times are not indicative for reperfusion damage and there 
is evidence that most IRI-induced hepatic injury develops due to an excess 
of reactive oxygen species after restoration of blood flow.22-24 Serum AST and 
ALT peaks within the first 7 days after DBD-OLT and DCD-OLT are considered 
markers of IRI.25,26 Despite a strict protocol in reducing CIT and RWIT for 
DCD donors, OLT with DCD donors still have higher peak AST and ALT and 
more NAS post-operatively than DBD-OLT, indicating more IRI in DCD-OLT. 
Microthrombi in the peri-biliary plexus and sinusoids may develop during 
the DWIT, and may be partially responsible for development of NAS and high 
ALT respectively in DCD-OLT. 27,28 Current preservation solutions and tech-
niques may be insufficient to flush out all microthrombi. Several attempts 
are being made to improve preservation and reduce IRI of liver grafts using 
machine liver perfusion, but also fibrinolytic agents are used to dissolve mi-
crothrombi in the donor liver.15,29 Other factors than microthombi may also 
be responsible for both the increased incidence of NAS and higher ALT in 
DCD-OLT as compared to DBD-OLT. Current data indicate that reducing IRI 
in DCD-OLT to the extent that peak ALT is below 1300 UI/L will probably 
diminish the incidence of NAS to around 10%, but will not completely 
eliminate NAS. Likewise since after DBD-OLT peak ALT ≥1300 IU/L was not a 
predictive factor for the development of NAS, other factors than IRI probably 
play a role in the development of NAS in liver grafts from DBD donors. This 
is consistent with the idea that NAS is most likely the result of a complex 
mechanism involving ischemic, immunologic and toxic processes which all 
affect the biliary tree or vascular supply.27,30,31 
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The current study has certain limitations. We used only ALT and not AST as 
marker for IRI occurring in the liver. AST is derived from mitochondria in 
liver cells but is also produced in heart, skeletal muscles and brain cells. 
After surgery, AST can also be elevated due to damage of the abdominal 
muscles during surgery, and this makes it less specific as a parameter of IRI 
after OLT. Furthermore, CCR5Δ32 determination and MMP-2 polymorphisms 
are not included although described by us in the past. These might prove 
useful in combination with ALT as risk factors for NAS, but are less readily 
available. The exact role of CCR5Δ32 needs to be determined in larger 
cohorts, but studies have shown that this receptor may be involved in the 
late occurrence of NAS.  This may indicate that several entities of NAS may 
exist and further studies should be performed in this field.32,33 
In conclusion, our data show that serum peak ALT ≥1300 IU/L is strongly 
and independently associated with the development of clinically relevant 
NAS after DCD-OLT and can be used in classifying patients as high-risk or 
low-risk for developing NAS. The current data indicate that the higher risk of 
NAS after DCD as compared to DBD is likely the result of more severe IRI 
due to DWIT in DCD-OLT when compared to DBD-OLT. Our observations also 
imply that in DBD-OLT and in DCD-OLT with a low peak ALT other mechanisms 
than in DCD-OLT with high peak ALT (i.e. ≥1300 IU/L) may play an important 
role in development of NAS. 
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Abstract
Background: After orthotopic liver transplantation (OLT) early detection of 
biliary strictures is important. Our aim was to evaluate the predictive value 
of routine serum liver chemistry profiling and abdominal ultrasound as 
non-invasive diagnostic tools in detecting biliary strictures after OLT.
Methods: We performed a retrospective study in which 141 primary OLTs, 
performed between 1992 and 2007 with more than 1 year follow-up, 
were included. Routinely assessed serum levels of alkaline phosphatase, 
alanine-aminotransferase, aspartate-aminotransferase, gamma-glutamyl 
transpeptidase and bilirubin at 3, 6, 9 and 12 months, and abdominal 
ultrasounds performed at 3, 6 and 12 months after OLT were evaluated. 
All biliary strictures requiring intervention occurring after 3 months were 
included. Time-dependent Cox regression analysis was performed to identify 
predictive factors for the development of biliary strictures.
Results: Eighteen grafts developed non-anastomotic strictures (12.8%) and 
18 grafts (12.8%) developed anastomotic strictures requiring intervention. 
An elevated gamma-glutamyl transpeptidase (HR 1.24 per 100 IU/L; p = 
0.05) and dilated bile ducts on ultrasound (HR 3.45; p < 0.01) were found to 
have an independent predictive value for the development of biliary strictures 
requiring intervention. Bilirubin and the other studied liver enzymes were
not independently predictive.
Conclusion: Dilated bile ducts on ultrasound and elevated gamma-
glutamyltranspeptidase after OLT are independent predictive factors for the 
development of biliary strictures requiring intervention. Routine assessment 
by serum gGT and US at 3-month intervals during the first year post-OLT is 




Biliary complications are common after orthotopic liver transplantation 
(OLT), with a reported prevalence of 6% to 35%.1-4 Biliary strictures occurring 
at the surgical anastomosis are classified as anastomotic strictures (AS), 
whereas strictures in the donor biliary tree are referred to as non-anastomotic 
strictures (NAS). Stricture formation is often insidious and usually only then 
detected when it leads to clinical symptoms as cholestasis, with serum liver
enzyme abnormalities, intrahepatic bile duct dilatation and/or infection.5 
The definite diagnosis is made by endoscopic retrograde cholangiopan-
creatography (ERCP), percutaneous transhepatic cholangiography (PTC) 
or by magnetic resonance cholangiopancreatography (MRCP).6,7 Although 
ERCP and PTC are considered the gold standard, they are invasive procedures 
and associated with considerable morbidity. ERCP and PTC are often 
immediately performed when clinical symptoms such as jaundice or cholangitis 
are present.8 Several uncontrolled series evaluated the efficacy of ERCP in 
predicting biliary complications.8,9 Most of these were evaluated in settings 
where patients present themselves with symptoms such as cholangitis due 
to a biliary stricture. It is therefore important to detect early signs of stricture 
formation before such symptoms develop. Transplantation centers differ in 
how they routinely assess these problems. Liver biochemistry and abdominal 
ultrasound (US) may be useful for early detection of rejection, recurrence of 
primary disease (e.g., primary sclerosing cholangitis (PSC) or hepatitis) and 
bile duct pathology, such as stricture formation, since abnormalities may be 
present long before patients develop symptoms such as fever or abdominal 
pain. Only few studies addressed the predictive value of routinely assessed 
serum liver chemistry profiles and abdominal ultrasonography (US) after 
OLT as predictors for the occurrence of biliary strictures in a post-transplant 
population.10 Although some studies did evaluate the prognostic value of 
liver chemistry and US, this was not in a time-dependent way and it remained 
unclear whether clinicians should routinely assess these diagnostic 
modalities in a post-transplant population for the early detection of biliary 
strictures, and at what time interval.10,11 The risk of developing biliary 
strictures varies over time, probably in association with the liver chemistry 
profile and US findings. The aim of the present study was to evaluate the 
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predictive value of routinely assessed serum liver chemistry and abdominal 
ultrasound as non-invasive predictors for the development of biliary strictures 





We examined 141 consecutive first OLTs with at least one year of follow-up 
and complete data on serum liver chemistry and enzymes and upper 
abdominal ultrasonography (US) performed between September 1992 and 
April 2007 at the Leiden University Medical Centre. Re-transplantations 
(n=31) were excluded. Clinical data were obtained from the medical digital 
records, the hepatological and surgical patient charts, and endoscopy reports. 
Followup was up to August 2008 with a median of 5.2 years (range 1.0 -15.6).
OLT was performed according to standard procedures with cavo-caval, 
porto-portal, and hepatic artery to hepatic artery anastomosis. A duct-to-
duct biliary anastomosis over a 8-12 Ch stent was performed, if possible. 
The biliary stent was removed after 6 weeks or removed earlier as indicated. 
In some cases the hepatic artery was anastomosed to the aorta via an iliac 
conduit. All patients received immunosuppressive agents according to 
protocol: cyclosporin A or tacrolimus, prednisone during the first half-year 
and patients with renal impairment received azathioprine before 2001 or 
mycophenolate mofetil from 2001 on. From 2001 on, basiliximab was given 
post OLT. In some cases sirolimus was used after month 3 in which case the 
calcineurin-inhibitor was discontinued. All patients received ursodeoxycholic 
acid in the first 3 months after transplantation.  
Biochemical variables
Serum liver enzyme levels of alkaline phosphatase (ALP), alanine-aminotransferase 
(ALAT), aspartate-aminotransferase (ASAT) and gamma-glutamyltranspeptidase 
(GGT) were determined daily during the first two weeks and weekly for two 
months, after that at 3, 6, 9, and 12 months post-operatively. The same was 
done for bilirubin. Only the latter 4 time points were included in the study 
because in the first three months after liver transplantation liver enzymes 
are very susceptible to change due to procedure-related causes such as 
ischemia-reperfusion damage, early vascular complications such as hepatic 
artery thrombosis, rejection and infections. Therefore, the first three months 
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of liver chemistry assessments, ultrasounds and biliary strictures after trans-
plantation were excluded. The upper limit of normal serum level was for ALP 
120 IU/L, for ASAT, ALAT and GGT the upper limits of normal were 40 IU/L, 
40 IU/L and 51 IU/L, respectively. The upper limit for bilirubin (total) was 17 
μmol/L.
Imaging variables
US was performed routinely on day 0, 1 and 7, and subsequently at 3, 6 and 
12 months after OLT. The USs performed at 3, 6 and 12 months were included 
in this study. These US were performed by different experienced radiologists. 
Due to lack of clear definition in the literature of dilated intrahepatic bile 
ducts a clear definition has been used by our radiologists with expertise in 
liver transplantation. In our institute a common bile duct of >7 mm and an
intrahepatic bile duct of >2mm on ultrasound were considered dilated and 
prompted either direct intervention by ERCP or PTC or additional MRCP 
which in turn might prompt ERCP or PTC. Other reported ultrasound findings 
of the biliary tree, such as sludge or a thickened biliary wall, were not taken 
into account in our analysis Routine abdominal CT scan was performed after 
3 to 7 days post-OLT and routine liver biopsies were performed at 6 months 
after transplantation. Additional liver biopsies were taken on indication. 
Virology monitoring, including CMV-DNA, was performed frequently in the 
first year.
Clinical variables
Presentation of a biliary stricture (anastomotic and non-anastomotic) was 
with clinical symptoms such as cholangitis, pruritus or jaundice and/or 
abnormal liver chemistry. Diagnostic tests to confirm the diagnosis were 
performed on indication but not included in the present analyses. Only strictures 
occurring more than three months after OLT that required intervention by 
ERCP, PTC or surgery were included in this study. From 2001 on, routine
ERCP with stent-removal was performed at week 6 post-OLT in case of a 
duct-to-duct anastomosis. Accompanying the stent removal, a cholangiogram 
was also performed and possible strictures occurring at this time-point 
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were excluded due to exclusion of liver enzymes and ultrasound findings in 
the first three months for the above-mentioned reasons. All strictures were 
treated endoscopically with ERCP and dilation and/or stenting, and 
percutaneously with percutaneous transhepatic cholangiodrainage (PTCD)
or with surgical intervention.
Statistical analyses
We have used a time-dependent Cox regression model to evaluate the 
diagnostic value of liver enzymes and routine US assessments in predicting 
biliary strictures. The Cox proportional-hazards regression model for time-
to-event data (e.g. the development of biliary strictures) takes into account 
the variable changes of variables over time, e.g. changes of liver enzymes 
and bile duct dilatation on US. Time dependent predictors (covariates) for 
stricture development in this study were liver chemistry variables ALP, GGT, 
ASAT, ALAT and bilirubin, obtained with an interval of three months at 3, 6, 
9 and 12 months post OLT and US performed 3, 6 and 12 months post OLT. 
Recipient characteristics, like etiology of liver disease and procedure-related 
variables were baseline characteristics. Variables at a p<0.20 level in the 
univariate analysis were included in the multivariate analysis. Coefficients 
were considered significant when p <0.05 in the multivariate analysis. The 
reported hazard ratios and p-values are per 100 international unit elevation 
for the liver enzymes. Bilirubin levels are reported per 10 μmol/L elevation.
Ethical committee
All data were obtained as part of patient care according to a strict protocol 
after OLT. There was permission from the local ethics committee to use 
these data.
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Results
Patients and biliary strictures
Baseline characteristics of recipients like etiology of liver disease and 
procedure-related variables are presented in Table 1. Non-anastomotic biliary 
strictures requiring intervention developed in 18 of the 141 grafts (12.8%). 
Median time from OLT to NAS was 8.5 months (range 3-29). Median follow-up 
after the diagnosis of NAS was 5.5 years (range 0.0 – 11.6). Anastomotic 
strictures developed in 18 out of 141 grafts (12.8%). Median time from OLT 
to AS was 5.5 months (range 3-72). Median follow-up after the diagnosis of 
an anastomotic stricture was 2.8 years (range 0.6-15.3). Forty-one percent of 
the patients who developed a biliary stricture, both anastomotic and non-
anastomotic, had biliary ducts dilatation on US whereas only 15% of the 
patients who had no biliary stricture requiring intervention had biliary ducts 
dilatation on US (p = 0.001, χ2 = 11.65). Patients who developed a biliary 
stricture requiring intervention had a mean lag time of 5.3 months (standard 
error of the mean (SEM) = 0.75) from OLT to aberrant US whereas for 
patients who did not develop biliary strictures requiring intervention this was 
6.2 months (SEM = 0.85). A total of twenty-one ERCPs and twelve PTCs for 
the management of strictures were performed in the included cases. In three 
cases a surgical intervention to resolve the stricture was necessary. There 
was no difference between the duct-to-duct type anastomosis and the 
Roux-en-Y anastomosis in the occurrence of biliary strictures (p = 0.88). 
Other possible risk factors as primary liver disease, such as PSC, PBC and 
HCV, or donation after cardiac death are also listed in Table 2.
Liver chemistry and abdominal ultrasound
Elevation of serum liver enzymes ALP, GGT, ASAT and ALAT above the upper 
limit of normal occurred in respectively 57.4%, 71.6%, 53.9%, and 61.0% 
of the patients at 3, 6, 9 or 12 months after OLT. Bilirubin was elevated in 
41.6% of the cases. There was a significant relationship between the level of 
GGT and the development of biliary strictures requiring intervention, both 
in the univariate and in the multivariate analysis (hazard ratios 1.35 and 1.25,      
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p < 0.001 and p = 0.04, respectively), as presented in Tables 2 and 3. ALP 
above the upper limit of normal was also found to be a significant indicator 
for the development of biliary strictures in the univariate analysis (p < 0.001), 
but not in the multivariate analysis (p =0.15). Elevated ALAT and ASAT were 
not associated with biliary strictures in the univariate analysis (p = 0.61. 
and p = 0.62 respectively). Elevation of bilirubin was not significant in both 
univariate and multivariate analysis for the prediction of the development of 
biliary strictures (p = 0.08 and p = 0.32 respectively (Table 3) Regarding the 
US assessments a significant relationship was found between dilated bile 
ducts on abdominal ultrasound and the successive development of a biliary 
stricture requiring intervention in both the univariate (hazard ratio = 4.48, 
p < 0.001) and multivariate analysis (hazard ratio = 3.45, p < 0.01). (Table 3)
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Table 1. Baseline characteristics of 141 orthotopic liver transplants.
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 N (141)  
Recipient data  
- Male/ Female 
            
91/50 
- Median age (years) (range) 50 (16 – 70) 
Etiology of liver disease  
Hepatitis B/C cirrhosis 












Donor and OLT procedure data  
DBD / DCD donor 
Choledochocholedochostomy (duct- o-duct)/ Roux-en-Y 
hepaticojejunostomy 
Donor warm ischemic time (DCD donors) (minutes) (range) 
Cold ischemic time (minutes) (range) 





17 (11 – 23) 
605 (268 – 1095) 



























Table 2. Univariate analysis of potential predictors for the development of biliary 
strictures (BS). Time-dependent analysis was used to calculate the predictive value 
of routinely performed liver chemistry profile assessments and dilated bile ducts on 
abdominal ultrasound (US) for detecting BS requiring intervention after OLT (n=141). 
The hazard ratios for liver enzymes are shown per 100 IU/L increase. The hazard ratio 
for bilirubin is shown per 10 μmol/L increase.
 13 
Clinical Variables Hazard Ratio 
(95% CI) 
P-Value 
Dilated bile ducts on US 4.48 (1.97 – 10.12) < 0.001  
GGT 1.35  (1.22 – 1.49) < 0.001 
ALP 1.55 (1.22 – 1.89) < 0.001 
ALAT  1.13 (0.74 – 1.82) 0.61 
ASAT 1.19 (0.61 – 2.45) 0.62 
Bilirubin 1.07 (0.99 – 1.16) 0.08 
Gender 0.64 (0.33 – 1.40)  0.23 
Donation after cardiac death 1.61 (0.38 – 6.80) 0.51 





0.04 (0.00 – 18.72) 
0.94 (0.38 – 2.29) 





Type of surgical anastomosis (duct-to-duct/Roux-en-Y) 0.90 (0.26 – 4.5) 0.88 
Cold Ischemic Time (CIT) 0.99 ( 0.99 – 1.00) 0.28 
























Clinical Variables  Hazard Ratio (95% CI)  P- value 
Dilated bile ducts on US 3.45  (1.46 – 8.17 ) < 0.01 
GGT 1.24 (1.00 – 1.54 ) 0.05 
ALP  1.34  (0.89 – 2.01) 0.15  
Bilirubin 0.92 (0.79 – 1.08) 0.32 




Clinical Variables  Hazard Ratio (95% CI)  P- value 
Dilated bile ducts on US 3.45  (1.46 – 8.17 ) < 0.01 
GGT 1.24 (1.00 – 1.54 ) 0.05 
ALP  1.34  (0.89 – 2.01) 0.15  
Bilirubin 0.92 (0.79 – 1.08) 0.32 
Age 0.97 (0.94 – 1.00) 0.62 
 
 
Table 3. Multivariate time-dependent Cox regression analysis for liver enzymes and 
dilated bile ducts on abdominal ultrasound (US) for detecting presence of BS requiring 
intervention after OLT (n=141). Gamma-glutamyltranspeptidase (GGT) and US remain 
significant predictors for the development of BS. The Hazard ratio for GGT shows the 
risk of having a stricture with each 100 IU/l increase. The hazard ratio for bilirubin was 
calculated for each 10 μmol/L increase.
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Discussion
Biliary strictures frequently complicate orthotopic liver transplantation and 
lead to significant morbidity, graft loss and mortality. Early diagnosis and 
prompt intervention is therefore of great clinical importance. Cholangio-
graphy remains the most sensitive and specific assessment in diagnosing 
biliary strictures but is invasive. The most commonly used and least invasive 
diagnostic modalities after OLT are serum liver chemistry profile determinations 
and abdominal ultrasound.12,13,14,15 The prognostic values of abdominal 
ultrasound and liver enzymes in detecting biliary strictures have been evaluated 
before. Hussaini et al.11, for example, showed that US was a valuable tool to 
diagnose biliary strictures with a sensitivity and specificity of 77% and 67%, 
respectively. Que et al.18 found US to detect biliary strictures with a 
sensitivity and specificity of 90% and 91% respectively, but reported GGT 
and ALP to be of poor diagnostic value even at 10-folds the upper limit of 
normal. However, many transplantation centers still differ in the way they 
routinely assess liver biochemistry and US to detect biliary strictures and 
therefore different protocols for follow-up of transplanted patients are used. 
From previous studies it remained unclear whether routine assessment of
these modalities can predict biliary strictures. In an outpatient clinic, patients 
often present themselves without symptoms., even if biliary strictures are 
present, but they have abnormal liver enzymes and US. Previous studies 
evaluated liver chemistry using sensitivity and specificity of US and liver 
enzymes in relation to the presence of biliary strictures. Although this is a 
common way to evaluate the diagnostic value of clinical tools it has several 
limitations: sensitivity and specificity only apply if the assessment of the 
liver biochemistry profile and biliary strictures occur simultaneously. Routine 
assessments of liver biochemistry and abdominal ultrasound in an outpatient 
clinic often precede the detection of a biliary stricture. In most previous 
studies sensitivity and specificity were based on dichotomized variables, e.g. 
liver enzymes were elevated or not. However, liver enzymes are continuous 
variables and change over time and probably concomitantly become elevated 
during stricture formation. This means that the risk of developing a biliary 
stricture for each patient varies along with the changes in liver enzymes or 
ultrasound findings. It is therefore more appropriate to use a time-dependent 
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regression model for exploring predictive relationships by using quantities 
such as liver enzymes that vary over time.19 The current findings are in 
accordance with non-transplantation studies in which GGT corresponds 
with the presence of biliary strictures, while mixed data are reported on the 
predictive value of liver chemistry for the presence of biliary complications after 
OLT.8,10,12,18 We found an independent association between the increased 
serum level of GGT assessed at fixed routine time-points and the risk of 
detecting a biliary stricture requiring intervention. Time-dependent analysis 
calculates the hazard ratio for developing biliary strictures per 1 IU/L of 
elevated GGT, which in our study was 1.0022. Thus, an elevation of 100 IU/L 
(i.e., 151 U/L) would result in 1.00217100 = 1.24 or a 24% increased risk. In 
formula terms, the hazard ratio for any elevation of GGT can be calculated 
(1.0022(elevation above upper limit in IU/L)) for the development of a biliary stricture.  
Abdominal ultrasound is a non-invasive, readily available and economic 
diagnostic tool. However, several studies observed that ultrasound is not 
very sensitive in detecting biliary strictures in a post-transplant population, 
whereas few studies reported the opposite.3,8,11,13 We found bile duct dilatation 
on abdominal ultrasound to be a powerful predictor of subsequent development 
of biliary strictures requiring therapy, exemplified by the high hazard ratio 
of 3.45 in the multivariate analysis. In clinical practice the calculated hazard 
ratios of both bile duct dilatation on US and the elevation of GGT are 
multiplied. In our example GGT levels 100 IU/L above the reference range 
together with dilated bile ducts on US result in a hazard ratio of 4.3 (3.45 x 
1.24), which indicates that the risk of developing a biliary stricture requiring 
intervention is 4.3 more likely compared to the standard risk. Other 
modalities such as MRCP are also non-invasive tools which are widely used 
in diagnosing biliary strictures. However, MRCP is usually considerably more 
expensive than US and often has a waiting list, which makes it less applicable as 
a routine diagnostic tool. MRCP can be considered if other diagnostic tools 
provide no conclusive information and if there is less urgency in performing 
an ERCP. We realize that our study has some limitations. We decided to use 
a follow-up of one year after the 3-month time point since most strictures 
develop within the first year after OLT. Liver enzymes within the first three 
months were not included because early after transplantation many variables 
influence liver enzyme levels, such as ischemia-reperfusion damage, 
Chapter 4
87
rejection and infection. A shorter follow-up would have weakened the 
statistical analysis. One should be careful using ultrasound findings which 
are not defined forehand. Unfortunately, there is no clear definition of dilated 
bile ducts in the literature and we therefore used a definition, which is being 
used by our radiologist with expertise in bile duct dilatation and liver trans-
plantation. Further prospective studies are needed to define a cut-off value 
for bile duct dilatation. Our timedependent regression analysis showed that 
detection of dilated bile ducts on US or elevated GGT are independent 
predictive factors for the development of biliary strictures requiring intervention 
in the first year after OLT. To our knowledge there are no other studies that 
evaluate the usefulness of routinely assessing liver chemistry and performing 
ultrasound after OLT. Routine assessment by serum GGT and US at 3-month 
intervals during the first year post-OLT is useful to screen for biliary strictures 
post-OLT. Elevated GGT or dilated bile ducts on US in the first year post-OLT 
should prompt cholangiography and may allow timely intervention before 
complications like cholangitis develop.
Sequential liver chemistry profiling and ultrasounds to detect NAS
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Abstract
Background: Nonanastomotic biliary strictures (NAS) are a serious com-
plication after orthotopic liver transplantation (OLT). Matrix metalloproteinases 
(MMPs) are involved in connective tissue remodelling in chronic liver 
disease and complications after OLT.
Aim: To evaluate the relationship between MMP-2 and MMP-9 gene 
polymorphisms and NAS. 
Methods: MMP-2 ( – 1306 C/T) and MMP-9 ( – 1562 C/T) gene promoter 
polymorphisms were analysed in 314 recipient–donor combinations. Serum 
levels of these MMPs were determined in subgroups of patients as well. NAS 
were identified with various radiological imaging studies performed within 
4 years after OLT and defined as any stricture, dilation or irregularity of the 
intra- or extrahepatic bile ducts of the liver graft followed by an intervention, 
after exclusion of hepatic artery thrombosis and anastomotic strictures.
Results: The average incidence of NAS was 15%. The major clinical risk factor 
for the development of NAS was PSC in the recipient. The presence of the 
MMP-2 CT genotype in donor and/or recipient was associated with a 
significantly higher incidence of NAS, up to 29% when both donor and 
recipient had the MMP-2 CT genotype (P = 0.003). In the multivariate analyses, 
pre-OLT PSC (hazard ratio 2.1, P = 0.02) and MMP-2 CT genotype (hazard 
ratio 3.5, P = 0.003) were found to be independent risk factors for the 
development of NAS after OLT. No obvious association was found between 
NAS and the MMP-9 genotype and serum levels of the MMPs.
Conclusion: MMP-2 CT genotype of donor and recipient is an independent 




Biliary complications are a common feature after orthotopic liver transplantation 
(OLT), with a reported incidence of up to 35%. Leaks and strictures are the 
most common complications, often requiring endoscopic, radiological or 
surgical intervention1–9. Anastomotic strictures result from surgical or local 
ischaemic causes. Main categories of risk factors for nonanastomotic biliary 
strictures (NAS) include ischaemia related injury, immunologically induced 
injury and cytotoxic injury by bile salts. A higher incidence of NAS is reported 
in patients transplanted for primary sclerosing cholangitis (PSC) and patients 
who suffered from a postoperative CMV infection10–17. Donation after cardiac 
death (DCD) procedures are also reported to have an increased risk of NAS 
compared with donation after brain death procedures18,19. NAS are often 
referred to as ischaemic-type biliary lesions, based on the resemblance with 
biliary abnormalities observed after hepatic artery thrombosis. The reported 
incidence of NAS varies in different publications from 1 to 19%4,5,20–25. If 
untreated, NAS may lead to cholestasis, severe graft dysfunction, septic 
complications, secondary cirrhosis and graft loss7,23,26.
Matrix metalloproteinases (MMPs) comprise a large family of proteolytic 
enzymes that are important in physiological and disease-related extracellular 
matrix remodelling processes27–30. MMP-2 and MMP-9 are capable of digesting 
components of the connective tissue matrix and type IV collagen within 
basement membranes. These MMPs are considered to play an  important 
role in cancer development, tissue remodelling, fibrosis and inflammation, 
including cirrhosis and liver trans-plantation31–35. We showed previously, for 
example, that serum MMP-2 levels increased, whereas MMP-9 levels 
decreased in relation to the severity of the cirrhosis31. These serum MMP 
levels were subsequently found to change irrespective of their gene polymor-
phisms in late phase injury or rejection (I/R) after liver transplantation36. The 
aim of the present study was to assess whether a relationship exists between 
MMP-2 and MMP-9 gene promoter polymorphisms in the donor and 
recipient DNA with the development of NAS after OLT.




All adult patients who received a liver transplant at the Leiden University 
Medical Center (LUMC) and University Medical Center Groningen (UMCG) 
in the Netherlands were eligible for inclusion. For this study, 202 patients 
were identified from the transplantation databases who underwent OLT at 
the LUMC between 1992 and 2005, of whom we were able to include 147 
patients whose DNA was available from both donor and recipient, and who
had at least 7 days of follow-up after liver transplantation. Also, patients who 
received OLT be-tween 2000 and 2005 at the UMCG were eligible for the 
study because data were available. Of the 224 available patients, 167 
unselected patients could be included of whom we had DNA from both 
recipient and donor, and who had at least 7 days of follow-up after trans-
plantation. Genomic DNA was extracted routinely from peripheral blood 
and/or tissue samples without given preference to any explicit clinical 
variables. All patients received standard immunosuppressive therapy 
consisting of corticosteroids, a calcineurin inhibitor (i.e., cyclosporine or 
tacrolimus) with or without mycophenolate mofetil or azathioprine and/or 
basiliximab. Azathioprine was used until 2001, and thereafter mycophenolate 
mofetil was given in case of impaired renal function. Demographical and 
clinicopathological characteristics of the recipient at the time of OLT (age, 
gender, indication for liver transplantation, laboratory MELD score), donor 
information (age, gender and donor type), transplantation procedure 
variables (warm and cold ischaemia time) and post-transplant follow-up 
data of up to 4 years were collected from the transplantation databases. This 
study was performed with informed consent from the patients according to 
the guidelines of the Medical Ethics Committee of both participating centres 
and in compliance with the Helsinki Declaration.
Nonanastomotic strictures
In this study, only biliary strictures followed that by an intervention were 
included. If a biliary stricture was suspected from clinical findings, liver      
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function tests or abdominal ultrasound, further imaging of the biliary tract 
was performed. In both centres, a biliary drain was placed routinely after OLT 
and cholangiography was performed if clinically indicated and in the LUMC, 
cholangiography was also performed routinely 6 weeks after OLT. 
All imaging studies of the biliary tree, performed within 4 years after OLT, 
were included [direct cholangiography via the biliary drain, percutaneous 
transhepatic cholangiodrainage (PTCD), ERCP as well as MRCP]. For the 
purpose of this study, NAS were defined as follows: any stricture, dilation 
or irregularity of the intrahepatic or extrahepatic bile ducts of the liver graft, 
either with or without biliary sludge formation, at least 1 cm above the biliary 
anastomosis and treated endoscopically with ERCP and dilation and/or 
stenting, percutaneously with PTCD or by surgical intervention. Hepatic 
artery thrombosis by either Doppler ultrasound or conventional angiography as 
well as isolated strictures/stenoses at the bile duct anastomosis and related 
dilations were, by definition, excluded from this analysis.
Genotyping
Genomic DNA was extracted by routine methods from peripheral blood 
leucocytes and/or tissue samples. In addition, DNA samples from the blood 
or tissue of the liver donor were obtained from the Eurotransplant Reference 
Laboratory or freshly isolated MMP-2: high-resolution DNA melting analysis.
MMP2 –1306 C/T (rs243865) genotyping, as most relevant SNP, was 
performed with the use of high-resolution DNA melting assay37. Sequences 
of the polymerase chain reaction (PCR) primers were 5’-CCAGTGCCTCTT-
GCTGTTTT-3’ (forward) and 5’- GACTTCTGAGCTGAGACCTGA-3’ (reverse). 
The unlabelled probe was designed according to the wild-type (C) genotype and 
had the following sequence: 5’- CCACCCAGCACTCCA CCTCTTTAGCTC-3’. 
The probe had a 3’-amino-C7 modification to prevent DNA polymerase 
extension during PCR. In brief, high-resolution melting analysis of PCR 
products amplified in the presence of a saturating double-stranded DNA dye 
(LCGreenPlus, Idaho Technology, Salt Lake City, Utah, USA) and a 3’-blocked 
probe, identified both heterozygous and homozygous sequence variants. 
Heterozygotes were identified by a change in melting curve shape, and 
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different homozygotes are distinguished by a change in melting temperature. 
In each experiment, sequence-verified control donors for each genotype were 
used. MMP-9: PCR-RFLP genotyping.
The MMP-9 SNP C/T at position – 1562 (rs3918242) was determined with 
PCR analysis followed by restric-tion enzyme fragment length polymorphisms 
(RFLP) analysis, the principles of which are described elsewhere36, and 
confirmed by direct sequence analysis of four patients. Briefly, the region 
flanking the SNP was ampli-fied with outer primers 5’- ATGGCTCATGCCCG-
TAATC-3’ and 5’-TCACCTTCTTCAAAGCCCTATT-3’ followed by RFLP analysis 
with SphI to produce 352, 35212071145 or 2071145 bp fragments in case of 
CC, CT and TT genotype respectively. Genotypes CC, CT and TT are easily 
identified from the migration pattern on agarose gels36,38–40.
Determination of serological MMP levels
From two subgroups of patients included in our study, we also assessed the 
serological levels of MMP-2 and MMP-9 before and after transplantation. This 
pretransplantation group consisted of 47 patients (30 males) with chronic 
liver disease of various aetiologies, including 27 patients who eventually 
underwent an OLT. Their median age was 46 years (range 16–68). Fourteen 
patients had chronic viral hepatitis, 14 patients had cholestatic liver disease, 
10 patients had alcohol-related liver disease and the remaining nine patients 
had miscellaneous liver diseases. From the group of 27 OLT patients, serum 
samples 1 month after transplantation were evaluated. All serum samples 
had been stored at – 80 °C until use. MMP-2 and MMP-9 concentrations 
were determined using highly specific enzyme-linked immunosorbent assays, 
which measures the pro-enzyme, active- and inhibitor complexed forms, as 
described previously31,36.
Statistical analysis
Data were analysed using SPSS 17.0 software (SPSS Inc.; Chicago, IL, USA). 
Characteristics of the liver transplant recipients, donors and post-transplant 
follow-up data with the risk of developing NAS were analysed using the 
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log-rank and two-tailed Student’s t-tests. Differences in the serological levels 
of MMP were analysed using ANOVA. Genotype frequencies were analysed 
by generating two-by-three contingency tables and statistical analysis was 
performed using the χ2-test or the Fisher’s exact test, where appropriate. 
Comparison of time with NAS was made using Kaplan–Meier statistics with 
a log-rank test. Univariate and multivariate analyses were performed using 
Cox’s proportional hazards method. Variables associated with an increased 
risk of NAS at the P < 0.15 level in the univariate logistic regression analysis 
were included in the backward stepwise multivariate logistic regression 
model. P-values ≤ 0.05 were considered statistically significant.
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Results
The study population consisted of 314 OLT donor/ recipient combinations of 
which 48 (15%)developed NAS within the first 4 years after transplantation.
MMP-2 genotype and NAS
The frequencies of MMP-2 and MMP-9 gene promoter polymorphisms in 
recipients and in donors vs. the occurrence of NAS are given in Table 1. 
Evaluation whether the MMP genotype is reflected in the serum level indicated 
that in patients with liver disease no such relation exists. Specifically, MMP-
2 levels in the pre-OLT serum of recipients with a CC (n = 32) genotype was 
5123 ± 553 ng/ml, whereas for those with a CT or TT genotype (n = 15), these 
levels were 5347 ± 886 (NS). For MMP-9, these levels were 129 ± 16 (n = 36) 
vs. 156 ± 28 (n = 11) respectively (NS). 
The presence of MMP-2 CT genotype in the recipient as well as in the donor 
was significantly associated with the development of NAS. Furthermore, the 
cumulative presence of MMP-2 CT genotype in both recipient and donor vs. 
the occurrence of NAS is shown in Tables 2 and 3. In the group of patients 
that developed NAS, the absence of a CT genotype was more frequent (21%) 
than in the patients that did not develop NAS (39%) and for CT in donor and 
recipient, exactly the opposite was observed (29% vs. 13%, Table 2). If CT 
genotype was present in neither recipient nor donor, the risk of developing 
NAS was 9% (10/115). When MMP-2 CT genotype was present in either 
donor or recipient, NAS developed in 16% (24/151) of cases. The occurrence 
of NAS increased to 29% if MMP-2 CT genotype was present in both recipient 
and donor (14/48; P <0.003, Table 3). Figure 1 shows the cumulative incidence 
of NAS within 48 months after OLT related to the presence of MMP-2 CT 
genotype in recipient and donor. We also evaluated whether this association 
between genotype MMP-2 and NAS was reflected in the serum levels. One 
month after OLT, the MMP-2 level in patients with NAS was showed a trend 
to be lower [i.e., 1892 ± 431 ng/ml (n = 5) vs. 2869 ± 287 (n = 22), P = 0.06], 
compared with the patients without NAS. Interestingly, a similar trend was 
observed in relation to the MMP-2 genotype, i.e. lower in relation to the 
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presence of CT [2969 ± 452 vs. 2540 ± 349 vs. 2396 ± 448 for no CT in donor 
or recipient (n = 10), CT in donor or recipient (n = 15) and CT in donor and 
recipient (n = 2), respectively, NS]. 
Figure 1
Further assessment of the impact of the MMP-2 genotypes and NAS-related 
morbidity by including re-OLTs showed a similar stepwise increase in relation 
to the MMP-2 genotype from 14% (16/115) to 20% (30/151) and 38% (18/48) 
respectively (χ2 11.66, P = 0.003). By including death in the follow-up, this 
increased to 26% (30/115), 29% (44/151) and 44% (21/48) respectively (25.18, 
P = 0.08). In a similar manner, the MMP-9 genotype distribution of recipient 
and donor vs. the occurrence of NAS was evaluated. However, no significant 
correlation was found between MMP-9 genotype and the development of 
NAS (Table 1) or with the serum levels of MMP-9 (data not shown).
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22 
Cumulative incidence of NAS within 48 months after OLT related to the 
presence of MMP-2 CT genotype in recipient (R) and donor (D). MMP, 
matrix metalloproteinase; NAS, nonanastomotic biliary strictures; OLT, 
orthotopic liver transplantation.
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Multivariate analysis of MMP-2 genotype and covariates
The development of NAS was significantly higher when PSC was the 
indication for OLT [15/48 cases (31%) vs. 33/ 257 cases (13%)], as expected. 
No significant association was found between the occurrence of NAS and 
other transplant characteristics, such as gender and age (both of recipient 
and donor), laboratory MELD score, length of warm or cold ischaemia time 
or DCD procedures. However, it should be noted that only 25 DCD procedures 
were included in this cohort. Also, in relation to immunosuppressive therapy, 
there was no association found with the development of NAS, i.e. patients 
on corticosteroids with a calcineurin inhibitor with or without basiliximab 
had a similar risk of developing NAS [13% (27/209) vs. 20% (21/105), 
respectively, NS]. 
Early (≤ 12 months) and late (12–48 months) onset of NAS was also looked at 
for all studied risk factors. NAS was diagnosed in 33 cases (10.5%) within the 




Genotype     Recipient    Donor   
          
     NAS  No NAS  NAS  No NAS 
dbSNP ID SNP    % (n) % (n)  % (n) % (n) 
            
MMP-2 – 1306 C  T CC   46 (22) 61 (162)  44 (21) 53  (142)  
rs243865   CT  52 (25)  33  (87)  56 (27) 41 (108)  
   TT  2 (1) 6 (17)  0 (0) 6 (16) 
     P < 0.03, 2 7.2    P = 0.05,  2 5.9  
MMP-9 – 1562  C  T CC   67 (32) 71  (185)   75 (36) 78 (206)  
rs3918242   CT  33 (16)  27 (71)  23 (11)  21  (56) 
   TT  0 (0) 2 (5)  2 (1) 1  (2) 
     P = 0.46,  2 1.6 (n = 309)  P = 0.66,  2 0.9 (n = 312)  
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     NAS  No NAS No NAS 
dbSNP ID SNP    % (n) % (n)  % (n) % (n) 
            
MMP-2 – 1306 C T C   46 (22) 61 (16 ) 44 21) 53  (142)  
rs243865   CT  52 (25)  33  (87) 56 2 41 (108)  
   TT  2 (1) 6 (17)  0 (0) 6 (16) 
     P < 0.03, 2 7.2    P = 0.05,  2 5.9  
MMP-9 – 1562  C T C   67 (32) 71  (185)  75 (36) 78 (206)  
rs3918242   CT  33 (16)  27 (71) 23 (11) 2  (56) 
   TT  0 (0) 2 (5)  2 (1)  (2) 
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Table 1. Frequencies of matrix metalloproteinase polymorphisms in orthotopic liver 
transplant recipients and donors (n = 314)
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Table 2. Comparison of donor, recipient and procedure variables between patients with and 
without nonanastomotic biliary strictures after orthotopic liver transplant (n =314)
Age, MELD scores, WIT and CIT differences were evaluated by Student’s t-test; frequency 
distribution data were analysed by χ2 or Fisher’s exact tests, where appropriate. CIT, cold 
ischaemia time; time between the start of cold perfusion of graft in the donor and the end of 
cold preservation of the liver graft; DBD, donation after brain death; DCD, donation after 
cardiac death; MELD, model for end-stage liver disease; MMP, matrix metalloproteinase; 
NAS, nonanastomotic biliary lesions; OLT, orthotopic liver transplantation; PBC, primary 
biliary cirrhosis; PSC, primary sclerosing cholangitis; SD, standard deviation; SSC, secondary 
sclerosing cholangitis; WIT, warm ischaemia  time; time between the end of cold ischaemic 
preservation of the liver graft and portal vein reperfusion in the recipient.
*Other cholestatic disease comprise PBC and SSC.
†Other diseases include predominantly autoimmune hepatitis, cryptogenic cirrhosis and 
metabolic disorders.
 Total NAS (n = 48) % No NAS (n = 266) % P-value 
        
Donor variables        
Age (in years, median, range) 44 (16–72) 43  (16–67) 44 (9–72) 0.80 
Gender        
Female 153  29  60 124 47 0.08 
Male 161  19  40 142 53   
Recipient variables        
Age (in years, median, range) 48 (16–70) 45  (16–61) 48 (17–70) 0.08 
Gender        
Female 122  16  33  106 40 0.39 
Male 192 32  67 160 60  
Primary liver disease       0.04 
Post viral cirrhosis 59 4  8 55  21   
Alcoholic cirrhosis 46 5  10 41 15   
PSC 57  15   31  42 16  
Other cholestatic disease* 28 6  13  22 8  
Other disease† 124 18   38 106 40  
Laboratory MELD score (median, range) 15  15 (6 –40)      15 (6 –40)  0.98 
OLT procedure variables       0.50 
DCD 25 5   10 20 8  
DBD 289 43  90 246 92  
WIT in minutes (mean ± SD) 44 ± 13  42 ± 10   44 ± 13   0.37 
 n = 296 n = 46  n = 250   
CIT in minutes (mean ± SD) 573 ± 188  595 ± 183   561 ± 189  0.38 
 n = 299 n = 46  n = 253    
MMP-2 [rs243865] CT        0.003 
No CT present 115  10  21  105  39  
CT in recipient or donor 151  24  50 127  48  
CT in recipient and donor 48 14  29 34 13   
        
 Total NAS (n = 48) % No NAS (n = 266) % P-value 
        
Donor variables        
Age (in years, median, range) 44 (16–72) 43  (16–67) 44 (9–72) 0.80 
Gender        
Female 153  29  60 124 47 0.08 
Male 161  19  40 142 53   
Recipient variables        
Age (in years, median, range) 48 (16–70) 45  (16–61) 48 (17–70) 0.08 
Gender        
Female 122  16  33  106 40 0.39 
Male 192 32  67 160 60  
Primary liver disease       0.04 
Post viral cirrhosis 59 4  8 55  21   
Alcoholic cirrhosis 46 5  10 41 15   
PSC 57  1   31  42 16  
Other cholestatic diseas* 28 6  13  22 8  
Other disease† 124 18   38 106 40  
Laboratory MELD score (median, range) 15 15 (6 –40)    15 (6 –40)  0.98 
OLT procedure variables       0.50 
DCD 25 5   10 20 8  
DBD 289 43  90 246 92  
WIT in minutes (mean ± SD) 44 ± 13  42 ± 10   44 ± 13  0.37 
 n = 296 n = 46  n = 250   
CIT in minutes (mean ± SD) 573 ± 188  595 ± 183   561 ± 189  0.38 
 n = 299 n = 46  n = 253    
MMP-2 [rs243865] CT        0.003 
No CT present 115  10  21  105  39  
CT in recipient or donor 151  24  50 127  48  
CT in recipient and donor 48 14  29 34 13   
        
 Total NAS (n = 48) % No NAS (n = 266) % P-value 
        
Donor variables        
Age (in years, median, r ) 44 (16–72) 43  (16–67) 44 (9–72) 0.80 
Gender        
Femal  153  29  60 124 47 0.08 
Male 161  19  40 142 53   
Recipi nt variables        
Age (in years, median, r ) 48 (16–70) 45  (16–6 ) 48 (17–70) 0.08 
Gender        
Femal  122  16  33  106 4  0.39 
Male 192 32  67 160 60  
Prima y liver disease       0.04 
Post viral ci rhosis 59 4  8 55  21   
Alcoholic cirrhosis 46 5  10 41 15   
PSC 57  15   31  42 16  
Other c olestatic disease* 28 6  13  22 8  
Other disease† 124 18   38 106 4   
Labor tory MELD score (m dian, ge) 15  15 (6 –40)      15 (6 –40) 0.98 
OLT procedur  va iables       0.50 
DCD 25 5   10 20 8  
DBD 289 43  90 246 92  
WIT in m utes (mean ± SD) 44 ± 13  42 ± 10   44 ± 13   0.37 
 n = 296 n = 46  n = 250   
CIT in m utes (mean ± SD) 573 ± 188  595 ± 18   561 ± 189  0.38 
 n = 299 n = 46  n = 253    
MMP-2 [rs 43865] CT        0.003 
No CT present 115  10  21  105  39  
CT in recipi nt or donor 151  24  50 127  48  
CT in recipi nt and donor 48 14  29 34 1   
        
 Total NAS (n = 48) % No NAS (n = 266) % P-value 
      
Donor variables        
Age (in years, median, range) 44 (16–72) 43 (16–67) 44 (9–72) 0.80 
Gender        
Femal  153  29 60 124 47 0.08 
Male 161  19 40 142 53   
Recipient variables        
Age (in years, median, range) 48 (16–70) 45 (16–6 ) 48 (17–70) 0.08 
Gender        
Femal  122  16 33  106 40 0.39 
Male 192 32 67 160 60  
Primary liver disease       0.04 
Post viral cirrhosis 59 4  8 55  21   
Alcoholic cirrhosis 46 5  10 41 15   
PSC 57  15  31  42 16  
Other c olestati  dis ase* 28 6  13  22 8  
Other disease† 124 18  38 106 40  
Laboratory MELD score (median, range) 15  15 (6 –40)      15 (6 –40)  0.98 
OLT procedure variables       0.50 
DCD 25 5   10 20 8  
DBD 289 43 90 246 92  
WIT in minutes ( ean ± SD) 44 ± 13  42 ± 10   44 ± 13  0.37 
 n = 296 n = 46  n = 250   
CIT in minutes ( ean ± SD) 573 ± 188  595 ± 183   561 ± 189  0.38 
 n = 299 n = 46  n = 253   
MMP-2 [rs243865] CT        0.003 
No CT present 115  10 21  105  39  
CT in recipient or donor 151  24 50 127  48  
CT in recipient and do or 48 14 29 34 13   
        
 Total NAS (n = 48) % No NAS (n = 266) % P-value 
        
Donor variables        
Age (in years, median, range) 44 (16–72) 43  (16–67) 44 (9–72) 0.80 
Gender        
Female 153  29  60 124 47 0.08 
Male 161  19  40 142 53  
Recipient variables        
Age (in years, median, range) 48 (16–70) 45  (16–61) 48 (17–70) 0.08 
Gender        
Female 122  16  33  106 40 0.39 
Male 192 32  67 160 60 
Primary liver d se se       0.04 
Post viral cirrhosis 59 4  8 55  21  
Alcoholic cirrhosis 46 5  10 41 15  
PSC 57  15   31  42 16 
Other chol static dis ase* 28 6  13  22 8  
Other disease† 124 18   38 106 40 
Laboratory MELD sc e (median, ange) 15  15 (6 –40)      15 (6 –40)  0.98 
OLT procedu e variables       0.50 
DCD 25 5   10 20 8  
DBD 289 43  90 246 92 
WIT in minutes (mean± SD) 44 ± 13  42 ± 10  44 ± 13   0.37 
 n = 296 n = 46 n = 250  
CIT in minutes (mean± SD) 573 ± 188  595 ± 183  561 ± 189  0.38
 n = 299 n = 46 n = 253   
MMP-2 [rs243865] CT        0.003 
No CT present 115  10  21  105  39  
CT in recipient or do r 151  24  50 127  48  
CT in recipient a d donor 48 14  29 34 13   
        
 Total NAS (n = 48) % No NAS (n = 266  P-value 
        
Donor variables        
Age (in years, m dia , ran ) 44 (16–72) 43  (16–67) 44 (9–72) 0.80
Gender        
Female 153  29  60 124 47 0.08 
Male 161  9  40 142 53   
Recipient variabl s        
Age (in years, m dia , ran ) 48 (16–70) 45  (16–61) 48 (17–70) 0.08 
Gender        
Female 122  6  33  106 4  0.39 
Male 192 32  67 160 60  
Primary liver disease       0.04 
Post viral cirrhosi  59 4  8 55  21   
Alcoholic irrhosis 46 5  10 41 15   
PSC 57  1   31  42 16  
Other cholestatic di eas* 28 6  13  22 8  
Other disease† 124 8   38 106 4   
Laboratory ME D score (medi n, ange) 15  15 (6 –40)      15 (6 –40) 0.98 
OLT procedure variables       0.50 
DCD 25 5   10 20 8  
DBD 289 43  90 246 92  
WIT in minutes (mean ± SD) 44 ± 13  2  0   4  ± 13   0.37 
 n = 296 n = 4   n = 250   
CIT in minutes (mean ± SD) 573 ± 188  595 ± 18   61 9  0.38 
 n = 299 n = 46  n = 253    
MMP-2 [rs243865] CT       0.003 
No CT present 115  10  21  105  39  
CT in recipient or do or 151  24  50 127  48  
CT in recipient and donor 48 14  29 34 13   
        
 Total NAS (n = 48) % No NAS (n = 266) % P-value
       
Donor variables       
Age (in years, media , range) 44 (16–72) 3  (16–67) 44 (9–72) 0.80
Gender       
Female 153  29  60 124 47 0.08 
Male 161  19  40 1 2 53   
Recipient variabl s       
Age (in years, media , range) 48 (16–70) 5  (16–61) 48 (17–70) 0.08 
Gender       
Female 122  16  33  106 40 0.39 
Male 192 32  67 1 0 60  
Primary liver disease      0.04 
Post viral cirrhosi  59 4  8 55  21   
Alcoholic cirrhosis 46 5  10 41 15   
PSC 57  15   31  42 16  
Other chol static disease* 28 6  13 22 8  
Other disease† 124 18   38 106 40  
Laboratory ME D score (median, range) 15  15 (6 –40)      15 (6 –40)  0.98 
OLT procedu e variables      0.50 
DCD 25 5   10 2  8  
DBD 289 43  90 246 92  
WIT in minutes (mean± SD) 44 ± 13  42 ± 10   44 ± 13   0.37 
 n = 296 n = 46  n = 250   
CIT in minutes (mean± SD) 573 ± 188  595 ± 183   561 ± 18   0.38 
 n = 299 n = 46  n = 253    
MMP-2 [rs243865] CT       0.003 
No CT present 115 10 21  105 39  
CT in recipient or don r 151  24 50 127 48  
CT in recipient and donor 48 14  29 34 13   





     Univariate analysis   Multivariate analysis (n = 299) 
          
Risk factor   NAS %   HR (95% CI) P-value  Adjusted HR (95% CI) P-value 
          
MMP-2 [rs243865] CT      0.01   0.008 
Donor and recipient Vs. none 14/48 29  3.48 (1.55 –7.84) 0.003     3.48 (1.54 – 7.87) 0.003 
Donor or recipient Vs. none 24/151  16  1.84 (0.88 – 3.84) 0.11      1.64 (0.78 – 3.46) 0.20 
None Reference 10/115  9  1 (reference)      1 (reference)  
Age recipient Continuous 48/314   0.98 (0.96 – 1.01) 0.13    
Age donor Continuous 48/314   1.00 (0.98 – 1.02) 0.72    
Gender recipient Female 16/122 13    0.74 (0.41 – 1.35) 0.32    
 Male 32/192 17   1 (reference)     
Gender donor Female 29/153 19  1.53 (0.86 – 2.73) 0.15     
 Male 19/161 12   1 (reference)     
Primary liver disease PSC 15/57  26  2.0 (1.11 – 3.76) 0.02      2.14 (1.13 – 4.06) 0.02 
 Other 33/257 13   1 (reference)     
Laboratory MELD score Continuous 48/314    1.00 (0.97 – 1.04) 0.84    
Procedure DCD 5/25 20  1.50 (0.60 – 3.80) 0.39    
 DBD 43/289 15   1 (reference)     
CIT  Continuous 46/299   1.000 (1.000 – 1.002) 0.15       1.001 (1.000 –1.003) 0.08 
WIT  Continuous 46/296   0.99 (0.96 – 1.01) 0.38    




     Univariate analysis   Multivariate analysis (n = 299) 
          
Risk factor   NAS %   HR (95% CI) P-value  Adjusted HR (95% CI) P-value 
          
MMP-2 [rs 43865] CT      0.01   0.008 
Donor and recipi nt Vs. none 14/48 29  3.48 (1.55 –7.84) 0.003     3.48 (1.54 – 7.87) 0.003 
Donor or recipi nt Vs. none 24/151  16  1.84 (0.88 – 3.84) 0.11      1.64 (0.78 – 3.46) 0.20 
None Reference 10/1 5  9  1 (reference)      1 (reference)  
Age recipi nt Continuous 48/314   0.98 (0.96 – 1.01) 0.13    
Age donor Continuous 48/314   1.00 ( .98 – 1.02) 0.72    
Gender recipi nt Femal  16/122 13    0.74 (0. 1 – 1.35) 0.32    
 Male 32/19  17   1 (reference)     
Gender donor Femal  29/153 19  1.53 (0.86 – 2.73) 0.15     
 Male 19/161 12   1 (reference)     
Prima y liver disease PSC 15/57  26  2.0 (1 11 – 3.76) 0.02      2.14 (1.13 – 4.06) 0.02 
 Other 33/257 13   1 (reference)     
Labor tory MELD score Continuous 48/314    1.00 ( .97 – 1.04) 0.84    
Procedur  DCD 5/25 20  1.50 (0.60 – 3.80) 0.39    
 DBD 43/289 15   1 (reference)     
CIT  Continuous 46/299   1.000 (1. 00 – 1.002) 0.15       1.00  (1.000 –1.003) 0.08 
WIT  Continuous 46/29    0.99 (0. 6 – 1.01) 0.38    




     Univariate an lysis   Multivariate an lysis (  = 299) 
          
Risk factor   NAS %   HR (95% CI) P-value  Adjusted HR (95% CI) P-value 
          
MMP-2 [rs 43865] CT     0.01   0.008 
Donor and recipient Vs. none 14/48 29  3.48 (1.55 –7.84) 0.003     3.48 (1.54 – 7.87) 0.003 
Donor or ecipient Vs. none 24/151  16  1.84 (0.88 – 3.84) 0.11      1.64 (0.78 – 3.46) 0.20 
None Refer nce 10/1 5  9  1 (refe nce)      1 (refe nce)  
Age recipient Continuous 48/314   0.98 (0.96 – 1.01) 0.13    
Age donor Continuous 48/314   1.00 ( .98 – 1.02) 0.72    
Gend r recipient Female 16/122 13    0.74 (0.41 – .35) 0.32    
 Male 32/192 17   1 (refe nce)     
Gend r onor Female 29/153 19  1.53 (0.86 – 2.73) 0.15     
 Male 19/161 12   1 (refe nce)     
Primary liver diseas  PSC 15/57  26  2.0 (1.11 – 3.76) 0.02      2.14 (1.13 – 4.06) 0.02 
 Other 33/257 13   1 (refe nce)     
Laborat y MELD score Continuous 48/314    1.00 ( .97 – 1. 4) 0.84    
Procedure DCD 5/25 20  1.50 (0.60 – 3.80) 0.39    
 DBD 43/289 15   1 (refe nce)     
CIT  Continuous 46/299   1.000 (1. – 1. 2) 0.15       1.00  (1.000 –1. 3) 0.08 
WIT  Continuous 46/296   0.99 (0.96 – 1.01) 0.38    




     Univariate analys s   Multivariate analys s (n = 299) 
          
Risk factor   NAS %   HR (95% CI) P-value  Adjusted HR (95% CI) P-value 
          
MMP-2 [rs243865] CT      0.01   0.008 
Donor and ecipie t Vs. none 14/48 29  3.48 (1 55 –7.84) 0.003    3.48 (1 54 – 7.87) 0.003 
Donor r recipient Vs. none 24/151  16  1.84 (0. 8 – 3. 4) 0.11      .64 (0.78 – 3.4 ) 0.20 
None Referenc  10/115  9  1 (referenc )      1 (referenc )  
Age recipient Continuous 48/31    0.98 ( . 6 – 1.01) 0.13    
Age donor Continuous 48/31    1.00 (0.98 – 1.02) 0.72    
Gender recipient Female 16/122 13    0.74 ( 41 – 1.35) 0.32    
 Male 32/192 17   1 (referenc )     
Gender donor Female 29/153 19  1.53 (0 86 – 2.73) 0.15     
 Male 19/16  12   1 (referenc )     
Primary live  d s ase PSC 15/57  26  2.0 (1.11 – 3.76) 0.02      .14 (1.13 – 4.06) 0.02 
 Other 33/257 13   1 (referenc )     
Laboratory MELD score Continuous 48/31     1.00 (0.97 – 1.04) 0.84    
Procedure DCD 5/25 20  1.50 (0 60 – 3.80) .39    
 DBD 43/289 15   1 (referenc )     
CIT  Continuous 46/299   1.000 (1. – 1.002) 0.15       1.001 (1. 0 –1. 03) .08 
WIT  Continuous 46/296   0.99 ( . 6 – 1. 1) 0.38    




     Univariate n lysis   Multivariate n lysis (n = 299) 
        
Risk factor   NAS %  HR (95  CI) P-value  Adj ste  HR (95% CI) P-value
        
MMP-2 [rs243865] CT     0.01  0.008 
Donor and recipient Vs. no e 14/48 29  3.48 (1.55 –7 84) 0.003     .48 (1.5 – 7.87) 0.003 
Donor or recipient Vs. none 24/151 16  1.84 (0.88 – 3.84) 0.11     1.64 (0.78 – 3. 6) 0.20
None Reference 10/115  9  1 (reference)      1 (reference)  
Age recipient Continu us 48/314   0.98 ( . 6 – 1.01) . 3   
Age donor Continu us 48/314   1.00 (0 98 – 1. 2) .72   
Gender recipi t Female 16/122 3    0.74 (0.41 – 1.35) 0.32   
 Male 32/192 17   1 (reference)    
Gender dono Female 29/153 9  1.53 (0.86 – 2.73) 0.15    
 Male 19/161 2   1 (reference)    
Primary liver disease PSC 15/57 26  2.0 (1.11 – 3.76) 0.02     2.14 (1.13 – 4 06) 0.02 
 Other 33/257 13   1 (reference)    
Laboratory MELD score Continu us 48/314    1.00 (0 97 – 1. 4) .84   
Procedure DCD 5/25 20  1.5 (0.6 – 3.80) 0.39   
 DBD 43/289 15   1 (reference)    
CIT  Continu us 46/299   1.000 (1.000 – 2) .15      1.0 1 (1. 0 –1. 3) .08 
WIT  Continu us 46/296   0.99 ( . 6 – 1.01) 0.38   




     Univariate analysis   Multivariate analysis (n = 299) 
          
Risk factor   NAS %   HR (95% CI) P-value  Adjusted HR (95% CI) P-value 
          
MMP-2 [rs243865] CT      0.01   0.008 
Donor and recipient Vs. on  14/48 29  3.48 (1.55 –7.8 ) 0 003     3.48 (1.54 – 7.87) 0.003 
Donor or recipie t Vs. none 24/151  16  .8 (0.8 – 3 4) 0.11     1.64 (0.78 – 3 46) 0.20 
None Referenc  10/115  9   (referenc )     1 (referenc )  
Age recipi nt Continuous 48/314   0.98 (0.96 – 1 01) 0. 3    
Age donor C nti uous 48/314   1.00 (0.98 – . 2) .72    
Gender r cipient Female 16/122 13  0.74 (0.41 – 1.35) 0.32    
 Male 32/192 17    (referenc )    
Gender donor Female 29/153 19  .53 (0.86 – 2.73) 0.15    
 Male 19/161 12    (referenc )    
Primary liver disease PSC 15/57  26  2.0 (1.11 – 3.7 ) 0.02      2.14 (1.13 – 4.06) 0.02 
 Other 33/257 13   1 (referenc )    
Laboratory MELD score C ntinuous 48/314   1.00 (0.97 – 1.04) .84    
Procedu e DCD 5/25 20  1.50 (0.60 – 3 8 ) 0. 9    
 DBD 43/289 15   1 (referenc )    
CIT  Continuous 46/299   1.000 ( – 1. 02) .15       1. 01 (1. 00 –1.0 3) .08 
WIT  Continuous 46/296   0.99 (0.96 – 1 01) 0.38    




    Univariate analysis   Multivariate analysis (  = 299) 
        
Risk factor   NAS %  HR (95% CI) P-value  Adjusted HR (95% CI) P-value 
        
MMP-2 [rs243865] CT    0.01   0.008 
Donor and recipie t Vs. n e 14/48 29  3.48 ( .55 –7.84) 0 00     3 48 (1.54 – 7.87) 0 003 
Donor or recipient Vs. e 24/151 16  1.84 (0.88 – 3.84) 0 11    .64 (0.78 – 3.46) .20 
None Refere ce 10/115 9  1 (reference)      1 (reference)
Age recipient Co nuous 48/314  0.98 (0.96 – . 1) .13    
Age donor Continuous 48/314  1.00 (0.98 – 1.02) 0 72    
Gender recipi nt Femal  16/122 13   0.74 (0.4 – 1.35) .32    
 Male 32/192 17   1 (reference)     
Gender do or Female 29/153 19  1.53 (0.86 – 2.73) 0 15     
 Male 19/161 12   1 (reference)     
Primary liver disease PSC 15/57  26  2.0 (1.11 – 3.76) 0 2      2.14 (1.13 – 4. 6) 0.02 
 Other 33/257 13   1 (reference)     
Laboratory ME D score C n inuous 48/314   1.00 (0.97 – 1.04) 0 84    
Procedure DCD 5/25 20  1.50 ( .60 – 3.80) 39    
 DBD 43/289 15  1 (reference)     
CIT  Continuous 46/299  1.000 (1.000 – 1. 2) 0 15       1. 01 (1.0 – . 3) 0. 8 
WIT  Continuous 46/296  0.99 (0.96 – 1.01) .38    




     Univariate analysis Multiv r te analysis (n = 299) 
         
Risk factor   NAS %  HR (95  CI) P-value  Adj sted HR (95% CI) P-value 
         
MMP-2 [rs243865] CT      0.01   0.008 
Donor and recipient Vs. no  14/48 29  3.48 (1.55 –7.8 ) 0.003     3. 8 (1.54 – 7.87) 0.003
Donor or recipient Vs. none 24/151 16  .84 (0.88 – 3.84) 0. 1     1 6  ( .78 – 3.46) 0.20
None Reference 10/115  9  1 (r ference)     1 (reference) 
Age recipient Continuous 48/314   0.98 (0.96 – 1.01) .13    
Age donor C ntinu us 48/314   1.00 (0.98 – 1.02) .72   
Gender recipi nt F male 16/122 3  0.74 (0.41 – 1.35) 0.32    
 Male 32/192 17   1 (reference)     
Gender do or F male 29/153 1  .53 (0.86 – 2.73) 0. 5    
 Male 19/161 2   1 (reference)     
Primary liver disease PSC 15/57  26  2.0 (1.11 – 3.76) .02     2.14 (1.13 – 4 6) 0.0
 Other 33/257 1   1 (reference)     
Laboratory MELD score Continuous 48/314    1.00 (0.97 – .04) .84    
Procedure DCD 5/25 20  1. 0 (0.60 – 3.8 ) 0.39    
 DBD 43/289 15   1 (reference)     
CIT  ontinuous 46/299   1.000 (1.000 – 1. ) .15      .001 ( – 3) . 8
WIT  Continuous 46/296   0.99 (0.9 – 1. 1) .38    




     Univariate analysis   Multivariate analysis (n = 299) 
          
Risk factor   NAS %   HR (95% CI) P-value  Adjusted HR (95% CI) P-value 
          
MMP-2 [rs243865] CT      0.01   0.008 
Donor and recipient Vs. none 14/48 29  3.48 (1.55 –7.84) 0.003     3.48 (1.54 – 7.87) 0.003 
Donor or recipient Vs. none 24/151  16  1.84 (0.88 – 3.84) 0.11      1.64 (0.78 – 3.46) 0.20 
None Reference 10/115  9  1 (reference)      1 (reference)  
Age recipient Continuous 48/314   0.98 (0.96 – 1.01) 0.13    
Age donor Continuous 48/314   1.00 (0.98 – 1.02) 0.72    
Gender recipient Female 16/122 13    0.74 (0.41 – 1.35) 0.32    
 Male 32/192 17   1 (reference)     
Gender donor Female 29/153 19  1.53 (0.86 – 2.73) 0.15     
 Male 19/161 12   1 (reference)     
Primary liver disease PSC 15/57  26  2.0 (1.11 – 3.76) 0.02      2.14 (1.13 – 4.06) 0.02 
 Other 33/257 13   1 (reference)     
Laboratory MELD score Continuous 48/314    1.00 (0.97 – 1.04) 0.84    
Procedure DCD 5/25 20  1.50 (0.60 – 3.80) 0.39    
 DBD 43/289 15   1 (reference)     
CIT  Continuous 46/299   1.000 (1.000 – 1.002) 0.15       1.001 (1.000 –1.003) 0.08 
WIT  Continuous 46/296   0.99 (0.96 – 1.01) 0.38    
          
 
NAS %
Table 3. Univariate and multivariate analysis for the association of risk factors of nonanastomotic 
biliary lesions in orthotopic liver transplant patients
CI, confidence interval; CIT, cold ischaemia time; time between the start of cold perfusion of graft in the 
donor and the end of cold preservation of the liver graft; DBD, donation after brain death; DCD, 
donation after cardiac death; HR, hazard ratio; MELD, model for end-stage liver disease; MMP, matrix 
metalloproteinase; NAS, nonanastomotic biliary strictures; OLT, orthotopic liver transplantation; PSC, 
primary sclerosing cholangitis; WIT, warm ischaemia time; time between the end of cold ischaemic 
preservation of the liver graft and portal vein reperfusion in the recipient. Univariate and backward 
multivariate analyses were performed using Cox’s proportional hazards method.
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Cold ischaemia time (CIT) was significantly longer for the group with early 
development of NAS (631 ± 179 vs. 520 ± 174 min; P = 0.05). Interestingly, the 
effect of increased CIT and the incidence of NAS was particularly present in the 
first 12 months after OLT (hazard ratio 1.002; P = 0.03). Late occurrence of NAS 
was observed relatively more frequently when patients were transplanted for PSC. 
With PSC as the indication for liver transplantation, the occurrence of NAS within 
the first 12 months after OLT was 27% (9/33) as opposed to 40% (6/15) from the 
late onset NAS. A pre-OLT  diagnosis of PSC was found to be 
accompanied particularly with an increased risk of late onset NAS (hazard 
ratio 3.1; P = 0.03). Multivariate Cox regression analyses and the backward 
elimination procedure, taking all patient and transplant characteristics into 
account with an increased risk of NAS (at the level of P ≤ 0.15), indicated that 
the presence of MMP-2 CT genotype in donor and recipient was an 
independent risk factor for the development of NAS with a higher hazard 
ratio than PSC as primary liver disease (3.5 vs. 2.1, respectively; Table 3).
Matrix metalloproteinase-2 genotype and NAS development post-OLT
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Discussion
In the present study, we report a strong association between the presence of 
MMP-2 CT genotype in donor and/or recipient and the development of NAS 
after OLT. In fact, MMP-2 genotype was a greater risk factor for NAS after 
OLT than PSC. The presence of the MMP-2 CT genotype in donor and/or 
recipient was found to increase the NAS incidence stepwise from 9% when 
absent, increasing to 16% when present in either recipient or donor, further
increasing to 29% when present in both donor and recipient. In contrast, no 
association was found between MMP-9 genotype and the development of NAS. 
Nonanastomotic strictures are considered to be the most troublesome 
biliary complication after OLT, associated with high retransplant rates in up 
to 20% of patients5,7,25,41. Interestingly, further assessment of the impact of 
the MMP-2 genotypes and NAS-related morbidity in our patients, by including 
re-OLTs, also revealed a stepwise increase in relation to the MMP-2 genotype 
from 14 to 38% and by including death in the follow-up, this increased even 
up from 26 to 44%. Apparently, the MMP-2 CT genotype also contributes to 
the morbidity accompanying NAS in the OLT patients. 
Various risk factors for NAS have been identified, suggesting a multifactorial 
origin9,14. The main categories include ischaemia-related injury, immune-
mediated injury such as ABO compatibility, pre-existing disease (especially 
PSC) and toxic injury by bile salts42,43. In addition to clinicopathological 
factors, we were also interested in the impact of the gelatinases MMP-2 and 
MMP-9 in the development of NAS. 
Matrix metalloproteinases comprise a large family of proteolytic enzymes 
involved in physiological and dis-ease-related connective tissue remodelling 
processes and the gelatinases MMP-2 and MMP-9 are considered to play an 
important role in inflammation, degradation and remodelling processes in 
the liver29,31,44. MMP activity is regulated by various factors and controlled by 
activation of latent pro-enzymes and by interaction with endogenous inhibitors 
such as tissue inhibitors of metalloproteinases (TIMPs). Recently, several 
single nucleotide polymorphisms (SNP) in the gene promoter regions of 
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MMPs have been found with an impact on the transcription rate30,32. The C/T 
transition at position –1306 in the promoter of MMP-2, which abolishes the 
Sp 1 binding site, and leads to decreased mRNA transcription and protein 
expression, is generally accepted to be the most relevant SNP for MMP-2. 
Other SNPs of MMP-2 have been reported as well, e.g. –1575 G/A, –790 C/T 
and –735 C/T, but these are in almost complete linkage (dis)equilibrium with  
–1306 C/T and thus provide no additional information30,32,33. In several stud-
ies, an association was demonstrated between MMP-2 polymorphisms and 
the development of cancer. It has even been suggested that MMP-2 
represents a potential target for tumour therapeutics (32, 33). 
In the MMP-9 gene, an SNP at position –1562 is because of a C to T substitution in 
the promoter region. In vitro studies have shown that this transition 
results in loss of binding of a nuclear repression protein and increased 
transcriptional activity in macrophages, associated with the severity of 
coronary atherosclerosis. 
Although other SNPs in the MMP-9 gene have been described, they were 
mainly nonsynonomous located in the exon part of the gene and found not 
to affect the activity or level of the enzyme34,35. In contrast, in cardiovascu-
lar disease, for example, the –1562 T allele was found to be associated with 
increased MMP-9 plasma levels35. 
In the liver, the hepatic stellate cell seems to be the main cellular source of 
MMP-2 and when activated these cells are involved in the synthesis of matrix 
proteins and in the regulation of matrix degradation leading to liver fibrosis. 
Following liver injury, the stellate cells become activated and can express a 
wide range of MMPs and TIMPs, but in particular MMP-244–46. Increased 
mRNA expression of MMP-2 was reported in liver biopsies of patients with 
cirrhosis44. We found previously serum levels of MMP-2 to be increased 
in patients with chronic liver disease and strongly correlated with serum 
markers indicative of a poor liver function31. After OLT, a gradual decrease 
of MMP-2 levels were found they remained higher, however, than found 
in healthy controls and increased with recurrent liver dis-ease. MMP-9 is 
released predominantly from neutrophils and macrophages, but the principal 
source in the liver is thought to be the Kupffer cell, the resident macrophage 
Matrix metalloproteinase-2 genotype and NAS development post-OLT
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Abstract
Background: Primary sclerosing cholangitis (PSC) is a chronic inflammatory 
disease of the bile ducts, frequently necessitating orthotopic liver trans-
plantation (OLT), often accompanied by inflammatory bowel disease (IBD). 
Matrix metalloproteinases (MMPs) are associated with fibrotic diseases due 
to involvement in tissue remodeling.
Aim: Evaluate the contribution of MMP-2 and -9 promoter polymorphisms 
to disease severity in PSC, as assessed by death or need for OLT.
Methods: MMP-2 (–1306 C/T) and -9 (–1562 C/T) promoter polymorphisms 
were analyzed in 132 PSC patients. Follow-up was from onset PSC until 
death, OLT or end of follow-up.
Results: Twenty-year cumulative incidence (CI) of death or OLT for PSC 
patients with MMP-2 CT genotype was 86.5% compared to 52.8% for CC 
genotype (p=0.030) and reached 100% at 11.3 years for TT genotype. In 
patients with IBD, CIs were similar: 20-years CI of death or OLT for MMP-2 
CT genotype was 86.0% compared to 49.0% for CC genotype and 100% at 
11.3 years for TT genotype. Patients without IBD showed a similar trend in 20 
year CI for MMP-2 CT (77.8%) compared to CC (57.8%) and CI for TT genotype 
reached 100% at 9.3 years. Multivariate analysis showed, along with age at 
diagnosis, a stepwise increase in hazard ratio for MMP-2 T-allele polymorphism 
for death or OLT. MMP-9 genotype was not associated with disease severity 
in PSC.
Conclusion: MMP-2 C to T –1306 promoter polymorphism in PSC is an 
independent risk factor for disease severity as reflected by need for OLT or 




In primary sclerosing cholangitis (PSC) the chronic inflammation of the bile 
ducts leads to fibrosis and eventually often to liver cirrhosis. As to date, the 
etiology of PSC remains unknown and no specific treatment can delay or 
arrest the progressive course of this disease. Therefore, orthotopic liver 
transplantation (OLT) remains the only curative option for endstage disease. 
Furthermore, PSC is often accompanied by inflammatory bowel disease 
(IBD), particularly ulcerative colitis (UC), affecting almost 70% of the PSC 
patients.1,2 Mean survival after onset of PSC until OLT, death by cholangitis, 
cholangiocarcinoma (CCA) or liver failure is reported to be 15 to 18 years.1,3 
The pathogenesis of PSC most likely involves genetic, environmental, 
immune and remodeling factors each contributing to inflammation, cell 
dysfunction and, in later stages, development of fibrosis. Genome-wide 
association studies (GWAS) on PSC have implicated the role of several genes 
such as FUT2, GPR35 and TCF4 as potential key players for the intracellular 
processing of bacterial pathogens in the intestinal mucosa.4,5. We have
previously identified three UC susceptibility loci to be associated with PSC 
involving both the innate immune system (REL, CARD9) as well as the 
adaptive system (IL-2 pathway).6 Moreover, mutations of the takeda 
G-protein-coupled bile acid receptor 5 (TGR5) gene located at 2q35 (TGR5) 
has been proposed as a plausible disease gene in PSC due to the expression 
in monocytes and macrophages, particularly since TGR5 has been reported 
to inhibit inflammatory cytokines from activated macrophages, including 
Kupffer cells.7-10 The identified genes are involved in disease development 
but are not necessarily involved in disease modification. The number of 
studies that describe demarcation markers for the clinical course of this 
potentially life-threatening disease is limited.11-13 Matrix metalloproteinases 
(MMPs) are a family of proteolytic enzymes which are involved in the 
degradation, processing and remodeling of the extracellular matrix 
(ECM).14,15  Dysregulation of MMPs is a feature of numerous conditions such 
as cancer and various inflammatory and fibrotic processes.16,17 Interestingly, 
previous studies have shown an impact of MMP-3 genotype on disease 
progression in PSC although from genome-wide association studies (GWAS) 
this gene was not identified to be associated with the development of the 
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disease.4,18 MMP-2 and -9 are known to play a key role in the degradation of 
type IV collagen and are also involved in the cleavage of galectin-3 which in 
turn is involved in chemoattraction and migration of cells, and in 
apoptosis.19,20 Collagen type IV is a major component of the basal membrane, 
which can also be found around bile ducts, and is considered to be essential 
for the development of intrahepatic bile ducts.21 In this study, the gene 
promoter polymorphisms of MMP-2 and MMP-9 were studied in relation to 
the clinical course of PSC patients using OLT or death as markers of severity 
of disease.
Patients and Methods
For this study a total of 132 adult patients with PSC of whom DNA was 
available could be included from the Leiden University Medical Center 
(LUMC, n=69) and the University Medical Center Groningen (UMCG, n=63). 
Both centers are tertiary referral centers and offer liver transplantation as 
treatment for end-stage PSC. Genomic DNA was extracted routinely from 
peripheral blood and/or tissue samples without given preference to any 
explicit clinical variable. All patients were routinely checked at the outpa-
tient clinic and PSC patients were screened regularly for the need for OLT. 
All patients were prospectively included and followed up in the centers until 
July 2012 and the combined endpoint death or first OLT was considered as 
primary end-point for this study. Clinical data including death or OLT were 
obtained from medical records and hepatological and surgical patient charts. 
This study was performed according to the guidelines of the Medical Ethics 
Committee of both participating centers and in compliance with the Helsinki 
Declaration.
PSC diagnosis and OLT
Patients with clinical suspicion of PSC were (re)evaluated with either endo-
scopic retrograde cholangioscopy (ERCP) or magnetic resonance cholangiography 
(MRCP). In case of clear characteristics on the cholangiogram PSC was 
classified as large duct PSC. A liver biopsy was performed on patients with 
Chapter 6
115
clinical symptoms but without clear characteristics of PSC on the 
cholangiogram, in which case a small duct PSC was the diagnostic feature. 
OLT was performed according to standard procedures. Post OLT standard 
immunosuppressive therapy was given consisting of corticosteroids, a 
calcineurin inhibitor with or without mycophenolate mofetil or azathiopurine. 
From 2001 on, basiliximab was given during and day 4 post OLT.
MMP-2: high-resolution DNA melting analysis
MMP2 –1306 C/T (rs243865) as most relevant SNP was assessed using high-
resolution DNA melting assay, as described previously.22 In brief, sequences 
of the primers used in the polymerase chain reaction (PCR) were 5’-CCAGT-
GCCTCTTGCTGTTTT-3’ (forward) and 5’- GACTTCTGAGCTGAGACCTGA-3’ 
(reverse). The wild-type (C) genotype sequence: 5’-CCACCCAGCACTCCAC-
CTCTTTAGCTC-3’ was assessed using an unlabelled probe designed accord-
ingly, with a 3’-amino-C7 modification to prevent DNA polymerase extension 
during PCR. High-resolution melting analysis of PCR products amplified in 
the presence of a saturating double stranded DNA dye (LCGreenPlus, Idaho 
Technology, Salt Lake City, Utah, USA) and a 3’-blocked probe to identify both 
heterozygous and homozygous sequence variants distinguished by differences 
in the melting curve shape. In each experiment, sequence-verified control 
donors for each genotype were used. Observed frequencies in our PSC 
patients were CC=70, CT=53 and TT=9, which is in Hardy-Weinberg equilibrium.
MMP-9: PCR-RFLP genotyping
The SNP C/T at position –1562 (rs3918242) of the MMP-9 gene promoter 
was determined by PCR-RFLP, also previously described.(19) The SNP flanking 
region was amplified using primers 5’-ATGGCTCATG-CCCGTAATC-3’ and 
5’-TCACCTTCTTCAAAGCCCTATT-3’ followed by restriction analysis with Sph I 
to produce 352+207+145 bp fragments that identify CC, CT and TT genotypes 
by the migration patterns on agarose gels.(22-24) Observed frequencies in 
our PSC patients were CC=102, CT=29 and TT=1, which is in Hardy-Weinberg 
equilibrium.
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Statistical analysis
Data were analyzed using SPSS 20.0 software (SPSS Inc.; Chicago, IL, USA). 
Log-rank statistics were used for follow-up data. Analysis of Variance (ANO-
VA) test was used for normal distributions. Non-parametric Mann-Whitney 
U test was used to analyze medians in case of non-normal distributions. 
Univariate and multivariate analysis were performed using Cox’s proportional 
hazards method. Variables associated with an increased risk at the p<0.20
level in the univariate analysis were taken into account in the multivariate 






A total of 132 patients were included with a median age of 38 years at onset 
of PSC and a median follow-up of 12.5 years. Sixty PSC patients (45.5%) were 
transplanted with a median age at OLT of 49 years. Eleven patients (8.3%) 
died before receiving transplantation of which 7 developed CCA (5.3%). 
Median follow-up from PSC diagnosis to OLT was 8.2 years (range 0.4 – 21 
years). Of all PSC patients 80.3% had concomitant IBD, with a predominance 
of UC (64.4%). Large duct PSC was diagnosed using ERCP in 72 cases
(54.5%) and in 36 patients (27.3%) the diagnosis was by MRCP. Small ducts 
PSC was diagnosed in 24 (18.2%) patients based on liver biopsy when no 
clear characteristics of PSC were present on the cholangiogram. A list of 
baseline characteristics of the patients is given in table 1.
MMP genotype association
MMP-2 CT and TT genotypes within the PSC patients were significantly asso-
ciated with a higher incidence of OLT or death during follow-up. The cumulative 
incidence of patients experiencing OLT or death in 20 years after diagnosis 
was 86.5% for the CT genotype compared to 52.8% for the CC genotype 
(CT vs. CC log-rank p=0.030). Patients with a TT genotype had cumulative 
incidence of death or OLT of 100% in 11.3 years after diagnosis, which was 
higher compared to patients with CT or CC genotype (overall comparison, 
logrank p=0.027, figure 1a). In addition, the MMP-2 promoter polymorphisms 
showed comparable results when PSC patients had IBD as concomitant 
disease, indicated by the cumulative incidence of death or OLT within 20 
years of 86.0% for the CT genotype group compared to 49.0% for PSC pa-
tients with IBD and a CC genotype (CT vs. CC log-rank p=0.038). Accordingly, 
PSC patients with a TT genotype also showed comparable results when IBD 
was concomitant, with a cumulative incidence of death or OLT of 100% in 
11.3 years compared to (overall comparison log-rank p=0.021). 
PSC patients with the MMP-2 CT (n=9) or TT (n=1) genotype but without 
IBD as concomitant disease had a similar trend in the cumulative incidence 
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of OLT or death of 77.8% for CT and 100% for TT compared to 57.8% for the 
CC genotype (n=16), although due to small numbers this difference did not 
reach statistical significance (p=0.437, figure 1c). In patients undergoing OLT 
the Model for End-stage Liver Disease (MELD) scores immediately preceding 
OLT were not significantly different in the CT or TT genotype group com-
pared to the CC group (median MELD score CC group 11 (n=25); CT group 12 
(n= 31); TT group 10 (n=4), ANOVA p=0.732). Furthermore, only 18% (11/60) 
had a MELD score >17 indicating more severe liver disease in these patients 
(CC=4; CT=6; TT=1, ANOVA p=0.625). 
The MMP-9 gene promoter polymorphisms were evaluated similarly but no 
association was found of these polymorphisms and the risk of OLT or death 
as indicators of disease severity. No association was found for MMP-2 or 
MMP-9 genotypes and the development of CCA in PSC patients.
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Characteristic  Total n=132  
Age at onset of PSC (median, range)  38 (18 – 75)  
Endpoint                                                  Death % (n)   8.3 (11)  
                                                   OLT % (n)   45.5 (60) 
Age at OLT (median, range)  49 (21 – 68) 
Follow-up after PSC (median, range)  12.5 (0.6 – 30) 
Gender % (n)                                           Male   66.7 (88) 
   Female  33.3 (44)  
IBD % (n)                                                 UC  64.4 (85) 
CD   10.6 (14) 
Indeterminate  5.3 (7)  
No IBD  19.7 (26) 
MELD score before OLT (median, range)  11 (6 – 34) 
Type of PSC (%)                                      Small duct   18.2 (24) 
                                                                 Large duct  81.8 (108) 
Table 1. Baseline characteristics
PSC, primary sclerosing cholangtitis; OLT, orthotopic liver transplantation;
MELD, Model for End-Stage Liver Disease; IBD, Inflammatory Bowel Disease;
UC, Ulcerative Coltis; CD, Crohn’s Disease.
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The cumulative incidence of death or OLT after onset of PSC. Cumulative incidence during 
20-years of follow-up after diagnosis of PSC was significantly higher in PSC patients with MMP-2 
CT genotype (86.5%) compared to the CC-genotype (52.8%; p=0.030). Patients with a TT geno-








The cumulative incidence of death or OLT in relation to IBD and MMP-2 genotype. Cumulative 
incidence of death or OLT during 20-years of follow-up PSC patients with the MMP-2 CT/TT 
genotype and IBD as concomitant disease was 86.0% compared to 49.0% for PSC patients with 
IBD and wild-type MMP-2 promoter (CC) (CT vs. CC, log-rank p=0.038). Patients wit a TT geno-
type reached a cumulative incidence of 100% after 11.3 years (overall comparison, log-rank p=0.021)






   Univariate analysis Multivariate analysis 
Variables  Total HR (95%CI)  p-value HR (95%CI)  p-value  
Gender Male 88/132 1.05 (0.63 – 1.76) 0.852   
 Female 44/132 1(reference)    
Age at PSC onset Continuous  1.03 (1.01 – 1.05)  0.001 1.03 (1.01 – 1.05)  0.004  
MMP-2 (rs243865) Overall   0.031  0.019  
 TT  9/132 2.65 (1.08 – 6.51)  0.031 2.87 (1.16 – 7.09) 0.023  
 CT  53/132  1.74 (1.05 – 2.88) 0.034 1.80 (1.09 – 2.99) 0.022  
 CC  70/132 1 (reference)  1 (reference)  
MMP-9 (rs3918242 ) Overall   0.560   
 TT  1/132  2.13 (0.29 – 15.56)  0.456   
 CT  29/132 1.27 (0.72 – 2.23) 0.408   
 CC  102/132  1 (reference)    
Type of PSC  Small duct 24/132 0.92 (0.50 – 1.69) 0.790   
 Large duct 108/132 1 (reference)    
IBD  IBD  106/132 0.54 (0.30 – 0.97) 0.039 0.61 (0.33 – 1.12)  0.112
 












Table 2. Univariate and multivariate analysis of risk factors for death or OLT in PSC 
patients. Multivariate analysis showed that age as well the presence of MMP-2 CT or 
TT genotype in PSC patients were significant risk factors for death or OLT.
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PSC patients with the MMP-2 CT/TT genotype but no IBD as concomitant disease had a 
cumulative incidence of death or OLT at twenty years of 77.8% compared to 57.8% for the CC 
genotype (overall comparison; log-rank p=0.437)
Figure 1c
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Univariate and multivariate analysis
In the univariate Cox regression analysis, the age at diagnosis of PSC, IBD 
and MMP-2 CT/TT genotype were found to be associated at the p<0.20 level 
and were thus taken into account in the multivariate analysis. No significant 
association was found for gender, subtype of PSC (e.g., large or small duct) 
or MMP-9 genotypes and the risk of OLT or death in the univariate analysis. 
Multivariate Cox regression analysis revealed age at onset of PSC as well as 
MMP-2 CT and TT genotype promoter polymorphisms to be significant and
independent risk factors for OLT or death for PSC patients (age at onset 
hazard ratio (adjusted HR) 1.03, p=0.004, MMP-2 CT adjusted HR 1.80, 
p=0.022, MMP-2 TT adjusted HR=2.87, p=0.023). (Table 2)
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Discussion
In this study we found the MMP-2 that the T-allele of the –1306 C/T promoter
polymorphisms is an important, gene-dose dependent and clinically 
independent diseasemodifying gene in PSC, also when the disease was 
accompanied by inflammatory bowel disease. This disease modifying effect 
was not observed with MMP-9 and therefore underlines the contribution of 
MMP-2 in progressive liver diseases accompanied with fibrotic tissue 
formation. PSC is still a disease of unknown origin but several hypotheses 
exist on the pathogenesis of PSC. One theory derives from the strong 
association of PSC with IBD and suggests that damage to the biliary tract 
might result from aberrant lymphocyte trafficking from the intestinal 
mucosa to the liver.25 Other studies suggest that cholangiocyte dysfunction 
involving mutations of the TGR5 gene, with impaired protection from toxic 
bile salts by the bicarbonate “umbrella” contributes to a decreased inhibition 
of inflammatory cytokines released from Kupffer cells.7,9,26 Although many of 
the above mentioned loci have been implicated in the pathogenesis of PSC, 
description of genes that contribute to disease progression is limited. This 
might be due to the fact that GWAS studies only focus on disease 
development rather than on disease outcome. Furthermore, investigating 
genetic associations with disease progression requires patients with long-term 
follow-up in contrast to disease association studies. Interestingly, genetic 
variants of MMP-3 have previously been associated with disease development 
and severity, although the gene did not emerge from the GWAS studies.4,5,27 
Jurdan et al. showed that genetic variants of MMP-3 were associated with 
increased disease progression and this progression was even more empha-
sized when PSC patients had concurrent UC.28 Satsangi et al. showed the 
MMP-3 5A allele to be more frequently present in PSC patients compared to 
UC patients and healthy controls suggesting the potential involvement of 
MMP-3 in PSC development.29 However, so far MMP-2 and MMP-9 were not 
investigated as potential disease modifiers in PSC. Matrix metallo-
proteinases are a large group of proteolytic enzymes involved in remodeling 
the extracellular matrix (ECM) in physiological as well as pathological conditions. 
MMP-2 and MMP-9 are thought to play a key role in the degradation of all 
kinds of ECM components, such as type IV collagen, a main component of 
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ECM. The C/T transition at position 1306 in the promoter of MMP-2, which 
abolishes the Sp 1 binding site and leads to decreased mRNA transcription 
and protein expression, is generally accepted as yet to be the most relevant 
SNP for MMP-2 and in almost complete linkage disequilibrium with several 
other single nucleotide polymorphisms in the MMP-2 promoter region.30 
In the current study we have shown a stepwise increase in hazard ratio for 
death or OLT in the multivariate analysis for the C/T transition for MMP-2 
independent of age at which PSC was diagnosed. Moreover, small or large 
duct PSC did not have an impact on survival or need for OLT in our popula-
tion. In a previous study we have shown that MMP-2 CT genotype was clearly 
associated with the development of nonanastomotic biliary strictures (NAS) 
within 4 years after OLT.22 We also found that for patients who developed 
NAS after OLT, serum levels of MMP-2 tended to be lower for the CT/TT-
genotype group compared to the CC-genotype group. The C/T transition 
likely leads to decreased activity of MMP-2, which may lead to decreased 
cleavage of collagen. In case of PSC, where the inflammation stimulus is 
continuously present, the pivotal role of a decreased locoregional MMP-2 
activity may be even more emphasized with subsequent collagen formation 
and deposition. Approximately 70% - 90% of PSC patients have IBD.31 
Interestingly, treatment of IBD with medication or even colectomy does not 
stop or alter the natural course of PSC in these patients.2,32 This is in line 
with our multivariate analysis where IBD was found to have no independent 
association and thus no impact on the progression of PSC. However, PSC 
patients without concomitant IBD also showed similar cumulative incidences 
of 77.8% for the CT genotype compared to 57.8% for PSC patients with CC 
genotype and no IBD. Only one patient without IBD had a TT genotype and 
had an event at 9.2 years. Although this did not reach statistical significance, 
most likely due to small numbers, it clearly shows that the MMP-2 CT/TT 
genotype is generally and consistently involved in disease progression in  PSC. 
Remarkably,in contrast to the association found with MMP-2 there was no 
association between the MMP- 9 promoter polymorphisms and PSC disease 
severity. This finding is in line with our previous observation where we found 
no association between the MMP-9 promoter polymorphisms and the 
development of NAS after OLT.22 These observations might imply that MMP-9 
polymorphisms are less likely to contribute to fibrotic processes in the liver. 
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The current study has some potential limitations. For instance, we evaluated 
MMP-9 –1562 C/T as most relevant SNP. Although several SNPs of MMP-9 
are known, only two of them seem to be functional, a –1562 C/T substitution 
(rs 3918242) and a microsatellite SNP at –90(CA)n (rs 3222264).33,34 One 
study previously showed that the MMP-9 –1562C/T polymorphism 
increased MMP-9 expression in vitro.35 However, in our previous study 
MMP-9 –1562C/T was not associated with the development of NAS and 
the present study also showed no association with disease progression in 
patients with PSC. Secondly, no MMP was associated with PSC in any of the 
performed GWAS studies so far. However, our current study is hypothesis 
driven based on our previous report on MMP-2 C/T polymorphisms and 
NAS development. The role of MMP-2 in NAS was previously observed, 
indicating the importance of MMP-2 in the turn-over of collagen surrounding 
bile ducts. Furthermore, in the present study we found a clear gene dose-
dependent relationship in the C/T polymorphism with disease progression 
in PSC patients. We realize that the current study has a relative small sample 
size (n=132) and larger studies are indicated to confirm the results of the 
present study. These studies might preferably also include longitudinal 
assessment of circulating levels and tissue expression of MMP-2 in PSC 
patients in relation to genotype, disease progression and fibrosis formation. 
It is important, however, to realize that the genotype of the PSC patient does 
not change over time, whereas we know from our previous studies that the 
MMP-2 levels change with disease progression, i.e., fibrosis and cirrhosis, 
irrespective of the phenotype and genotype, and that these levels change 
after OLT but these levels depend on donor and recipient mismatch of the 
MMP-2 genotype.22,36,37 Furthermore, we did not determine serum IgG4 
levels to distinguish for possible IgG4-related sclerosing cholangitis 
(IgG4-SC). However, involvement of IBD is highly unusual in IgG4- SC, 
while IBD was present in 80.4% of the cases in our population. In addition, 
no patients had involvement of other organs such as the pancreas, which is 
common in IgG4-mediated disease. 
In summary, the MMP-2 –1306 C/T gene promoter polymorphism in PSC 
patients is an independent risk factor for a more severe phenotype resulting 
in more frequent and earlier OLT or patient’s mortality. Our current study is 
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in line with previous studies on MMPs and PSC severity and indicates the 
important role of MMPs in regulating liver matrix homeostasis in PSC. These 
findings contribute to our understanding of the pathophysiologic processes
involved in PSC and may provide an additional diagnostic tool to identify 
high-risk patients for timely referral to a hospital with transplantation facilities.
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Purpose: Chimerism in transplantation medicine refers to the coexistence 
of cells of donor and recipient origin. Their existence in relation to possible 
pathological mechanisms remains largely unknown. We used donor/recipient 
mismatches for matrix metalloproteinases (MMP) gene polymorphisms in 
liver biopsies and in blood as a marker for chimerism after orthotopic
liver transplantation (OLT). The second aim of this study was to evaluate 
these polymorphisms in relation to clinical outcome such as ischemia/
reperfusion injury (IRI) and acute cellular rejection (ACR).
Methods: MMP-2 and MMP-9 promoter polymorphism donor/recipient 
mismatches were determined in 147 OLT patients. The relationship between 
these MMP polymorphism mismatches in donor and recipient DNA with the 
development of IRI and ACR after OLT was evaluated. Liver biopsy specimens 
and peripheral blood samples were subsequently evaluated for the presence 
of chimerism, also in relation to these complications.
Results: MMP polymorphism donor/recipient mismatches were found in 
53.7% (MMP-2) and 35.5% (MMP-9) of the OLT patients but no relation was 
observed with IRI or ACR. Chimerism in liver biopsy specimens was found 
to be present in 28.8% (MMP-2) and 16.2% (MMP-9) of the cases. Liver 
chimerism in MMP-2 was found to be significantly associated with ACR after 
OLT (χ2 6.4, p=0.01). Multivariate analysis revealed MMP-2 chimerism to 
be an independent risk factor for ACR after OLT adjusted for MELD score 
(HR=3.83, p=0.03). In addition, evidence of donor chimerism was found in 
peripheral blood samples of the recipients in some cases.
Conclusion: Chimerism after liver transplantation can be found in liver 
biopsy specimens and in peripheral blood. MMP donor/recipient polymorphism 
mismatches are good markers for assessing chimerism after OLT. In the 
multivariate analysis liver chimerism in MMP-2 was found to be significantly 




Chimerism after solid organ transplantation is a fascinating phenomenon. 
In the earliest days of organ transplantation, back in the 1960s, Medawar 
hypothesized that chimerism could lead to graft tolerance.1 The existence of 
chimerism after transplantation have been studied by many, but the clinical 
significance remains unraveled.2-5 Previously, we have addressed different 
aspects of chimerism within the liver, both after orthotopic liver 
transplantation (OLT) and after allogeneic bone marrow transplantation 
(BMT).6,7 In these earlier studies we used in situ hybridization techniques 
targeting Y-chromosomes. A major drawback of this technique is that only a 
small fraction of sex mismatched donor/recipient combinations are relevant 
to be studied, i.e., male recipients receiving a female liver and female recipients 
receiving a male BMT. In the present study we have used a different technique 
to investigate chimerism after OLT, which allowed us to include a larger 
number of liver transplant recipients. Gene polymorphisms of matrix 
metalloproteinases (MMP) 2 and 9 were analyzed. We previously reported on 
MMP polymorphisms in relation to different complications of liver 
transplantation and found preliminary indications that chimerism did occur.8,9
Mismatches between donor and recipients were selected to study the 
presence of chimerism in liver biopsy specimens and in peripheral blood 
after liver transplantation. The aim of the present study was to further explore 
the existence of chimerism in MMP-2 and MMP-9 promoter polymorphism 
donor/recipient mismatches in both liver biopsy specimens and in peripheral 
blood after OLT. The association between these MMP mismatches and the
clinical occurrence of ischemia/reperfusion injury (IRI) and acute cellular 
rejection (ACR) after OLT was also assessed.




All patients who received a liver transplant at Leiden University Medical 
Center (LUMC) between 1992 and 2005 were eligible for inclusion. Of these 
202 patients, donor and recipient DNA was available of 147 patients with at 
least 7 days of follow-up after OLT. Demographical and clinicopathological 
characteristics of the study population were obtained from the transplantation 
database. The study was performed according to the guidelines of the
Medical Ethics Committee of the Leiden University Medical Center and in 
compliance with the Helsinki Declaration.
Genotyping
Genomic DNA was extracted by routine methods from peripheral blood 
leukocytes and/or tissue samples. In addition, DNA samples from the blood 
of the liver donors were obtained from the Eurotransplant Reference 
Laboratory or freshy isolated from donor blood or spleen tissue. Also, 
DNA was isolated from liver biopsy tissue of the allograft in the recipients, 
obtained several months (median 17, range 5 to 48) after OLT. 
MMP-2: high resolution DNA melting analysis (HRMA) 
MMP-2 –1306 C/T promoter SNP was determined using a high resolution 
DNA melting assay with the 5’-CCACCCAGCACTCCACCTCTTTAGCTCF-3’ 
wild-type (C) gene probe, and the primers 5’-CCAGTGCCTCTTGCTGTTTT-3’ 
(forward) and 5’-GACTTCTGAGCTGAGACCTGA-3’ (reverse).9,10 This –1306 
C/T MMP-2 gene promoter polymorphism was also determined by tetra-primer 
amplification refractory mutation systempolymerase chain reaction (PCR) 
analysis, the principles of which are described elsewhere9, and confirmed 
by direct sequence analysis of 4 patients. Briefly, the region flanking the SNP 
was amplified with outer primers 5’-ACCAGACAAGCCTGAACTTGTCTGA-3’ 
and 5’-TGTGACAACCGTCTCTGAGGAATG-3’ together with inner allelic 
specific primers 5’-ATATTCCCCACCCAGCACGCT-3’ and 
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5’-GCTGAGACCTGAAGAGCTAAAGAGTTG-3’. Genotypes CC, CT and TT 
(542+379; 542+379+211; 542+211 bp, respectively) are easily identified from 
the migration pattern on agarose gels. 
This common functional polymorphism abolishes an Sp1 binding site within 
the promoter region of MMP-2. In brief, high-resolution melting analysis of 
PCR products amplified in the presence of a saturating double-stranded DNA 
dye (LCGreenPlus, Idaho Technology) and the 3’-blocked probe, identifies 
both heterozygous and homozygous sequence variants. Heterozygotes and 
homozygotes are distinguished by differences in the melting curve shape, 
due to differences in melting temperature. In each experiment, sequence-
verified control donors for each genotype were used. MMP-2 genotype distri-
bution was as follows: in recipients CC 67.3% (n=99), CT 27.9% (n=41), TT 
4.8% (n=7) and in donors CC 45.6% (n=67), CT 49.7% (n=73), TT 4.8% (n=7). 
MMP-9: PCR-Restriction Fragment Length Polymorphism (RFLP) genotyping. 
The SNP C/T at position –1562 of the MMP-9 gene promoter was determined 
by PCR-RFLP. The SNP flanking region was amplified using primers 
5’-ATGGCTCATG-CCCGTAATC-3’ and 5’-TCACCTTCTTCAAAGCCCTATT-3’ 
followed by restriction analysis with Sph I to produce 352, 352+207+145 or 
207+145 bp fragments in case of CC, CT and TT genotype, respectively, which 
are easily identified from the migration patterns on agarose gels.8,11-13 
MMP-9 genotype distribution was as follows: in recipients CC 75.9% (n=107), 
CT 23.4% (n=33), TT 0.7% (n=1) and in donors CC 73.0% (n=103), CT 27.0% 
(n=38) and none of the donors had TT genotype.
Assessment of MMP gene mismatch and chimerism in liver biopsy 
specimens and peripheral blood samples
Mismatch in the MMP-2 or -9 genes is defined as a non-identical genotype in 
OLT recipient and donor. Chimerism is defined as the presence of an MMP 
genotype signal in the DNA of the liver biopsy after OLT that originates from 
the recipient and in the blood DNA of the recipient after OLT when an MMP 
genotype signal appears from the donor.
Matrix metalloproteinase-2 genotype chimerism and acute cellular rejection
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Ischemia and reperfusion injury (IRI) and acute cellular rejection (ACR)
The degree of hepatocellular IRI was evaluated by measurement of aspartate 
aminotransferase (AST) during the first week after OLT. Patients were classified 
into 2 groups depending on whether the serum AST peak was lower than 
1,500 IU/L (no or mild IRI) or higher than 1,500 IU/L (more severe IRI), 
respectively. 
Liver biopsies were taken according to our protocol at approximately 1 week, 
3 months, 6 months and one year after OLT, or when there was a suspicion 
of ACR, and then each year. ACR was graded according to the Banff scheme. 
The rejection had to be clinically relevant for this study, i.e. histologically 
confirmed and treated with additional immunosuppression.
Statistical Analysis and Ethical committee
Genotype frequencies were analyzed by generating two- by-two contingency 
tables. Statistical analysis was performed using the Chi-square test or 
Fischer’s Exact test, where appropriate, using SPSS software (SPSS Inc; 
Chicago, IL, USA). Univariate and multivariate analysis was performed using 
Cox regression analysis. Variables entering the univariate analysis that were 
significant at the p<0.20 level were taken into account in the multivariate
analysis. Variables in the multivariate analysis were considered to be 
significant at P- values of ≤ 0.05.
This retrospective study was approved by the institutional medical ethics 





Our study population consisted of 147 OLT donor/recipient combinations; 
median age at OLT was 48 years (range 16 – 69 years) with a predominance 
of male recipients(65.3%). A list of baseline characteristics is given in Table 1. 
MMP polymorphism mismatches between recipient and donor were found in 
53.7% for MMP-2 (79/147) and in 35.5% for MMP-9 (50/141).
No statistically significant relation was found between the absence or presence 
of a mismatch at –1306 C/T MMP-2 or –1562 C/T MMP-9 in relation to the 
development of IRI or ACR after OLT, as illustrated in Table 2.
Matrix metalloproteinase-2 genotype chimerism and acute cellular rejection
Characteristic   Total n=147  
Recipient age at  OLT (median, range)   48 (16 – 69)  
Donor age   43 (9 – 71)  
Recipient gender % (n)    
Female   34.7 (51)  
Male   65.3 (96)  
Donor gender % (n)    
Female   44.9 (66)  
    Male   55.1 (81)  
MELD score before OLT (median, range)   15 (4 – 50)  
CIT (median, range)   649 (224 – 1200)  
WIT(median, range)   36   (16 – 127)  
Table 1. Baseline characteristics
OLT: Liver transplantation, MELD: Model for end stage liver disease; 
CIT: Cold ischemic time; WIT: Warm ischemic time
138
Chimerism in liver biopsy specimens
Of the 79 MMP-2 mismatches, liver biopsy specimens of 59 cases could be 
adequately studied for the presence of chimerism, which was found in 28.8% 
(17/59, Figure 1). For the MMP-9 mismatches, 50 in total, liver tissue of 37 
patients could reliably be scored for chimerism, which was found in 16.2% 
(6/37). The presence of chimerism in liver tissue was investigated in relation 
to IRI and ACR. A statistically significant association was found between 
chimerism for MMP-2 (but not MMP-9) and the occurrence of ACR, i.e., 
41.2% versus 11.9% in the patients without chimerism (χ2=6.4; P=0.01). 
No association was found with IRI and MMP-2 or MMP-9 (Table 3).
Chimerism in peripheral blood
To assess chimerism in peripheral blood, donor/recipient combinations 
were selected that consisted of a MMP-2 genotype homozygote recipient and 
either a MMP-2 heterozygote donor or a donor of a different homozygote 
genotype. 27 patients could be included of whom blood DNA samples were 
available 3 to 12 years after OLT. Indications of blood chimerism was 
observed in 18.5% (5/27, Figure 2) of these patients, i.e., 6.3% (5/79) of the 
MMP-2 mismatches and 3.4% (5/147) of the total OLT population, where the 
donor MMP-2 gene signal was discernable in the recipient’s blood DNA, in 
addition to the recipient’s own MMP-2 gene signal. MMP-9 chimerism in 
blood of the recipients was not observed.
Univariate and Multivariate analysis
Univariate analysis showed that Model for End-stage Liver Disease (MELD) 
score and MMP-2 chimerism were significant risk factors at the p<0.20 level 
and were thus taken into account for the multivariate analysis. No significant 
relationship was found between recipient gender, donor gender, recipient 
age, donor age, cold ischemic time (CIT) and warm ischemic time (WIT). 
Multivariate analysis revealed MMP-2 chimerism to be an independent risk 




Matrix metalloproteinase-2 genotype chimerism and acute cellular rejection
Complication   
IRI  ACR  
Genotype  Mismatch   
no  yes  no  yes  
no  49 (72.1)  19 (27.9)  59 (86.8)  9 (13.2)  
-1306 C/T MMP -2  
recipient -donor 
yes  51 (64.6)  28 (35.4)  64 (81.0)  15 (19.0)  
Statistical 
significance  
 2=0.95; P=0.33  2=0.89; P=0.35  
 
no  60 (65.9)  31 (34.1)  77 (84.6)  14 (15.4)  
-1562 C/T MMP -9  
recipient -donor  
yes  37 (74.0)  13 (26.0)  43 (86.0)  7 (14.0)  
Statistical 
significance  
 2=0.98; P=0.32  2=0.05; P=0.83  
Complication   
IRI  ACR  
Genotype  Mismatch   
no  yes  no  yes  
no  49 (72.1)  19 (27.9)  59 (86.8)  9 (13.2)  
-1306 C/T MMP -2  
recipient -donor 
yes  51 (64.6)  28 (35.4)  64 (81.0)  15 (19.0)  
Statistical 
significance  
 2=0.95; P=0.33  2=0.89; P=0.35  
 
no  60 (65.9)  31 (34.1)  77 (84.6)  14 (15.4)  
-1562 C/T MMP -9  
recipient -donor  
yes  37 (74.0)  13 (26.0)  43 (86.0)  7 (14.0)  
Statistical 
significance  
 2=0.98; P=0.32  2=0.05; P=0.83  
Complication   
IR  ACR  
Genotype  Mismatch   
no  yes  no  yes  
no  49 (72.1)  19 (27.9)  59 (86.8)  9 (13.2)  
-1306 C/T M P -2  
recip ent -donor 
yes  51 (64.6)  28 (35.4)  64 (81.0)  15 (19.0)  
Sta istical 
significance  
 2=0.95; P=0.33  2=0.89; P=0.35  
 
no  60 (65.9)  31 (34.1)  77 (84.6)  14 (15.4)  
-1562 C/T M P -9  
recip ent -donor  
yes  37 (74.0)  13 (26.0)  43 (86.0)  7 (14.0)  
Sta istical 
significance  
 2=0.98; P=0.32  2=0. 5; P=0.83  
Complication   
IR  ACR  
Genotype  Mismatch   
no  yes  no  yes  
no  49 (72.1)  19 (27.9)  59 (86.8)  9 (13.2)  
-1306 C/T M P -2  
recip ent -donor 
yes  51 (64.6)  28 (35.4)  64 (81.0)  15 (19.0)  
Sta istical 
significance  
 2=0.95; P=0.33  2=0.89; P=0.35  
 
no  60 (65.9)  31 (34.1)  77 (84.6)  14 (15.4)  
-1562 C/T M P -9  
recip ent -donor  
yes  37 (74.0)  13 (26.0)  43 (86.0)  7 (14.0)  
Sta istical 
significance  
 2=0.98; P=0.32  2=0. 5; P=0.83  
Complication   
IRI  ACR  
Genotype  Mismatch   
no  yes  no  yes  
no  49 (72.1)  19 (27. )  59 (86.8)  9 (13.2)  
-1306 C/T MMP -2  
recipient -donor 
yes  51 (64.6)  28 (35.4)  64 (81.0)  15 (19.0)  
Statistic l 
significance  
 2=0.95; P=0.33  2=0.89; P=0.35  
 
no  60 ( 5.9)  31 (34.1)  77 (84.6)  14 ( 5.4)  
-1562 C/T MMP -9  
recipient -donor  
yes  37 (74.0)  13 (26.0)  43 (86.0)  7 (14.0)  
Statistic l 
significance  
 2=0.98; P=0.32  2=0.05; P= .83  
Complication   
IRI  ACR  
Genotype  Mismatch   
no  yes  no  yes  
no  49 (72.1)  19 (27. )  59 (86.8)  9 (13.2)  
-1306 C/T MMP -2  
recipient -donor 
yes  51 (64.6)  28 (35.4)  64 (81.0)  15 (19.0)  
Statistic l 
significance  
 2=0.95; P=0.33  2=0.89; P=0.35  
 
no  60 ( 5.9)  31 (34.1)  77 (84.6)  14 ( 5.4)  
-1562 C/T MMP -9  
recipient -donor  
yes  37 (74.0)  13 (26.0)  43 (86.0)  7 (14.0)  
Statistic l 
significance  
 2=0.98; P=0.32  2=0.05; P= .83  
Complication   
IRI  ACR  
Genotype  Mismatch   
no  yes  no  yes  
no  49 (72.1)  19 (27. )  59 (86.8)  9 (13.2)  
-1306 C/T MMP -2  
recipient -donor 
yes  51 (64.6)  28 (35.4)  64 (81.0)  15 (19.0)  
Statistic l 
significance  
 2=0.95; P=0.33  2=0.89; P=0.35  
 
no  60 (65.9)  31 (34.1)  77 (84.6)  14 (15.4)  
-1562 C/T MMP -9  
recipient -donor  
yes  37 (74.0)  13 (26.0)  43 (86.0)  7 (14.0)  
Statistic l 
significance  
 2=0.98; P=0.32  2=0.05; P= .83  
Complication   
IRI  ACR  
Genotype  Mismatch   
no  yes  no  yes  
no  49 (72.1)  19 (27. )  59 (86.8)  9 (13.2)  
-1306 C/T MMP -2  
recipient -donor 
yes  51 (64.6)  28 (35.4)  64 (81.0)  15 (19.0)  
Statistic l 
significance  
 2=0.95; P=0.33  2=0.89; P=0.35  
 
no  60 (65.9)  31 (34.1)  77 (84.6)  14 (15.4)  
-1562 C/T MMP -9  
recipient -donor  
yes  37 (74.0)  13 (26.0)  43 (86.0)  7 (14.0)  
Statistic l 
significance  
 2=0.98; P=0.32  2=0.05; P= .83  
Complication   
IRI  ACR  
Genotype  Chimerism   
no  yes  no  yes  
no  31 (73.8)  11 (26.2)  37 (88.1)  5 (11.9)  MMP -2  
in liver biopsy 
after OLT  yes  11 (64.7)  6 (35.3)  10 (58.8)  7 (41.2)  
Statistical 
significance  
 2=0.49; P=0.48  2=6.4; P=0.01  
 
no  22 (71.0)  9 (29.0)  26 (83.9)  5 (16.1)  MMP -9  
in liver biopsy 
after OLT  yes  5 (83.3)  1 (16.7)  4 (66.7)  2 (33.3)  
Statistical 
significance  
 2=0.39; P=0.48  2=0.97; P=0.32  
Complication   
IRI  ACR  
Genotype  Chimerism   
no  yes  no  yes  
no  31 (73.8)  11 (26.2)  37 (88.1)  5 (11.9)  MMP -2  
in liver biopsy 
after OLT  yes  11 (64.7)  6 (35.3)  10 (58.8)  7 (41.2)  
Statistical 
significance  
 2=0.49; P=0.48  2=6.4; P=0.01  
 
no  22 (71.0)  9 (29.0)  26 (83.9)  5 (16.1)  MMP -9  
in liver biopsy 
after OLT  yes  5 (83.3)  1 (16.7)  4 (66.7)  2 (33.3)  
Statistical 
significance  
 2=0.39; P=0.48  2=0.97; P=0.32  
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IRI  ACR  
Genotyp  Chimerism   
no  yes  no  yes  
no  31 (73.8)  11 (26.2)  37 (88.1)  5 (11.9)  MMP -2  
in liver biopsy 
after OLT  yes  11 (64.7)  6 (35.3)  10 (58.8)  7 (41.2)  
Statistical 
significance  
 2=0.49; P=0.48  2=6.4; P=0.01  
 
no  22 (71.0)  9 (29.0)  26 (83.9)  5 (16.1)  MMP -9  
in liver biopsy 
after OLT  yes  5 (83.3)  1 (16.7)  4 (66.7)  2 (33.3)  
Statistical 
significance  
 2=0.39; P=0.48  2=0.97; P=0.32  
Complication   
IRI  ACR  
Genotyp  Chimerism   
no  yes  no  yes  
no  31 (73.8)  11 (26.2)  37 (88.1)  5 (11.9)  MMP -2  
in liver biopsy 
after OLT  yes  11 (64.7)  6 (35.3)  10 (58.8)  7 (41.2)  
Statistical 
significance  
 2=0.49; P=0.48  2=6.4; P=0.01  
 
no  22 (71.0)  9 (29.0)  26 (83.9)  5 (16.1)  MMP -9  
in liver biopsy 
after OLT  yes  5 (83.3)  1 (16.7)  4 (66.7)  2 (33.3)  
Statistical 
significance  
 2=0.39; P=0.48  2=0.97; P=0.32  
Complicat on   
IRI  ACR  
Genotype  Chimerism   
no  yes  no  yes  
no  31 (73.8)  11 (26.2)  37 (88.1)  5 (11.9)  MMP -2  
in liver biopsy 
after OLT  yes  11 (64.7)  6 (35.3)  10 (58.8)  7 (41.2)  
Statistical 
significan e  
 2=0.49; P=0.48  2=6.4; P=0.01
 
no  22 (71.0)  9 (2 .0)  26 (83.9)  5 (16.1)  MMP -9  
in liver biopsy 
after OLT  yes  5 (83.3)  1 (16.7)  4 (66.7)  2 (33.3)  
Statistical 
significan e  
 2=0.39; P=0.48 2=0.97; P=0.32
Complicat on   
IRI  ACR  
Genotype  Chimerism   
no  yes  no  yes  
no  31 (73.8)  11 (26.2)  37 (88.1)  5 (11.9)  MMP -2  
in liver biopsy 
after OLT  yes  11 (64.7)  6 (35.3)  10 (58.8)  7 (41.2)  
Statistical 
significan e  
 2=0.49; P=0.48  2=6.4; P=0.01
 
no  22 (71.0)  9 (2 .0)  26 (83.9)  5 (16.1)  MMP -9  
in liver biopsy 
after OLT  yes  5 (83.3)  1 (16.7)  4 (66.7)  2 (33.3)  
Statistical 
significan e  
 2=0.39; P=0.48 2=0.97; P=0.32
Table 2. Mismatch at -1306 C/T MMP-2 or -1562 C/T MMP-9 recipient-donor genotype 
in relation to the development of IRI or ACR after OLT.
Table 3. MMP chimerism in liver tissue after OLT in relation to IRI and ACR. The presence of 
MMP-2  chimerism in liver biopsy speci ens was significantly associated with ACR after ortho-
topic liver transplantation.
MMP: matrix metalloproteinase, IRI: ischemia-reperfusion injury, ACR: acute cellular injury, 
OLT: orthotopic liver transplantation
MMP: matrix metalloproteinase, IRI: ischemia-reperfusion injury, ACR: acute cellular injury, 
OLT: orthotopic liver transplantation
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Figure 1. Chimerism in liver biopsy specimens of OLT patients. 
Upper: Reference MMP-2 HMRA curves in blood: TT in blue, CC in grey and 
CT in red
Bottom: Chimeric MMP-2 HMRA curves in biopsies. Donor TT and recipient 
CC in dark blue; donor TT and recipient CT in green; donor CC and recipient 
CT in light blue; donor CC and recipient TT in red.
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Figure 2: Chimerism in biopsies and blood of OLT patients.
Upper: MMP-2 HMRA curves of a TT recipient and CC donor in dark blue and 
light blue. Liver biopsy chimerism of the patient as shown by the CT curve in 
green. Blood chimerism is indicated by the arrow pointing at a minor peak at C 
in the purple TT curve of the recipient.
Bottom: Blood chimerism in CC recipients with CT donors in light blue, with 
the arrow pointing at minor chimeric T peaks; donor CT indicated in red, 
reference TT in green and recipient CC in grey. TT and recipient CT in green; 
donor CC and recipient CT in light blue; donor CC and recipient TT in red.
Figure 1. Chimerism in liver biopsy specimens of OLT patients. 
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  Univariate analysis  Multivariate analysis  
Variables   HR (95% CI)  p-value  HR (95% CI)  p-value  
Recipient gender  Male  0.53 (0.17 – 1.64 )  0.27    
 Female (reference)  1 (reference)    
Recipient age at OLT  Continuous  0.98 (0.94 – 1.03 )  0.47   
Donor gender  Male   0.63 (0.19 – 2.11 )  0.46   
 Female  (reference)  1 (reference)    
Donor age  Continuous  1.01 (0.98 – 1.05 )  0.52    
MELD  Continuous  1.04 (0.99 – 1.10 )  0.15  1.03 (0.96 – 1.08)  0.33  
MMP -2 chimerism  Yes  4.19 (1.33 – 13.26)  0.02 3.83 (1.18 – 12.40)  0.03 
 No (reference)   1 (reference)    
CIT  Continuous  1.00 (0.99 – 1.00 )  0.74   
WIT  Continuous  1.02 (0.97 – 1.08)  0.41    
  Univariate an lysis  Multivariate an lysis  
Variables   HR (95% CI)  p-value  HR (95% CI)  p-value  
Recip ent gender  Male  0.53 (0.17 – 1.64 )  0.27    
 Female (ref r nce)  1 (ref r nce)    
Recip ent age at OLT  Continuous  0.98 (0.94 – 1.03 )  0.47   
Donor gender  Male   0.63 (0.19 – 2.11 )  0.46   
 Female  (ref r nce)  1 (ref r nce)    
Donor age  Continuous  1.01 (0.98 – 1.05 )  0.52    
MELD  Continuous  1.04 (0.99 – 1.10 )  0.15  1.03 (0.96 – 1.08)  0.33  
M P -2 chimerism  Yes  4.19 (1.33 – 13.26)  0. 2 3.83 (1.18 – 12.40)  0. 3 
 No (ref r nce)   1 (ref r nce)    
CIT  Continuous  1.00 (0.99 – 1.00 )  0.74   
WIT  Continuous  1.02 (0.97 – 1.08)  0.41    
  Univari te an lysis  Multivari te an lysis  
Vari bles   HR (95% CI)  p-value  HR (95% CI)  p-value  
Recipi nt g der  Male  0.53 (0.17 – .64 )  0.27    
 Femal  (reference)  1 (reference)    
Recipi nt age at OLT  Conti uo s  0.98 (0.94 – 1.03 )  0.47   
Don r gender  Male   0.63 (0.19 – 2.11 )  0.46   
 Femal  (reference)  1 (reference)    
Don r age Conti uo s  1.0  (0.98 – 1.05 )  0.52    
MELD  Conti uo s  1.04 (0.99 – 1.10 )  0.15  1.03 (0.96 – 1.08)  0.33  
M P -2 chimer sm  Yes  4.19 (1.33 – 1 .26)  0.02 3.8  (1.18 – 12.40)  0.03 
 No (reference)   1 (reference)    
CIT  Conti uo s  1.00 ( .99 – 1.00 )  0.74   
WIT  Conti uo s  1.02 (0.97 – 1.08)  0.41    
  Univariate n lysi  Multivariate n lysi  
Variables   HR (95% CI)  p-value  HR (95% CI)  p-value  
Recipient gender  Male  0.53 (0.17 – 1 64 )  0.27    
 Female (ref r nce)  1 (ref r nce)    
Recipient ag  OLT  Continu us  0.98 ( . 4 – 1.03 )  0.47   
Donor ge der  Male   0.63 (0.19 – 2 1 )  0.46   
 Female  (ref r nce)  1 (ref r nce)    
Donor age  Continu us  1.01 (0.98 – 1 05 )  0.52    
MELD  Continu us  1.04 ( .9  – 1. 0 )  0.15  1.03 ( .96 – 1.08)  0.33  
M P -2 chimerism  Yes  4.19 (1.33 – 3.26)  0. 2 3.83 (1.  – 2.40)  0. 3 
 No (ref r nce)   1 (ref r nce)    
CIT  Continu us  1.0  ( 9  – 1.0 )  0.74   
WIT  Continu us  1.02 ( .97 – 1 08)  0.41    
  Univari te an lysis  Multivari te an lysis  
Vari bles   HR (95% CI)  p-value  HR (95% CI)  p-value  
Recipient gend r  Male  0.53 (0.17 – 1.64 )  0.27   
 Female (refer nce)  1 (refer nce)    
Recipient age OLT Conti u s  0.98 (0.94 – 1.03 )  0.47  
Don r ge d r  Male   0.63 (0.19 – 2.11 ) 0.46  
 Female  (r fer nce)  1 (refer nce)    
Don r age  Conti u s  1.01 ( .98 – 1. 5 ) 0.52   
MELD  Conti u s  1.04 ( .99 – 1.1 )  0.15  1.03 ( .96 – 1.08) 0.33  
M P -2 chimerism  Yes  4.19 (1.33 – 3.26)  0.02 3.83 (1.18 – 12.40)  0.03 
 No (refer nce)   1 (refer nce)    
CIT  Conti u s  1.00 ( .99 – 1.00 )  0.74  
WIT  Conti u s  1.02 ( .97 – 1.08) 0.41   
  Univar ate nalysis  Multivar ate nalysis  
Variables   HR (95% CI)  p-value  HR (95% CI)  p-value  
Recipient g d r  Male  0.53 ( .17 – 1.64 )  0.27    
 Femal  (r f r nc )  1 (refer nc )    
Recipient age at OLT  Continuous  0.98 (0.94 –1. 3 )  0.47   
Donor gend  Male   0.63 (0.19 – 2.1 )  0.46   
 Femal  (refer nc )  1 (refer nc )    
Donor age  Continuous  1.01 ( .98 – 1.05 )  0.52    
MELD  Continuous  1.04 (0.9  – 1.10 )  .15  .03 ( .96 – 1. 8)  3  
MMP -2 chimeris  Yes 4.19 ( 3 – 1 26)  0.02 3.83 (1 18 – 2.40)  .03 
 No (refer nc )   1 (refer nc )    
CIT  Continuous  1.0  (0.9  – 1. )  0.74   
WIT  Continuous  1.02 (0.97 – 1. 8)  0.41    
Table 4. Multivariate analysis shows that MMP-2 chimerism was an independent risk 
factor for acute cellular rejection (ACR) after OLT (Hazard ratio (HR) =3.83, p = 0.03). 
OLT: Orthotopic liver transplantation; MELD: Model for end stage liver disease; MMP: matrix 
metalloproteinase; CIT: cold ischemic time, WIT; warm ischemic time  
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Discussion
In the current study we analyzed MMP DNA polymorphisms as a marker for 
chimerism. Assessment of the MMP-2 and MMP-9 genotypes in DNA of OLT 
patients showed clear evidence of chimerism, both in liver tissue specimens 
and in peripheral blood, even years after transplantation. 
In a previous study we already described liver chimerism in sex-mismatched 
donor/recipient mismatches.6 Combinations selected for that study were 
male transplant recipients and female donors in whom cells of recipient 
(male) origin could be readily identified with the use of an Y-chromosome 
specific in-situ hybridization technique. In addition, patients who received an 
HLA-mismatched liver transplant were studied and chimerism was evaluated 
using immunohistochemistry with HLA class I-specific antibodies. To 
discriminate between cells of recipient and/or donor origin, double staining 
techniques were used with antibodies against specific cell types and subsets, 
i.e., endothelial and bile duct epithelial cells, lymphocytes, monocytes and 
other inflammatory cells. Endothelial cell chimerism was found to be quite 
common, whereas chimerism for biliary epithelial cells and hepatocytes 
could be shown only in a minority of cases. The limitation of using 
Y-chromosomes as a marker of chimerism is that only a small fraction of 
donor/recipient combinations (i.e., female/male) could be included. HLA 
staining could not differentiate hepatocytes from inflammatory cells with 
certainty and another limitation was the occasionally poor quality of liver 
biopsy samples for immunohistochemical analysis. 
MMPs are involved in connective tissue remodeling processes associated 
with chronic liver disease and complications after OLT.8,14-16 In earlier 
studies we investigated, for example, MMP gene polymorphisms and their 
relation to IRI, ACR and non-anastomotic biliary strictures (NAS) after OLT 
and found the MMP-2 CT genotype to be an independent risk factor for the 
development of NAS.9 Now we specifically studied several single nucleotide 
polymorphisms (SNP) in the gene promotor regions of MMP-2 and MMP-9, 
that were determined in DNA samples of peripheral blood leukocytes and/
or liver tissue samples, for liver chimerism after OLT. For that purpose MMP 
gene mismatches were selected for the assessment of chimerism. Using 
this method we could include a far greater number than with the previously 
Matrix metalloproteinase-2 genotype chimerism and acute cellular rejection
OLT: Orthotopic liver transplantation; MELD: Model for end stage liver disease; MMP: matrix 
metalloproteinase; CIT: cold ischemic time, WIT; warm ischemic time  
144
used methods (79/147 for MMP-2 and 50/141 for MMP-9). RFLP and HRMA 
for MMP-2 polymorphisms gave identical results and worked well, whereas 
for MMP-9 only the RFLP SNP analysis was found to be suitable, but this 
technique was not sensitive enough for blood chimerism. Major advantage 
of the HRMA technique is that it was suitable for analyzing peripheral blood 
DNA samples of possible chimeric post-OLT patients. There are, however, 
also several limitations. The existence of chimerism can only be shown in a 
qualitative fashion. A quantification of chimerism would be very interesting, 
both in relation to donor/recipient and procedure-related variables and 
complications, and in the follow-up of chimerism over time after the 
transplant procedure. Another limitation of this HRMA technique is that 
chimerism in liver tissue biopsies cannot be specified for different cell lineages, 
because tissue samples are processed for DNA extraction. 
The MMP gene chimerism observed in liver tissue after OLT was assessed in 
relation to IRI and ACR, and an association was found between the chimeric 
MMP-2 genotype and the occurrence of ACR, but not for chimeric MMP-9 
due to its low frequency. This was not unexpected, since acute rejection is 
characterized by a portal mixed inflammatory infiltrate (of recipient origin), 
in combination with bile duct damage and endothelitis. A functional 
upregulation in ACR was previously described for MMP-9 and not for 
MMP-2.16 The relation of MMP-2 chimeric gene expression and ACR in the 
post OLT biopsies can simply be explained by the influx of a mixed leukocyte 
infiltrate of recipient origin. MMP-2 chimerism in the liver biopsies was 
found to be an independent risk factor for the development of ACR after OLT 
in the multivariate analysis, even adjusted for MELD score (HR 3.83, p=0.03). 
Other potential risk factors such as (donor) gender, (donor) age, CIT and 
WIT were also assessed but no significant association was found. 
Indication of chimerism in peripheral blood samples after OLT was found 
in a minority of patients (18.5% of selected patients, i.e. 6.3% MMP-2 
mismatches and 3.4% of the total OLT population) where the donor MMP-2 
gene signal was detected in the recipient’s blood DNA. As such an interesting 
observation was that a liver donor DNA signal is discernable in the DNA of 
circulating blood cells of the recipients. Further analyses need to be done in 
order to evaluate whether this is an indication of tolerance and where the 
signal is coming from, i.e., (re)circulating liver (stem)cells or donor  
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(stem)cells that have migrated to and recirculate from the recipients 
bone marrow.
In conclusion, this study indicates that chimerism after OLT persists both 
within the transplanted liver as well as in peripheral blood. There was a 
relationship between MMP-2 chimerism and ACR, also in the multivariate 
analysis. The clinical relevance of chimerism in relation to pathological 
mechanisms such as graft tolerance, ACR or outcome remains unclear and 
requires further elucidation.
Matrix metalloproteinase-2 genotype chimerism and acute cellular rejection
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Orthotopic liver transplantation (OLT) is an established therapy with an 
excellent survival rate. The transplantation program at the Leiden University 
Medical Center (LUMC) started in 1992 and has led to more than two 
decades of experience in OLT with current 1, 5 and 10-year survival rates of 
91%, 83% and 77% which exceed the average rates in Europe.1 
Chapter 2 describes the systematic evaluation of potential factors that are 
involved in the improved patient survival. Indications for which OLT is 
currently performed are not much different from the first ten years of OLT 
since the initiation of the liver transplantation (LT) program in our center. 
Hepatocellular carcinoma (HCC) was found to be the most frequent indication 
in both the first and the second ten years of OLT at our institute. Blood loss 
during OLT was much lower in the second decade compared to the first 
period, which probably reflects improved operative techniques. In addition, 
causes of recipient mortality were examined and this revealed that in the first 
decade infection was the most common cause of death post-OLT followed by 
recurrence of HCC. However, in the second decade death due to infection 
as well as mortality due to recurrence of HCC declined significantly. This 
reduced mortality caused by infection is probably indicative of improved early 
diagnosis of infection and better antibiotic regimens, in addition to better 
intensive care unit (ICU) treatment. The reduced mortality from HCC 
recurrence is likely the results of the introduction of adjuvant treatment of
HCC before OLT with transarterial chemo-embolization (TACE) and radio 
frequency ablation (RFA). With OLT currently being the standard treatment 
for end-stage liver disease for many etiologies, demand has increased 
disproportionally to the availability of potential donor livers. As a result 
patients listed on the waiting list have a median waiting period of 
approximately two years. In an attempt to reduce organ shortage, partially 
due to a decrease in donation after brain death (DBD), the LT centers in 
the Netherlands have expanded their donor pool by using donor livers from 
donation after cardiac death (DCD). DCD livers are known to have more 
ischemia-reperfusion injury (IRI) due to an additional donor warm ischemia 
time (DWIT). Since 2001, this national multi-organ donation protocol 
has been introduced that allows the use of livers from DCD of Maastricht        
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category 3.2 DCD livers from donors below 55 years of age, with a DWIT 
below 30 minutes, a body mass index <28, and a mean arterial pressure <50 
mm Hg for maximum 15 minutes were accepted, which excludes about 25% 
of DCD donors. In addition, in DCD-OLT cold ischemia time (CIT) was kept 
as short as possible to minimize IRI. In our center this has resulted in 
significant shorter CITs than for DBDOLT. However, biliary complications 
such as nonanastomotic strictures (NAS) occur significantly more often 
after DCD-OLT than after DBD-OLT. NAS often results in cholangitis and 
retransplantation making it a significant source of morbidity and mortality. 
In the studied cohort, graft survival was significantly more affected by NAS 
development after DCD-OLT when compared to DBD-OLT. Patient survival in 
DCDOLT was not significantly lower than in DBD-OLT but this did not reach 
statistical significance, which is in line with previous reports.3
IRI and NAS development
As to date it is not fully clarified as to how NAS develops after both DCD-OLT 
and DBD-OLT. It is clear, however, that NAS results from IRI, which most likely 
involves immunological and toxic factors.4,5 IRI is reflected by peak alanine 
aminotransferase (ALT) and aspartate aminotransferase (AST) occurring within 
the first week post-OLT. Previous reports have used the degree of IRI in 
relation to clinical outcomes such as infection.6,7 In these studies, the degree 
of IRI has been arbitrarily divided in categories that correspond with severity, 
i.e., mild, moderate and severe. We analyzed the relationship between peak 
ALT and the development of NAS after DCD-OLT and DBDOLT in patients 
from two independent liver transplantation centers in the Netherlands, i.e., 
the University Medical Center in Groningen and the LUMC, as described in 
chapter 3. In this study we determined the optimal cut-off value using 
log-rank statistics of peak ALT and the development of NAS post DCD-OLT to 
be at ≥1300 IU/L and categorized grafts in recipients with a peak ALT <1300 
IU/L as having mild IRI and recipients with ≥1300 IU/L as having a graft 
with severe IRI. After DCD-OLT severe IRI showed a clear and independent 
relationship with the development of NAS. Four-year cumulative incidence 
of NAS development reached 51.4% in case of severe IRI compared to 11.4% 
in case of mild IRI. This strong relationship was also evaluated in the two 
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included cohorts separately, which showed similar results. No independent 
relationship was found to exist between NAS and ischemia times. Peak-ALT 
has the advantage of measuring the impact of reperfusion in addition to 
ischemia. The incidence of NAS after DBD-OLT was approximately 10%. 
Interestingly, no relationship was observed between peak ALT and NAS 
development after DBD-OLT in both centers. Moreover, no cut-off value for 
ALT in relation to development of NAS could be established for DBD-OLT. 
Remarkably, the incidence of NAS after DCD-OLT in case of mild IRI is 
similar to the incidence of NAS after DBD-OLT. This finding could imply 
that other factors are involved in the extra IRI-related NAS induced in DCD-
OLT with high peak-ALT than those involved in the development of NAS in 
DBD-OLT and in DCD-OLT with low peak-ALT.It may also indicate that DWIT 
exacerbates the similar pathway which results in NAS after both DBD-OLT 
and DCD-OLT with peak ALT<1300 IU/L. It also implies that a peak-ALT>1300 
IU/L can be indicative of a high likelihood for development of NAS in DCD-
OLT. Treatment that is able to reduce IRI, and consequently reduces the
peak-ALT to below 1300 IU/L, in DCD-OLT may also reduce the NAS inci-
dence of DCD-OLT to that of DBD-OLT.
Clinical markers of biliary stricture formation
The development of biliary strictures, both anastomotic and nonanastomotic, 
after OLT is often insidious and patients usually present themselves either 
in the outpatient clinic or in the emergency room with symptoms such as 
jaundice, fever, itching and/or abdominal pain.8,9 Most liver transplantation 
centers offer routine follow-up for patients after OLT in the clinic, including 
history and physical exam and blood tests for liver enzymes and graft function 
and -less often- abdominal ultrasound examinations. These routine
measurements may harbor early signs of stricture formation. Early detection 
of NAS is important since prompt intervention can prevent cholangitis and 
admissions, it may slow progression, and may even prevent or delay 
retransplantation. However, there is relatively few data on the value of 
routinely performing blood tests and ultrasound examinations in predicting 
possible stricture formation.10-12 The study described in chapter 4 illustrates 
that a time-dependent Cox regression model was a valuable tool in establishing a 
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strong predictive relationship between an elevated gamma-glutamyl transferase 
(GGT) as well as dilated bile ducts on ultrasound (US) at routine assessments 
on the one hand and the development of bile duct strictures in the subsequent 
period of 3 months on the other hand. Other liver enzymes had no independent 
predictive value next to GGT for the development of biliary strictures. These 
data suggest that routinely assessing GGT and US are useful screening tools 
for early detection of biliary stricture formation.This may eventually result in 
presymptomatic referral for diagnosis and treatment.
Matrix metalloproteinases and biliary complications before and after OLT
IRI is inevitable after OLT in the current setting of organ procurement and 
preservation procedures. Recent literature has shown that reperfusion likely 
is responsible for most of the preservation damage that occurs after OLT. 
This seems for an important part due to the release of reactive oxygen 
species (ROS) derived from mitochondria.13,14 Hepatic stellate cell (HSC) 
activation, for example, may occur due to different stimuli such as ROS, 
apoptotic bodies and paracrine stimuli, including Kupffer cells.15,16 HSC 
are further stimulated by several key cytokines into myofibroblasts which 
produce type IV collagen.17 During this process, Kupffer cells and HSC also 
secrete MMP-2 and MMP-9 which creates a delicate equilibrium between 
collagen deposition due to inflammation and breakdown of extracellular 
matrix (ECM).18 HSC are the main cellular source of MMP-2 in the liver which 
is capable of degrading type IV collagen and MMP-2 and MMP-9 have been 
associated with both physiological as well as pathological conditions such 
as inflammation, cancer and OLT.19-22. We and others previously showed that 
MMP-9 is released in the anhepatic phase and especially early after reperfusion, 
and that this peak is related to tissue injury.23,24 In the first week after OLT 
neither MMP-2 nor MMP-9 levels were related to peak-ALT, while MMP-9 
levels increased in case of rejection, produced by neutrophils in the portal 
triads. We now performed studies on the gene level and found that the -1306 
C/T MMP-2 gene promoter polymorphism of both donor and recipient was 
associated with the development of NAS after OLT. (Chapter 5) The risk of 
developing NAS within 48 months after OLT increased if the C/T polymorphism 
was present in both donor and recipient and this was an independent risk 
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factor, even when adjusted for PSC as indication, and for CIT. We also 
described that the serum levels of MMP-2 were, though non-significantly, 
lower with the C/T genotype than in the presence of the CC genotype. MMP-
2 may thus play a role in late-phase subsequent matrix degradation after OLT. 
Hypothetically, after IRI a decreased activity of MMP-2 may lead to insufficient 
degradation of collagen surrounding bile ducts leading to more NAS in the 
long-term follow-up. 
Many chronic inflammatory conditions of the liver lead to fibrosis and 
cirrhosis and form an indication for OLT. In primary sclerosing cholangitis 
(PSC) chronic inflammation of the bile ducts leads to scarring and biliary 
stricture formation which can lead to OLT before cirrhosis ensues.27 Patients 
with PSC often develop cholangitis, likely due to reflux of bacterial pathogens 
from the intestine and 15% to 20% of PSC patients develop cholangiocar-
cinoma.28 Remarkably, PSC is accompanied by inflammatory bowel disease 
(IBD) in approximately 60% to 80% of cases.29 It is thought that PSC might 
result from aberrant trafficking of intestinal lymphocytes from the gut to the 
liver.30,31 Interestingly, MMPs were not among the discovered genes in 
genetic studies that tried to discover etiological or pathogenetic factors in 
PSC. Interestingly MMPs have been previously associated with IBD where 
serological evaluations revealed that MMP-2 levels increased in patients 
Crohn’s disease (CD) upon effective treatment with Infliximab.32 In PSC 
severe scarring of tissue surrounding bile ducts occurs, only later  followed 
by fibrosis and cirrhosis. Therefore different pathways may be involved in
etiology and initial pathogenesis of PSC on the one hand and in progression 
of PSC on the other hand. It is assumable that different stimuli involving liver 
injury may activate shared pathways in fibrosis, i.e., resulting in NAS after OLT 
or stricture formation in bile duct diseases such as PSC, and eventually cirrhosis. 
In chapter 6 we describe the gene promoter polymorphisms of MMP-2 and 
MMP-9 in relation to disease severity, as defined by death or OLT, in patients 
with PSC. PSC patients from the two independent LT centers with the MMP-
2 –1306 C/T or T/T genotype showed a clear stepwise increase in hazard of 
death or OLT compared to patients with the CC (wild type) genotype. This 
was the case for patients both with and without IBD as concomitant disease, 
implying that impaired MMP-2 activity is associated with a more severe   
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phenotype in PSC. Genes such as NOD2, GPR35 and TCF4 have been discovered 
in genome wide association studies as factors involved in etiology and 
pathogenesis of PSC, and these are all key players for the intracellular 
processing of bacterial pathogens in the intestinal mucosa.33,34 Although 
MMPs were not among the genes discovered in these studies, several 
reports revealed MMP-3 to be associated with both disease development as 
well as disease progression in patients with PSC.35,36 These observations 
support our theory that MMPs are involved in PSC and our data add MMP-2 
as a new key player in disease progression in patients with PSC. Thus, the 
studies from chapter 5 and 6 consistently indicate that MMP-2 is involved 
in bile duct-related liver injury following IRI or other inflammatory processes 
like in PSC.
Matrix metalloproteinases and chimerism
Besides complications that may occur within the biliary tract, such as NAS, 
acute cellular rejection (ACR) is still a complication in about 20% of recipients in 
OLT. Graft tolerance seems to be variable as indicated by the fact that different 
levels of immunosuppression are needed in different patients for prevention of 
rejection.37-39 Several studies have reported chimerism as a potential tool in 
diagnosing graft-versus-host disease (GVHD) after liver transplantation.40-42 
Although much debated, it has been hypothesized that chimerism might 
play a role in the development of graft tolerance and ACR.43,44 Chimerism 
of both recipient and donor has been first demonstrated in 1968 with livers 
that had been transplanted to female recipients from male cadaveric donors 
and our own study group later confirmed this observation.45,46 The use of sex- 
chromosomes in determining the presence of chimerism has limitations since 
only donor-recipient pairs of  the opposite sex can be included. One previous 
study performed a serial  quantitative analysis of donor chimerism (DC) levels 
in serum samples after LT. The authors observed that high levels of DC was 
associated with recurrent disease and rejection and suggested that DC could 
be a marker for graft tolerance.47 In chapter 7 we report on the use of similar 
techniques regarding MMP-2 and MMP-9 gene promoter polymorphisms as 
markers for the presence of chimerism. This MMP-related chimerism was 
found in liver biopsy specimens in 28.8% of cases for MMP-2 and 16.8% for 
Summarizing discussion
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MMP-9. In addition, chimerism was also detectable in peripheral blood after 
OLT and was observed in 18.5% of the MMP-2 mismatches and in 3.4% of 
the MMP-9 mismatches. In a multivariate analysis the presence of MMP-2 
chimerism was found to be a significant independent risk factor for the 
development of ACR and even when adjusted for the Model for End-Stage 
Liver Disease score (MELD). The presence of donor DNA in the circulation 
of the recipient is consistent with previous studies that have shown that 
donor cells entering the recipient’s circulation and lymph nodes largely 
induce tolerance in solid graft transplantation.48-50
Conclusion and future perspectives
Liver transplantation has evolved from an experimental treatment, with relative 
high mortality, to the current standard treatment for end-stage liver diseases 
with excellent survival rates. However, expanding the pool of potential donor 
livers by using donor livers from DCD is not without consequences. We have 
shown that livers from DCD donors are far more susceptible for developing 
NAS after liver transplantation. This is very likely caused by the donor warm 
ischemia time (DWIT), which is inevitable in the current setting of DCD 
procurement. A theory states that during DWIT microthrombi might develop 
in the hepatic sinusoids and peri-biliary microvasculature, which after
 reperfusion could result in release of ROS from mitochondria. ROS are 
known to cause severe damage to cells like hepatocytes leading to cell death. In 
the clinical setting this translates into an increase in ALT in the first week after 
reperfusion as the result of combined injury resulting from ischemia and 
reperfusion. We demonstrated that peak ALT above 1300 IU/L is associated 
with NAS development after DCD-OLT, but not after DBD-OLT. This implies 
that reducing peak ALT to below 1300 IU/L in DCD-OLT probably will bring back 
the incidence of NAS after DCD-OLT to that of DBD-OLT. It also indicates that 
DWIT is responsible for both the higher ALT and the higher incidence of NAS 
after DCD-OLT. However, reducing IRI will probably not eliminate development 
of NAS since other factors such as loss of CCR5Δ32 function, toxic bile salts and 
loss of the bicarbonate “umbrella” have also been reported to contribute 
significantly.
Activation of Kupffer cells and stellate cells results in collagen deposition and 
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production of MMPs, especially MMP-9 and MMP-2, which are capable of 
degrading components of the ECM such as collagen type IV. Our group 
previously found indications that MMP- 9 is released during early phase IRI 
and is derived from Kupffer cells and neutrophils. The current results indicate 
that MMP-2 also plays a prominent role in the long-term progression of two 
different conditions that probably share common pathways, namely chronic 
peribiliary inflammation in the context of PSC but also in the development of 
NAS after OLT. We have shown that the MMP-2 gene promoter polymorphism 
(–1306 C/T) constitutes a functional SNP indicated by the fact that C/T 
polymorphisms are characterized by less circulation of MMP-2 in relation 
to the genotype. We now also demonstrate that these polymorphisms are 
related to the risk for development of NAS after OLT. Furthermore, in PSC 
patients we observed a striking increase in disease severity in relation to the 
MMP-2 C/T and TT genotype as defined by death or OLT. These data suggest 
a prominent role of MMPs in the degradation of collagen surrounding bile 
ducts before and after liver transplantation. The studies that are described in 
this thesis provide further insight into  clinical markers for development of 
NAS post liver transplantation but also  evaluate the role of MMPs in stricturing 
of the bile ducts both before (in PSC) and after (in NAS) liver transplantation. 
Currently several protocols using machine perfusion are being developed to 
reduce IRI during and after procurement of donor livers in order to prevent 
complications such as graft failure and NAS.51-55 However, it is unclear when, 
how and especially where the use of machine perfusion should take place. 
Several studies reported that back table hypothermic oxygenated machine 
perfusion could resuscitate severely injured livers.56,57 There are also promising 
results in reducing IRI with hypothermic or (sub)normothermic machine 
perfusion.58 However, apart from practical limitations, it is unclear whether 
these interventions will reduce NAS after LT. Some data indicate that use of 
fibrinolytics during preservation may reduce IRI after OLT.52,59 Our findings 
indicate that well-timed stimulation or inhibition of the activity of MMP-2 
and -9 might also contribute to the reduction of NAS  incidence and may 
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Levertransplantatie is een standaard behandeling geworden voor eindstadium 
leverziekte met een sterk verbeterde korte en lange termijnoverleving. Het 
Leids Universitair Medisch Centrum (LUMC) voert levertransplantaties uit 
sinds 1992 en behoort daarmee tot een van de 3 centra in Nederland, naast 
Groningen en Rotterdam, waar deze behandeling aangeboden wordt. 
Inmiddels bedraagt de 1, 5 en 10-jaars overleving na levertransplantatie in 
het LUMC respectievelijk 91%, 83% en 77%, ruim boven het gemiddeld in 
Europa. Het verbeteren van de chirurgische technieken heeft ertoe bijgedragen dat 
de overleving op korte termijn sterk verbeterd is. Ook afname van infecties 
na levertransplantatie, minder acute en chronische afstoting en verbeterde 
preservatietechnieken van het donororgaan hebben vrijwel zeker significante 
bijdragen geleverd aan de verbeterde overleving. Ondanks de verbeterde 
patiënt- overleving na OLT blijven er complicaties. In het bijzonder complicaties 
aan de galwegen zoals vernauwingen (stricturen) vormen een significant 
probleem na levertransplantatie waarvoor patiënten frequent worden 
opgenomen, en in het uiterste geval opnieuw getransplanteerd moeten worden. 
De toegenomen beschikbaarheid van levertransplantatie als behandeling, 
evenals de verbeterde overleving hebben ertoe geleid dat meer patiënten die 
lijden aan het eindstadium van een leverziekte in aanmerking komen voor 
levertransplantatie. Het succes van levertransplantatie is slechts mogelijk bij 
voldoende beschikbaarheid van donororganen. Het aantal hersendode donoren 
is in Nederland gedaald. Dit heeft geleid tot een toename van de wachttijd 
voor levertransplantatie welke kan oplopen tot een jaar. De oplossing van 
het tekort is in grote lijnen tweeledig: enerzijds is het noodzakelijk om meer 
potentiële donoren te werven, anderzijds is het van groot belang om maximaal 
gebruik te maken van het huidige aanbod aan donorlevers. Om meer 
potentiële donoren te werven is goede informatievoorziening voor mensen 
die donatie overwegen essentieel, en zijn er verschillende campagnes vanuit 
de overheid en (semi)publieke instanties gestart om dit te realiseren. Ook 
zou een zogenaamd geen-bezwaar systeem, zoals dit in België en Oostenrijk 
functioneert, opnieuw overwogen kunnen worden.
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Het optimaal benutten van het huidig donoraanbod is complex. Tot 2001 
werden in Nederland uitsluitend gebruik gemaakt van donorlevers van 
hersendode donoren (donation after brain death (DBD)). Deze donoren 
hebben bij donatie een intacte circulatie waardoor de lever nog voldoende 
geoxygeneerd wordt. Levers van DBD donoren zijn daarmee van relatief 
goede kwaliteit. Sinds 2001 wordt er in Nederland ook gebruik gemaakt van 
organen van hartdode donoren (donation after cardiac death (DCD)) waarbij 
er kort voor en tijdens donatie geen sprake meer is van een intacte circulatie, 
zodat de warme donorlever niet meer van zuurstofrijk bloed wordt voorzien. 
Deze periode lijkt cruciaal in de vorming van stricturen aan de galwegen 
na levertransplantatie met DCD donoren. Vorming van galwegstricturen na 
levertransplantatie wordt in grofweg twee typen verdeeld: de anastomotische 
stricturen (AS), dit zijn stricturen die ter plaatse van de chirurgische naad 
plaatsvinden, en de nonanastomotische stricturen (NAS). NAS zijn stricturen 
die zich minimaal 1cm boven de chirurgische naad ontwikkelen in extra- en/
of intrahepatische galwegen. 
Verbeterde overleving na levertransplantatie
In de afgelopen twee decennia hebben vele factoren bijgedragen aan de 
verbeterde overleving na levertransplantatie in het LUMC. In hoofdstuk 2 
is er systematisch gezocht naar factoren die hebben bijgedragen aan deze 
verbetering. De indicaties waarvoor patiënten getransplanteerd worden, zijn 
in het LUMC in vergelijking met het eerste decennium niet veranderd in 
het tweede decennium. Het bleek dat hepatocellulair carcinoom de meest 
voorkomende indicatie was voor levertransplantatie in beide decennia. De 
chirurgische technieken hebben een sterke verbetering ondergaan in het 
tweede decennium gekenmerkt door een sterk gedaalde hoeveelheid bloed-
verlies tijdens de operatie. Vervolgens is er gekeken naar de doodsoorzaken 
na transplantatie in beide decennia. Hieruit bleek dat in het eerste decennium 
infectie de meest voorkomende oorzaak was voor overlijden na levertrans-
plantatie, gevolgd door overlijden door terugkeer van de oorspronkelijke 
ziekte, met name hepatocellulair carcinoom. Beide oorzaken van overlijden 
kenden een significante daling in het tweede decennium, hoewel infectie nog 
steeds de belangrijkste oorzaak is van overlijden na transplantatie. Deze 
Nederlandse samenvatting
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daling van sterfte aan infectie is toe te schrijven aan verbeterde behandel-
protocollen direct na levertransplantatie op de intensive care, verbeterde 
diagnostiek en behandeling met antibiotica. De sterke afname aan sterfte 
door terugkeer van HCC na OLT was vrijwel zeker het gevolg van de introductie 
van neo-adjuvante behandeling met transarteriële chemo-embolisatie (TACE) 
en ablatie van de levertumor middels radiofrequentie (RFA) van patiënten 
met hepatocellulair carcinoom op de wachtlijst. Vanaf 2001 is er een strikt 
protocol ingevoerd om ook DCD donorlevers te gebruiken voor levertrans-
plantatie. DCD donoren zijn onderhevig aan strenge selectie eisen, zoals een 
donorleeftijd van <55 jaar, een circulatiestilstand (donor warme ischemie tijd 
(DWIT)) van bij voorkeur niet langer dan 30 minuten, een body mass index 
<28, en een arteriële bloeddruk van <50 mm Hg niet langer dan 15 minuten. 
Op basis van voorgenoemde selectiecriteria wordt ongeveer 25% van alle 
DCD donoren geëxcludeerd. Hiernaast wordt getracht preservatietijden zoals 
de koude ischemie tijd (CIT) die tijdens het transport van het donororgaan 
optreedt te beperken, met als doel de ischemie-reperfusie schade(IRI) tot 
een minimum te reduceren. Ondanks deze maatregelen blijkt de IRI na 
levertransplantatie met DCD donoren significant hoger te zijn dan na 
levertransplantatie met DBD donoren. Dit uit zich in een hogere piek in 
de leverenzymen alanine aminotransferase (ALT) en aspartaat aminotrans-
ferase (AST) in de eerste week na levertransplantatie. Op de langere termijn 
blijken levers van DCD donoren ook vaker NAS te ontwikkelen na OLT, en 
ondergaan deze patiënten vaker retransplantaties door NAS waardoor de 
transplantaatoverleving significant korter is dan na DBD levertransplantatie. 
Verdere analyse heeft aangetoond dat de patiëntoverleving niet significant 
lager is na DCD levertransplantatie ten opzicht van DBD-OLT.
IRI en ontwikkeling van galwegstricturen
Het ontstaan van AS wordt vaak gezien als een chirurgische complicatie door 
verlittekening op de choledochus-naad, die vaak relatief eenvoudig met 
endoscopische technieken te behandelen is. NAS vormen na transplantatie 
een veel groter probleem. NAS ontstaat in ongeveer 20% - 40% na levertrans-
plantatie met DCD donoren. NAS ontstaat waarschijnlijk door een samenspel 
van ischemische, immunologische en toxische factoren die inspelen op de 
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bloedvoorziening van de galwegen, ook wel bekend als de peri-biliare plexus, 
en op de galwegen zelf. Een afgenomen microcirculatie in de peri-biliare plexus 
kan wellicht een rol spelen bij het ontstaan van NAS. De peri-biliare plexus 
wordt enkel van bloed voorzien door de arteria hepatica. Men vermoedt dat 
stase van bloed tijdens de DWIT en CIT in de arteria hepatica leidt tot 
microtrombusvorming in de peri-biliare plexus. Mogelijk spelen microthrombi 
ook in de sinusoiden een rol bij het ontstaan van IRI. Na levertransplantatie 
stijgen de leverenzymen ALT en AST als gevolg van lekkage uit hepatocyten die 
afsterven tijdens de DWIT, CIT, RWIT en reperfusie. De maximale hoogte (piek) 
van deze stijging in de eerste week na OLT vormt een goede indicator van IRI 
van het transplantaat. Hoofdstuk 3 beschrijft de relatie tussen de piek ALT in 
de eerste week en het ontstaan van NAS na DCD levertransplantatie in twee 
transplantatiecentra, namelijk het LUMC en het Universitair Medisch Centrum 
Groningen (UMCG). In deze twee cohorten gecombineerd is gezocht naar de 
optimale cut-off waarde die het ontstaan van NAS kan voorspellen na DCD 
levertransplantatie, en deze werd vastgesteld op ≥1300 IU/L. Hierbij werd de 
IRI in twee categorieën verdeeld: een piek ALT van <1300 IU/L werd beschouwd 
als milde IR-schade en een piek ALT ≥1300 IU/L als ernstige IR-schade. In de 
gecombineerde cohorten bleek dat DCD transplantaten die ernstige IR-schade 
vertoonden significant vaker NAS ontwikkelden in vergelijking met DCD 
transplantaten die een milde IR-schade hadden ontwikkeld: De 4-jaars 
cumulatieve incidentie van NAS ontwikkeling na ernstige IR-schade was 51.4% 
ten opzichte van 11.6% in het geval van milde IR-schade. Ook in de afzonderlijke 
cohorten bleek deze relatie duidelijk te bestaan. Echter, er kon geen 
associatie gevonden worden tussen de piek ALT en het ontstaan van NAS 
bij DBD transplantaten. Voor dit type donor kon tevens geen cut-off waarde 
vastgesteld worden voor piek ALT om patiënten met hoge en lage kans op NAS 
te scheiden. Dit kan erop wijzen dat wellicht andere aspecten, zoals toxische 
of immunologische schade een rol spelen bij het ontstaan van NAS na DBD 
transplantatie. In ieder geval blijkt dat zowel IRI als NAS toenemen door de 
DWIT bij levertransplantatie met hartdode donoren.
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Klinische variabelen voor galwegstricturen
De ontwikkeling van NAS is vaak sluipend en patiënten presenteren zich 
vaak op de eerste hulp of polikliniek pas als er een significante occlusie is 
van de galwegen, waardoor er klachten ontstaan als koorts, buikpijn, geel-
zucht, al dan niet gecombineerd met jeuk. De presentatie van patiënten met 
galwegstricturen, zoals AS of NAS, is gelijk en er zijn geen klinische tekenen 
die dit onderscheid kunnen maken. De definitieve diagnose wordt gesteld 
met behulp van endoscopische retrograde cholangio- en pancreaticografie 
(ERCP) of percutane cholangiografie (PTC); beide onderzoeken zijn echter 
invasief en gaan gepaard met morbiditeit. MRCP is niet invasief maar wel 
duur en daarbij is voor interventie is vervolgens alsnog PTC of ERCP nodig. 
In veel transplantatiecentra wordt een uitgebreid programma aan postoperatieve 
zorg aangeboden, waarbij patiënten frequent worden gezien op de polikliniek 
ter controle met als primaire doel de leverfunctie te evalueren, maar ook 
complicaties zoals afstoting, terugkeer van oorspronkelijke ziekte en 
galwegstricturen vroeg op te kunnen sporen. Er is slechts een beperkt aantal 
studies dat de voorspellende waarde van het routinematig screenen van deze 
patiënten, met behulp van bloedcontroles en echografie bij de opsporing van 
galwegstricturen geëvalueerd hebben. In hoofdstuk 4 werd met een tijds-
afhankelijke Cox regressie model aangetoond, dat het routinematig bepalen 
van GGT en het uitvoeren van echo’s een sterk voorspellende waarde had 
voor het optreden van NAS in de daaropvolgende 3 maanden. Andere 
leverenzymen waren niet onafhankelijk voorspellend voor galwegstricturen. 
Een verhoogde GGT en gedilateerde galwegen op de echo rechtvaardigen 
hiermee het gebruik van invasieve methoden, zoals ERCP en PTC om de 
strictuur aan te tonen en te behandelen.
Matrix metalloproteinasen en galwegstricturen
Matrix metalloproteinasen (MMPs) vormen een groep eiwitklievende enzymen 
die betrokken zijn bij het hermodelleren van bindweefsel. Inmiddels zijn er 
meer dan 26 varianten bekend. In gezond weefsel wordt voortdurend weefsel 
aangemaakt en afgebroken waarbij MMPs een cruciale rol spelen. Onder 
invloed van verschillende stimuli kan de productie van MMP toe- of afnemen. 
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Als gevolg van IRI kunnen zuurstofradicalen (reactive oxygen species (ROS)) 
ontstaan ten gevolge van metabole reacties die bepaalde mononucleaire 
(Kupffer) cellen kunnen activeren. Deze activeren vervolgens stellate cellen in 
de lever die vervolgens MMP-2 en MMP-9 produceren. MMP-9 wordt ook in 
endotheel, de Kupffercellen, neutrofielen en endotheel gevormd. MMP-2 en 
MMP-9 zijn in staat om type IV collageen af te breken, een van de hoofd-
componenten van bindweefsel en zijn reeds in verband gebracht met 
verschillende ziektebeelden als tumorvorming, ontstekingsziekten en verbind-
weefseling (fibrose). (Figuur 1) In hoofdstuk 5 werden single nucleotide 
polymorfismen (SNP) in de promotorregio van MMP-2 en MMP-9 onderzocht 
in relatie tot het ontstaan van NAS na levertransplantatie. Hieruit bleek dat 
patiënten die drager waren van het MMP-2 –1306 CT of TT promoter 
polymorfisme significant vaker NAS ontwikkelden ten opzichte van patiënten 
die drager waren van het wild-type (CC) allel. De cumulatieve incidentie nam 
verder toe indien het CT/TT polymorfisme ook aanwezig was in de donorlever. 
In een multivariate analyse bleek dat de aanwezigheid van het CT/TT polymorfisme 
onafhankelijk voorspellend was voor het ontstaan van NAS, gecorrigeerd voor 
CIT en primaire scleroserende cholangitis (PSC) als indicatie voor levertrans-
plantatie. Een interessante bevinding was het feit, dat bloedspiegels van MMP-2 
lager was in patiënten die NAS ontwikkelden ten opzichte van hen zonder NAS 
en dat deze tevens lager warenindien de patiënten drager waren van het CT/TT 
polymorfisme. Dit wijst erop dat het polymorfisme waarschijnlijk een functio-
neel effect heeft op de beschikbaarheid (en mogelijk ook activiteit) van MMP-2. 
Naast IRI kan ook een andere oorzaak van ontsteking een bron van MMP 
activering zijn. Verschillende ontstekingsziekten in de lever kunnen bij aan-
houdende ontsteking leiden tot fibrose en ze vormen frequent aanleiding tot 
levertransplantatie. Een goed voorbeeld is primaire scleroserende cholangitis 
(PSC), waarbij chronische ontsteking van de galwegen uiteindelijk leiden tot 
strictuurvorming. PSC gaat bovendien vaak gepaard met inflammatoir darmlijden 
(IBD). Door verminderde afvloed van gal kunnen patiënten infecties ontwikkelen 
welke gepaard gaan met ziekenhuisopname, behandeling met antibiotica en 
endoscopische behandeling van de galwegen. Ongeveer 15% - 20% van de 
PSC patiënten ontwikkelt kanker van de galwegen. Infecties die elkaar snel 
opvolgen vormen vaak een reden om de PSC patiënt te transplanteren. Gezien 
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de voorheen beschreven relatie tussen de ontwikkeling van galwegstricturen 
na levertransplantatie en genetische polymorfismen van MMP-2, is er gekeken 
of er een relatie bestond bij andere fibrotische aandoeningen zoals PSC met 
MMP-2 polymorfismen. In hoofdstuk 6 werd de ziekte-ernst van PSC patiënten 
getoetst aan MMP-2 polymorfismen, waarbij ziekte-ernst werd gedefinieerd als 
overlijden of levertransplantatie. Hieruit kwam naar voren dat PSC patiënten 
die drager waren van het CT polymorfisme er slechter aan toe waren, en dus 
vaker overleden of getransplanteerd werden dan patienten die drager waren 
van het wild-type (CC) allel. Bovendien was de ziekte-ernst nog groter indien 
PSC patiënten drager waren van het TT allel. De associatie met de aanwezigheid 
van het T-allel en ziekte-ernst werd bevestigd in subgroepen van PSC patiënten 
met en zonder IBD. In een multivariate regressie analyse werden de 
bevindingen bevestigd waarbij een stapsgewijze toename in ziekte-ernst werd 
gezien naar gelang het aanwezig zijn van T-allel. De resultaten uit deze studie 
geven aan dat MMP-2 sterk betrokken is bij ziekteprogressie in patiënten 
met PSC. 
Hoofdstuk 5 en 6 onderschrijven het belang van MMP-2 in ziekteprocessen 
waarbij collageendepositie een cruciale rol speelt zoals bij de ontwikkeling van 
NAS en PSC. 
Chimerisme
Met chimerisme wordt de aanwezigheid van cellen bedoeld met verschillende 
genetische achtergronden in een individu. Bij transplantatie is deze aan-
wezigheid vanzelfsprekend, aangezien er een donorlever met een andere 
genetische achtergrond wordt getransplanteerd. De vormen van chimerisme 
kunnen nog een tweetal andere vormen aannemen. Studies hebben uitgewezen 
dat afstoting gerelateerd is aan de aanwezigheid van ontvanger cellen in de 
donor lever, en de aanwezigheid van cellen afkomstig van de donorlever in 
de bloedbaan en in perifeer weefsel (met name lymfeklieren) van de ontvanger. 
Hoewel een laag normale waarde wordt geassocieerd met een vorm van 
tolerantie van de ontvanger, worden hogere percentages van donor cellen 
geassocieerd met afstoting, graft-versus-host ziekte en terugkeer van de 
oorspronkelijke ziekte waarvoor getransplanteerd werd. Chimerisme werd 
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voor het eerst aangetoond in 1968 na levertransplantatie bij vrouwelijke 
ontvangers met donor levers afkomstig van mannen. Hierbij werd op basis van 
de aanwezigheid van het mannelijk geslachtschromosoom aangetoond dat er 
sprake was van chimerisme. Een nadeel van het gebruik van geslachts-
chromosomen bij het aantonen van chimerisme is dat slechts donor-ontvanger 
combinaties van verschillende sekse gebruikt kunnen worden. In hoofdstuk 7 
werden MMP-2 en MMP-9 promotor polymorfismen bepaald in donor en 
ontvanger om chimerisme aan te tonen. Deze bepalingen werden verricht op 
leverbiopten en bloed van de ontvanger. Chimerisme werd aangetroffen in 
28.8% van de leverbiopten voor MMP-2 en in 16.8% voor MMP-9. Ook in 
bloed werd chimerisme aangetroffen, namelijk in 18.5% voor het MMP-2 
polymorfisme en 3.4% voor het MMP-9 polymorfisme. Hiernaast werd er een 
significante associatie gevonden voor de aanwezigheid van chimerisme en het 
optreden van afstoting. Ook hier werd in een multivariate analyse aangetoond 
dat deze associatie onafhankelijk was, gecorrigeerd voor de score voor de ernst 




Levertransplantatie is uitgegroeid van experimentele behandeling tot standaard-
behandeling voor eindstadium leverziekte met uitstekende lange termijn 
overleving. Als gevolg hiervan kunnen meer patiënten in aanmerking komen 
voor levertransplantatie terwijl het aantal hersendode donoren afneemt. Deze 
onevenwichtige toename heeft ertoe geleid dat transplantatiecentra beter 
gebruik maken van het huidig aanbod aan donorlevers: Momenteel worden 25 
– 35% van alle transplantaties verricht met hartdode (‘DCD’) donorlevers. Het 
gebruik van DCD donorlevers leidt tot minder sterfte op de wachtlijst, maar 
een nadeel is dat tot wel 35% van alle getransplanteerde DCD levers nona-
nastomotische galwegstricturen (NAS) ontwikkelt. NAS leidt tot meer opnames 
en meer retransplantaties welke gepaard gaat met aanzienlijke morbiditeit en 
zelfs mortaliteit. Het is waarschijnlijk dat NAS ontstaat door een samenspel 
van IRI (ischemie-reperfusie-schade), immunologische en toxische factoren. 
IRI ontstaat bij DCD waarschijnlijk doordat tijdens de DWIT extra schade 
ontstaat, mogelijk door microstolsels gevormd in de kleinste aftakkingen van 
de peri-biliare plexus. Bij het aansluiten van de donorlever in de ontvanger met 
reperfusie als gevolg, komen vervolgens ROS vrij die aan het leverweefsel 
schade kunnen aanrichten waaronder aan hepatocyten. Bij het afsterven van 
hepatocyten komt ALT vrij, wat zich uit als een piek die te meten is in de eerste 
week na levertransplantatie. We hebben aangetoond dat een piek ALT van 
meer dan 1300 IU/L in de eerste week sterk voorspellend is voor het ontstaan 
van NAS na levertransplantatie met DCD donoren. Deze associatie werd niet 
gevonden na levertransplantatie met DBD donoren. Het reduceren van de 
piek ALT tot minder dan 1300 IU/L zal dus de incidentie van NAS na DCD 
transplantatie waarschijnlijk reduceren tot aan die van levertransplantatie met 
DBD donoren. ROS kunnen direct en indirect Kupffer cellen en stellate cellen 
activeren, die op hun beurt respectievelijk MMP-9 en MMP-2 produceren. 
Deze MMP’s zijn in staat om type IV collageen af te breken. In een eerdere 
studie hebben wij aangetoond dat MMP-9 vrijkomt tijdens de vroege fase van 
IR-schade, afkomstig van met name Kupffer cellen en neutrofielen. De huidige 
studies in deze thesis laten zien dat MMP-2 betrokken is bij complicaties die 
zich op de lange termijn manifesteren zoals ziekteprogressie bij PSC en de 
ontwikkeling van NAS na levertransplantatie. Het is waarschijnlijk dat     
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laatstgenoemde ziektebeelden verschillende initiërende reactiepaden hebben 
maar uiteindelijk kunnen leiden tot eenzelfde strictuurvorming van de 
galwegen. In de huidige thesis hebben we aangetoond dat het MMP-2 -1306 
C/T polymorfisme leidt to een verminderde circulatie van MMP-2, welke duidt 
op een functionele SNP. Bovendien lopen dragers van het CT/TT polymorfisme 
een groter risico op het ontwikkelen van NAS en dit effect is groter indien deze 
polymorfismen ook aanwezig waren in de donorlever. De rol van het MMP-2 
C/T polymorfisme komt ook bij PSC patiënten sterk naar voren waarbij dragers 
van het CT respectievelijk TT allel een stapsgewijze toename lieten zien wat 
betreft de ernst van het ziektebeeld bij PSC zich uitend als eerder overlijden of 
vroegtijdiger en in een hoger percentage getransplanteerd worden. Deze data 
suggereert dat MMP-2 een essentiële rol heeft na IRI en bij de chronische 
peribiliaire inflammatie en in de afbraak van collageen rondom de galwegen. 
Dit biedt verder inzicht in mogelijke klinische markers en aangrijpinspunten 
voor behandeling van ontwikkeling van galwegstricturen, zowel bij primaire 
sccleroserende cholangitis als na levertransplantatie (NAS). 
Inmiddels zijn er meerdere therapieën in ontwikkeling met als voornaamste 
doel IRI na levertransplantatie te reduceren en daarmee complicaties zoals 
NAS en het falen van het transplantaat te voorkomen. Een van deze onderzoeken 
omvat het gebruik van machine perfusie waarbij de donorlever onder fysio-
logische omstandigheden wordt voorzien van onder andere zuurstof. Recente 
studies hebben al veelbelovende resultaten getoond met het “verbeteren” van 
donorlevers. Het is tot op heden echter nog onduidelijk waar en wanneer het 
gebruik van machineperfusie toegepast zou moeten worden. Ook zijn er nog 
geen data die ondersteunen dat machineperfusie de ontwikkeling van NAS kan 
voorkomen. Andere therapieën die in ontwikkeling zijn omvatten het gebruik 
van stolseloplossende medicijnen die tijdens de uitnameprocedure van DCD 
donorlevers toegepast kunnen worden om microstolsels op te lossen. Onze 
data ondersteunen het idee dat MMPs een belangrijke rol spelen in IRI en 
ontstaan van NAS na levertransplantatie. Dit geeft mogelijk aangrijpingspunten 
voor het beperken van IRI en NAS na OLT en wellicht ook bij PSC. Andere 
strategieën gericht op bijvoorbeeld toxische galzouten en immunologische 




ACR  Acute Cellular Rejection
ALT  Alanine Aminotransferase
AST  Aspartate Aminotransferase
AS   Anastomotic Strictures
CIT   Cold Ischemia Time 
CCR5Δ32  Chemokine Receptor 5 delta 32
DCD   Donation after Cardiac Death
DBD   Donation after Brain Death
DWIT   Donor Warm Ischemia Time
ECM   Extracellular Matrix
EGF   Epidermal Growth Factor
EMMPRIN  Extracellular Matrix Metalloproteinase Inducer
FGF   Fibroblast Growth Factor
HCC   Hepatocellular Carcinoma
HR   Hazard Ratio
HSC   Hepatic Stellate Cells
HTK   Histidine-tryptophan-ketoglutarate (preservation fluid)
IBD   Inflammatory Bowel Disease
IL-1   Interleukin-1
IRI   Ischemia-Reperfusion Injury
ITBL   Ischemic-Type Biliary Lesions
LT   Liver transplantation
MDR3   Multidrug Resistance Protein 3
MMP   Matrix Metalloproteinase
MT-MMP  Membrane-type Matrix Metalloproteinase
NAS   Nonanastomotic Strictures
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NGF   Nerve Growth Factor
NK   Natural Killer cells
OLT   Orthotopic Liver Transplantation
PA   Plasmin Activator
PDGF   Platelet Derived Growth Factor
PNF   Primary Nonfunction
PSC   Primary Sclerosing Cholangitis
RFA   Radiofrequency Ablation
ROS   Reactive Oxygen Species
RWIT   Recipient Warm Ischemia Time
Sp-1  Specificity Protein-1
SNP   Single Nucleotide Polymorphism
TACE   Transarterial Chemo Embolization
TGF-β   Transforming Growth Factor β
TIMP   Tissue Inhibitors of Metalloproteinases
TNF-α  Tumor Necrosis factor α
UW   University of Wisconsin (preservation fluid)
VEGF   Vascular Endothelial Growth Factor
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